Tricyclic compounds

Abstract

The present invention is to provide novel tricyclic compounds having leukotriene antagonistic action and represented by the formula: 1

Description

TECHNICAL FIELD

[0001] This invention relates to a tricyclic compound or a pharmaceutically acceptable salt thereof having leukotriene C4 antagonistic action and leukotriene E4 antagonistic action in addition to potent leukotriene D4 antagonistic action, and available for an antiallergic agent and an anti-inflammatory agent.

BACKGROUND ART

[0002] As a compound having leukotriene D4 antagonistic action as in the present invention and having a similar structure to that of the present invention, there has been known, for example, those disclosed in WO94/19345 publication, and as a compound having a partially similar structure, there has been known compounds such as 5-[3-[3-(2-quinolinylmethoxy)phenoxy]-propyl]-1H-tetrazole (RG7152; J.Med. Chem., 33, 1186(1990)) or 5-[[2-[[4-(2-quinolinylmethoxy)phenoxy]methyl]phenyl]-methyl]-1H-tetrazole (RG12525; J.Med. Chem., 33, 1194(1990)), or compounds disclosed in WO95/18107 publication, etc.

[0003] In the present invention, as a result of research for long years about syntheses of compounds having potent leukotriene D4 antagonistic action, as well as having antagonistic action to leukotriene C4 and leukotriene E4 and their pharmaceutical effects, the inventors have found that novel tricyclic compounds have excellent leukotriene D4 antagonistic action, as well as having leukotriene C4 and leukotriene E4 antagonistic action with good balance, and have excellent oral absorbability and durability of the action to accomplish the present invention.

DISCLOSURE OF THE INVENTION

[0004] A tricyclic compound represented by the formula (I): 2

[0005] wherein R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a carboxyl group, a C1-C4 alkoxy-carbonyl group, a 1H-tetrazol-5-yl group, C1-C4 alkyl group, a fluoro C1-C4 alkyl group, a hydroxy C1-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group, a C1-C4 alkoxy group, a fluoro C1-C4 alkoxy group, a C1-C4 alkylthio group, a C1-C4 alkylsulfinyl group or a C1-C4 alkylsulfonyl group, R2 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, C1-C4 alkyl group or a C1-C4 alkoxy group, A represents a 5-membered or a 6-membered heteroaromatic ring group containing 1 to 3 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or a fused heteroaromatic ring group in which the heteroaromatic ring group and a benzene ring are fused, said heteroaromatic ring group or fused heteroaromatic ring group may have a halogen atom, a nitro group, a cyano group, a C1-C4 alkyl group, a fluoro C1-C4 alkyl group, a C1-C4 alkoxy group,a fluoro C1-C4 alkoxy group, a C1-C4 alkylthio group, a fluoro C1-C4 alkylthio group or a C3-C4 alkylene group as a substituent(s), B represents a formula: —OCH2—, a formula: —CH2CH2—, a formula: —SCH2—, a formula: —CH2O— or a formula: —CH2S—, X represents an oxygen atom, a sulfur atom, a methylene group or a formula: ═CH—, Y represents a C1-C10 alkylene group, phenylene group or a group of a formula (a): 3

[0006] wherein o and p each is an integer of 0 to 2, and q is an integer of 1 to 4,

[0007] each of which may have a halogen atom, a C1-C4 alkyl group or a C1-C4 alkoxy group as a substituent(s), Z represents a carboxyl group which may be protected; a 1H-tetrazol-5-yl group; a formula: —SO3H group; a formula: —NH—SO2—R3; or a formula: —CO—NH—SO2—R3,

[0008] wherein R3 represents a C1-C4 alkyl group, a fluoro C1-C4 alkyl group or a phenyl group which may have at least one substituent selected from the group consisting of a halogen atom, a C1-C4 alkyl group, a fluoro C1-C4 alkyl group, a C1-C4 alkoxy group, a fluoro C1-C4 alkoxy group, a nitro group and a cyano group as a substituent(s),

[0009]

[0010] represents a single bond or a double bond,

[0011] m is an integer of 1 to 4, and when m is 2 or more, then

[0012] R1 may be the same or different from each other, and n is an integer of 1 to 3, and when n is 2 or more, then R2 may be the same or different from each other,

[0013] or a pharmaceutically acceptable salt thereof.

BEST MODE FOR CARRYING OUT THE INVENTION

[0014] In the compound represented by the above-mentioned formula (I), as the halogen atom of R1, there may be mentioned, for example, a fluorine, chlorine, bromine or iodine atom, preferably fluorine, chlorine or bromine atom, more preferably fluorine or chlorine atom, particularly preferably a fluorine atom.

[0015] As the C1-C4 alkoxycarbonyl group of R1, there may be mentioned, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl or t-butoxycarbonyl group, preferably methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or isopropoxycarbonyl group, more preferably a methoxycarbonyl or ethoxycarbonyl group, particularly preferably a methoxycarbonyl group.

[0016] As the C1-C4 alkyl group of R1, there may be mentioned methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or t-butyl group, preferably methyl, ethyl, propyl or isopropyl group, more preferably methyl or ethyl group, particularly preferably methyl group.

[0017] As the fluoro C1-C4 alkyl group of R1, there may be mentioned, for example, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 2-fluoropropyl, 3-fluorpropyl or 4-fluorobutyl group, preferably fluoromethyl, difluoromethyl, trifluoromethyl or 2-fluoroethyl group, more preferably fluoromethyl, difluoromethyl or trifluoromethyl group, particularly preferably difluoromethyl or trifluoromethyl group.

[0018] As the hydroxy C1-C4 alkyl group of R1, there may be mentioned, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxy-1-methylethyl, 1-hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-hydroxybutyl or 4-hydroxybutyl group, preferably hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxy-1-methylethyl, 1-hydroxypropyl or 2-hydroxypropyl group, more preferably hydroxymethyl, 1-hydroxyethyl, 1-hydroxy-1-methylethyl or 1-hydroxypropyl group, particularly preferably hydroxymethyl or 1-hydroxy-1-methylethyl group.

[0019] As the C2-C4 alkenyl group of R1, there may be mentioned, for example, vinyl, 1-propenyl, allyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl or 2-methyl-2-propenyl group, preferably vinyl, 1-propenyl, allyl, 1-butenyl, 2-butenyl or 2-methyl-1-propenyl group, more preferably vinyl, 1-propenyl or allyl group, particularly preferably a vinyl group.

[0020] As the C2-C4 alkynyl group of R1, there may be mentioned, for example, ethynyl, 1-propynyl, propargyl, 1-butynyl, 2-butynyl or 3-butynyl group, preferably ethynyl, 1-propynyl or 1-butynyl group, more preferably ethynyl or 1-propynyl group, particularly preferably an ethynyl group.

[0021] As the C1-C4 alkoxy group of R1, there may be mentioned, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy or t-butoxy group, preferably methoxy, ethoxy, propoxy or isopropoxy group, more preferably methoxy or ethoxy group, particularly preferably a methoxy group.

[0022] As the fluoro C1-C4 alkoxy group of R1, there may be mentioned, for example, a fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, 2-fluoro propoxy, 3-fluoro propoxy or 4-fluoro butoxy group, preferably fluoromethoxy, difluoromethoxy, trifluoromethoxy or 2-fluoroethoxy group, more preferably a fluoromethoxy, difluoromethoxy or trifluoromethoxy group, particularly preferably a difluoromethoxy or trifluoromethoxy group.

[0023] As the C1-C4 alkylthio group of R1, there may be mentioned, for example, a methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, sec-butylthio or t-butylthio group, preferably methylthio, ethylthio, propylthio or isopropylthio group, more preferably a methylthio or ethylthio group, particularly preferably a methylthio group.

[0024] As the C1-C4 aalkylsulfinyl group of R1, there may be mentioned, for example, a methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, isobutylsulfinyl, sec-butylsulfinyl or t-butylsulfinyl group, preferably a methylsulfinyl, ethylsulfinyl, propylsulfinyl or isopropylsulfinyl group, more preferably a methylsulfinyl or ethylsulfinyl group, particularly preferably a methylsulfinyl group.

[0025] As the C1-C4 alkylsulfonyl group of R1, there may be mentioned, for example, a methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl or t-butylsulfonyl group, preferably a methylsulfonyl, ethylsulfonyl, propylsulfonyl or isopropylsulfonyl group, more preferably a methylsulfonyl or ethylsulfonyl group, particularly preferably a methylsulfonyl group.

[0026] In particular, as R1 in the formula (I), there may be preferably mentioned, a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a propyl group, an isopropyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a 2-fluoroethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a 2-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-1-propenyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 2-fluoroethoxy group, a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group or an isopropylsulfonyl group,

[0027] more preferably a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, an ethylthio group, a methylsulfinyl group, an ethylsulfinyl group, a methylsulfonyl group or an ethylsulfonyl group,

[0028] still further preferably a hydrogen atom, a fluorine atom, a nitro group, a cyano group, a formyl group, a methoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxy-1-methylethyl group, a vinyl group, an ethynyl group, a methoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, a methylsulfinyl group or a methylsulfonyl group,

[0029] particularly preferably a hydrogen atom, a fluorine atom, a cyano group, a trifluoromethyl group or an ethynyl group.

[0030] In the formula (I), the halogen atom, a C1-C4 alkyl group and a C1-C4 alkoxy group of R2 each have the same meanings as those mentioned in the above R1, and as R2, it is preferably a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a nitro group, a cyano group, a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, an ethoxy group, a propoxy group or an isopropoxy group, more preferably a hydrogen atom, a fluorine atom, a chlorine atom, a nitro group, a cyano group, a methyl group, an ethyl group, a methoxy group or an ethoxy group, still further preferably a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group or a methoxy group, particularly preferably a hydrogen atom.

[0031] In the formula (I), as “the 5-membered or a 6-membered heteroaromatic ring group containing 1 to 3 hetero atoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, or a fused heteroaromatic ring group in which the heteroaromatic ring group and a benzene ring are fused” of A, there may be mentioned, for example, a 5-membered heteroaromatic ring group such as furan, thiophene, oxazole, thiazole, imidazole, pyrazole or thiadiazole; a 6-membered heteroaromatic ring group such as pyridine, pyrimidine, pyridazine or pyrazine; or a fused heteroaromatic ring group such as benzofuran, benzothiophene, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline or quinoxaline group,

[0032] preferably an oxazole, thiazole, imidazole, pyrazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline or quinoxaline group, more preferably a thiazole, thiadiazole, pyridine, pyrimidine, benzoxazole, benzothiazole, quinolone or quinazoline group, particularly more preferably a pyridine, benzothiazole or quinoline group.

[0033] The above-mentioned heteroaromatic ring group or fused heteroaromatic ring group may have a substituent(s), and as a substituent(s), there may be mentioned, for example, a halogen atom having the same meaning as in R1, a nitro group, a cyano group, a C1-C4 alkyl group having the same meaning as in R1, a fluoroC1-C4 alkyl group having the same meaning as in R1, a C1-C4 alkoxy group having the same meaning as in R1, a fluoro C1-C4 alkoxy group having the same meaning as in R1, a C1-C4 alkylthio group having the same meaning as in R1, or a C3-C4 alkylene group such as a trimethylene, tetramethylene group (said alkylene group forms a 5-membered ring or a 6-membered ring by biding to a carbon atom adjacent thereto on a heteroaromatic ring),

[0034] preferably a fluorine, chlorine, bromine atom, a nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, methoxy, ethoxy, propoxy, isopropoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, methylthio, ethylthio, propylthio, isopropylthio, trimethylene or tetramethylene group,

[0035] more preferably a fluorine, chlorine atom, a nitro, cyano, methyl, ethyl, isopropyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, ethylthio, trimethylene or tetramethylene group, still further preferably a fluorine, chlorine atom, a nitro, cyano, methyl, isopropyl, t-butyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, methylthio or tetramethylene group, particularly preferably a fluorine, chlorine atom, a trifluoromethyl or tetramethylene group.

[0036] A number of the substituent(s) on the heteroaromatic ring group or fused heteroaromatic ring group is 1 to 4, preferably 1 to 2.

[0037] As A in the formula (I), there may be specifically mentioned, preferably a 2-oxazolyl, 2-thiazolyl, 2- or 4-imidazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2- or 4-pyrimidinyl, 3-pyridazinyl, 2-pyrazinyl, 2-benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, quinolin-2-yl, quinazolin-2-yl, quinoxaline-2-yl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-ethyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-diethyl-2-pyridyl, 6-trifluoromethyl-2-pyridyl, 6-methylthio-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidin-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzo-thiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzo-thiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoro-quinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoroquinazolin-2-yl, 7-chloro-5-fluoro-quinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl or 5,6,7-trifluoroquinazolin-2-yl group, more preferably a 2-thiazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzothiazolyl, quinolin-2-yl, quinazolin-2-yl, 4-methyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidine-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoro-quinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoro-quinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoro-quinazolin-2-yl, 7-chloro-5-fluoroquinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl or 5,6,7-trifluoroquinazolin-2-yl group,

[0038] still further preferably a 2-pyridyl, 2-benzothiazolyl, quinolin-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6,7,8-tetrahydroquinolin-2-yl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzo-thiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl or 5,6,7-trifluoroquinolin-2-yl group,

[0039] particularly preferably a 7-fluoroquinolin-2-yl, 7-chloroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl or 5,6,7,8-tetrahydroquinolin-2-yl group.

[0040] In the above-mentioned formula (I), B represents a formula: —OCH2—, a formula: —CH2CH2—, a formula: —SCH2—, a formula: —CH2O— or a formula: —CH2S—, preferably a formula: —OCH2—, a formula: —CH2O— or a formula: —CH2CH2—.

[0041] In the above-mentioned formula (I), X is an oxygen atom, a sulfur atom, methylene group or a formula: ═CH—, preferably a methylene group, an oxygen atom or a sulfur atom.

[0042] As the C1-C10 alkylene group of Y in the above-mentioned formula (I), there may be mentioned, for example, a methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene or decamethylene group, preferably a C1-C5 alkylene group, more preferably a methylene, ethylene or trimethylene group, particularly preferably an ethylene or trimethylene group.

[0043] The above-mentioned alkylene group may have a substituent(s), and a halogen atom, a C1-C4 alkyl group and a C1-C4 alkoxy group as said substituent(s) are the same as the above-mentioned halogen atom, the C1-C4 alkyl group and the C1-C4 alkoxy group.

[0044] As a substituent(s) for an alkylene group of Y, there may be preferably mentioned a fluorine, chlorine atom, a methyl, ethyl, propyl, methoxy, ethoxy or propoxy group, more preferably a fluorine atom, a methyl, ethyl or methoxy group, particularly preferably a fluorine atom or a methyl group.

[0045] As the phenylene group of Y, there may be mentioned a 1,2-phenylene, 1,3-phenylene or 1,4-phenylene group, preferably a 1,2-phenylene or 1,3-phenylene group, more preferably a 1,2-phenylene group.

[0046] As a group shown by the formula (a) of Y, there may be preferably mentioned a group wherein o=0, p=0 and q=1 (hereinafter referred to as group (a-1)), a group wherein o=0, p=1 and q=1 (hereinafter referred to as group (a-2)), a group wherein o=0, p=1 and q=2 (hereinafter referred to as group (a-3)), a group wherein o=1, p=0 and q=1 (hereinafter referred to as group (a-4)), a group wherein o=1, p=1 and q=1 (hereinafter referred to as group group (a-5)), a group wherein o=1, p=1 and q=2 (hereinafter referred to as group (a-6)) or a group wherein o=1, p=1 and q=3 (hereinafter referred to as group (a-7)), more preferably a group (a-4), a group (a-5) or a group (a-6), particularly more preferably a group (a-5).

[0047] As the preferred group in the formula (I) of Y, there may be specifically mentioned, a methylene, ethylene, trimethylene, tetramethylene, pentamethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-methoxyethylene, 2-methoxyethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 2,2-diethyltrimethylene, 2-methoxytrimethylene, 3-methoxytrimethylene, 2,2-dimethoxytrimethylene, 3,3-dimethoxytrimethylene, 1,2-phenylene or 1,4-phenylene group, the above-mentioned group (a-1), group (a-2), group (a-3), group (a-4), group (a-5) or group (a-6),

[0048] further preferably a methylene, ethylene, trimethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene group, a group (a-4), a group (a-5) or a group (a-6),

[0049] further more preferably a methylene, ethylene, trimethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 2,2-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene group or a group (a-5), particularly preferably methylene, ethylene, trimethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1,2-phenylene group or a group (a-5).

[0050] In the group represented by the formula: —NH—SO2—R3 or a formula: —CO—NH—SO2—R3 of Z, the halogen, C1-C4 alkyl, fluoro C1-C4 alkyl, C1-C4 alkoxy and fluoro C1-C4 alkoxy group which are a substituent(s) on the C1-C4 alkyl group, the fluoro C1-C4 alkyl group and the phenyl group of R3, have the same meanings as the halogen atom, the C1-C4 alkyl group, the fluoro C1-C4 alkyl group, the C1-C4 alkoxy group and the fluoro C1-C4 alkoxy group of the above-metioned R1, respectively.

[0051] As R3, it is preferably a methyl, ethyl, propyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, phenyl, (o, m or p-)fluorophenyl, (o, m or p-)chlorophenyl, (o, m or p-)methylphenyl, (o, m or p-)ethylphenyl, (o, m or p-)(trifluoromethyl)phenyl, (o, m or p-)methoxyphenyl, (o, m or p-)ethoxyphenyl, (o, m or p-)(difluoromethoxy)phenyl, (o, m or p-)(trifluoromethoxy)phenyl, (o, m or p-)nitrophenyl or (o, m or p-)cyanophenyl group,

[0052] further preferably a methyl, ethyl, trifluoromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, phenyl, (o or p-)fluorophenyl, (o or p-)chlorophenyl, (o or p-)methylphenyl, (o or p-)(trifluoromethyl)phenyl, (o or p-)methoxyphenyl, (o or p-)(difluoromethoxy)phenyl, (o or p-)(trifluoromethoxy)phenyl, (o or p-)nitrophenyl or (o or p-)cyanophenyl group,

[0053] further more preferably a methyl, ethyl, trifluoromethyl, phenyl, p-fluorophenyl, p-chlorophenyl, (o or p-)methylphenyl, p-(trifluoromethyl)phenyl, (o or p-)methoxyphenyl, p-(difluoromethoxy)phenyl, p-(trifluoromethoxy)phenyl, p-nitrophenyl or p-cyanophenyl group,

[0054] particularly preferably a methyl, trifluoromethyl, phenyl, o-methylphenyl or p-methylphenyl group.

[0055] As the preferred group of Z in the formula (I), there may be preferably mentioned, a carboxyl, a formula: —SO3H, 1H-tetrazol-5-yl, methanesulfonylamino, ethanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, p-fluorophenylsulfonylamino, p-chlorophenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, p-trifluoromethylphenylsulfonylamino, o-methoxyphenylsulfonylamino, p-methoxyphenylsulfonylamino, p-difluoromethoxyphenylsulfonylamino, p-trifluoromethoxyphenylsulfonylamino, p-nitrophenylsulfonylamino, p-cyanophenylsulfonylamino, methanesulfonylaminocarbonyl, ethanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, p-fluorophenylsulfonylaminocarbonyl, p-chlorophenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl, p-methylphenylsulfonylaminocarbonyl, p-trifluoromethylphenylsulfonylaminocarbonyl, o-methoxyphenylsulfonylaminocarbonyl, p-methoxyphenylsulfonylaminocarbonyl, p-difluoromethoxyphenylsulfonylaminocarbonyl, p-trifluoromethoxyphenylsulfonylaminocarbonyl, p-nitrophenylsulfonylaminocarbonyl or p-cyanophenylsulfonylaminocarbonyl group,

[0056] more preferably a carboxyl, a formula: —SO3H, 1H-tetrazol-5-yl, methanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, methanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl or p-methylphenylsulfonylaminocarbonyl group,

[0057] particularly preferably a carboxyl, a formula: —SO3H, methanesulfonylamino, trifluoromethanesulfonylamino, methanesulfonylaminocarbonyl or trifluoromethanesulfonylaminocarbonyl group.

[0058] Incidentally, when Z is a carboxyl group, the carboxyl group may be protected by a protective group. As the protective group, it is not particularly limited so long as it can be easily converted into a carboxyl group in vivo, there may be mentioned, for example, the C1-C4 alkyl group which has the same meanings as defined in R1; a C7-C10 aralkyl group such as a benzyl, phenylethyl or phenylpropyl group; a C1-C4 alkyl group substituted by a C2-C5 alkanoyloxy group such as an acetoxymethyl, 1-acetoxyethyl, 1-acetoxypropyl, 1-acetoxybutyl, propanoyloxymethyl, 1-propanoyloxyethyl, butanoyloxymethyl, 1-butanoyloxymethyl, pivaloyloxymethyl, 1-pivaloyloxyethyl, 1-pivaloyloxypropyl or 1-pivaloyloxybutyl group; a C1-C4 alkyl group substituted by a (C1-C4 alkoxy)carbonyloxy group such as a methoxycarbonyloxymethyl, 1-(methoxycarbonyloxy)ethyl, ethoxycarbonyloxymethyl, 1-(ethoxycarbonyloxy)ethyl, propoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, 1-(isopropoxycarbonyloxy)ethyl, butoxycarbonyloxymethyl, 1-(butoxycarbonyloxy)ethyl, t-butoxycarbonyloxymethyl or 1-(t-butoxycarbonyloxy)ethyl group; a C1-C4 alkyl group substituted by a N,N-di(C1-C4 alkyl)aminocarbonyl group such as N,N-dimethylaminocarbonylmethyl, 2-(N,N-dimethylaminocarbonyl)ethyl or N,N-diethylaminocarbonylmethyl group; a C1-C4 alkyl group substituted by a N,N-di(C1-C4 alkyl) amino group or by a 5 or 6-membered cyclic amino group which may contain an oxygen atom such as a 2-(N,N-dimethylamino)ethyl, 2-(N,N-diethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-piperidinoethyl, 2-(4-methyl)piperidinoethyl, 3-piperidinopropyl or 2-morpholinoethyl group; or a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group and the like.

[0059] As a protective group for a carboxyl group, there may be preferably mentioned a C1-C4 alkyl group, a benzyl group, a C1-C2 alkyl group substituted by a C2-C5 alkanoyloxy group, a C1-C2 alkyl group substituted by a (C1-C4 alkoxy)carbonyloxy group, or a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group,

[0060] more preferably a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, acetoxymethyl, 1-acetoxyethyl, pivaloyloxymethyl or 1-pivaloyloxyethyl group.

[0061] In the above-mentioned formula (I), m is an integer of 1 to 4, preferably m is 1, 2 or 3, particularly preferably 1 or 2. When m is 2 or more, R1 may be different from each other.

[0062] In the above-mentioned formula (I), n is an integer of 1 to 3, preferably n is 1 or 2, particularly preferably 1. When n is 2 or more, R2 may be different from each other.

[0063] In the Compound (I) of the present invention, there exist an optical isomer(s) (including diastereomer) due to an asymmetric carbon atom(s) in the molecule, or there exist a case in which a geometric isomer due to a double bond exists, and these respective isomers are included in the present invention.

[0064] Also, the Compound (I) of the present invention can be converted into a pharmaceutically acceptable salt, if necessary. Such a salt may be mentioned an acid addition salt of a mineral acid such as hydrochloride, hydrobromide, hydroiodide, sulfate or phosphate; an acid addition salt of an organic acid such as a trifluoroacetic acid salt, a methane-sulfonic acid salt, an ethanesulfonic acid salt, a benzenesulfonic acid salt, a p-toluenesulfonic acid salt, an oxalate, a maleate, a fumarate, a tartarate or a citrate; a metal salt of a carboxylic acid such as a sodium salt, a potassium salt, a calcium salt, a magnesium salt, a manganese salt, an iron salt or an aluminum salt; or a salt with an organic base such as an ammonium salt, a triethylamine salt, aguanidine salt, ahydrazine salt, aquinine salt or a cinchonine salt, and the like.

[0065] Incidentally, the Compound (I) of the present invention can also exist as a hydrate.

[0066] In the tricyclic compounds having the above-mentioned formula (I) according to the present invention, there may be preferably mentioned

[0067] (1) tricyclic compounds wherein R1 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a propyl group, an isopropyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a 2-fluoroethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a 2-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-1-propenyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 2-fluoroethoxy group, a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group and an isopropylsulfonyl group,

[0068] (2). tricyclic compounds wherein R1 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, an ethylthio group, a methylsulfinyl group, an ethylsulfinyl group, a methylsulfonyl group and an ethylsulfonyl group,

[0069] (3). tricyclic compounds wherein R1 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a nitro group, a cyano group, a formyl group, a methoxycarbonyl group, a 1H-tetrazol-5-yl group, methyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxy-1-methylethyl group, a vinyl group, an ethynyl group, a methoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, a methylsulfinyl group and a methylsulfonyl group,

[0070] (4). tricyclic compounds wherein R1 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a cyano group, a trifluoromethyl group and an ethynyl group,

[0071] (5). tricyclic compounds wherein R2 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a nitro group, a cyano group, a methyl group, an ethyl group, a methoxy group and an ethoxy group,

[0072] (6). tricyclic compounds wherein R2 in the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a methyl group and a methoxy group,

[0073] (7). tricyclic compounds wherein R2 in the compound represented by the formula (I) is a hydrogen atom,

[0074] (8). tricyclic compounds wherein the ring shown by A in the compound represented by the formula (I) is selected from the group consisting of a furan, thiophene, oxazole, thiazole, imidazole, pyrazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, benzofuran, benzothiophene, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline and quinoxaline rings,

[0075] (9). tricyclic compounds wherein the ring shown by A in the compound represented by the formula (I) is selected from the group consisting of an oxazole, thiazole, imidazole, pyrazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline and quinoxaline rings,

[0076] (10). tricyclic compounds wherein the ring shown by A in the compound represented by the formula (I) is selected from the group consisting of a thiazole, thiadiazole, pyridine, pyrimidine, benzoxazole, benzothiazole, quinoline and quinazoline rings,

[0077] (11). tricyclic compounds wherein the ring shown by A in the compound represented by the formula (I) is selected from the group consisting of a pyridine, benzothiazole and quinoline rings,

[0078] (12). tricyclic compounds wherein the heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent(s) selected from a fluorine, chlorine, bromine atom, a nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, methoxy, ethoxy, propoxy, isopropoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, methylthio, ethylthio, propylthio, isopropylthio, trimethylene and tetramethylene groups,

[0079] (13). tricyclic compounds wherein the heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent(s) selected from a fluorine, chlorine atom, a nitro, cyano, methyl, ethyl, isopropyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, ethylthio, trimethylene and tetramethylene groups,

[0080] (14). tricyclic compounds wherein the heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent(s) selected from a fluorine, chlorine atom, a nitro, cyano, methyl, isopropyl, t-butyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, methylthio and tetramethylene groups,

[0081] (15). tricyclic compounds wherein the heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent(s) selected from a fluorine, chlorine atom, a trifluoromethyl and tetramethylene groups,

[0082] (16). tricyclic compounds wherein A in the compound represented by the formula (I) is selected from the group consisting of a 2-oxazolyl, 2-thiazolyl, 2- or 4-imidazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2- or 4-pyrimidinyl, 3-pyridazinyl, 2-pyrazinyl, 2-benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, quinolin-2-yl, quinazolin-2-yl, quinoxaline-2-yl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-ethyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-diethyl-2-pyridyl, 6-trifluoromethyl-2-pyridyl, 6-methylthio-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidine-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzo-thiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoro-quinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoro-quinazolin-2-yl, 7-chloro-5-fluoroquinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl and 5,6,7-trifluoroquinazolin-2-yl groups,

[0083] (17). tricyclic compounds wherein A in the compound represented by the formula (I) is selected from the group consisting of a 2-thiazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzothiazolyl, quinolin-2-yl, quinazolin-2-yl, 4-methyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidine-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzo-thiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzo-thiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoro-quinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyanoquinolin-2-yl, 7-cyano-6-fluoro-quinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoro-quinazolin-2-yl, 7-chloro-5-fluoroquinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl and 5,6,7-trifluoro-quinazolin-2-yl groups,

[0084] (18). tricyclic compounds where in A in the compound represented by the formula (I) is selected from the group consisting of a 2-pyridyl, 2-benzothiazolyl, quinolin-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6,7,8-tetrahydroquinolin-2-yl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzo-thiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl and 5,6,7-trifluoroquinolin-2-yl groups,

[0085] (19). tricyclic compounds wherein A in the compound represented by the formula (I) is selected from the group consisting of a 7-fluoroquinolin-2-yl, 7-chloroquinolin-2-yl, 6,7-difluoro-quinolin-2-yl, 6,7-dichloroquinolin-2-yl, 7-chloro-6-fluoro-quinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl and 5,6,7,8-tetrahydroquinolin-2-yl groups,

[0086] (20). tricyclic compounds wherein B in the formula (I) is a formula: —OCH2—, a formula: —CH2O— or a formula: —CH2CH2—,

[0087] (21). tricyclic compounds wherein X in the formula (I) is a methylene group, a sulfur or an oxygen atom,

[0088] (22). tricyclic compounds wherein Y in the formula (I) is, selected from the group consisting of a methylene, ethylene, trimethylene, tetramethylene, pentamethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-methoxyethylene, 2-methoxyethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 2,2-diethyltrimethylene, 2-methoxytrimethylene, 3-methoxytrimethylene, 2,2-dimethoxytrimethylene, 3,3-dimethoxytrimethylene, 1,2-phenylene, 1,3-phenylene group, a group shown by a group (a) wherein o=0, p=0 and q=1, a group wherein o=0, p=1 and q=1, a group wherein o=0, p=1 and q=2, a group wherein o=1, p=0 and q=1, a group wherein o=1, p=1 and q=1 and a group wherein o=1, p=1 and q=2,

[0089] (23). tricyclic compounds wherein Y in the formula (I) is selected from the group consisting of a methylene, ethylene, trimethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene group, in a group shown by the formula (a), a group wherein o=1, p=0 and q=1, a group wherein o=1, p=1 and q=1 and a group wherein o=1, p=1 and q=2,

[0090] (24). tricyclic compounds wherein Y in the formula (I) is selected from the group consisting of a methylene, ethylene, trimethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 2,2-difluorotrimethylene, 1-methyltrimethylene, 2-methyl-trimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene and in a group shown by the formula (a), a group wherein o=1, p=1 and q=1,

[0091] (25). tricyclic compounds wherein Y in the formula (I) is selected from the group consisting of a methylene, ethylene, trimethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1,2-phenylene and in a group shown by the formula (a), a group wherein o=1, p=1 and q=1,

[0092] (26). tricyclic compounds wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a 1H-tetrazol-5-yl, a formula: —SO3H, methanesulfonylamino, ethanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, p-fluorophenylsulfonylamino, p-chlorophenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, p-trifluoromethylphenylsulfonylamino, o-methoxyphenylsulfonylamino, p-methoxyphenylsulfonylamino, p-difluoromethoxyphenylsulfonylamino, p-trifluoromethoxyphenylsulfonylamino, p-nitrophenylsulfonylamino, p-cyanophenylsulfonylamino, methanesulfonylaminocarbonyl, ethanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, p-fluorophenylsulfonylaminocarbonyl, p-chlorophenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl, p-methylphenylsulfonylaminocarbonyl, p-trifluoromethylphenylsulfonylaminocarbonyl, o-methoxyphenylsulfonylaminocarbonyl, p-methoxyphenylsulfonylaminocarbonyl, p-difluoromethoxyphenylsulfonylaminocarbonyl, p-trifluoromethoxyphenylsulfonylaminocarbonyl, p-nitrophenylsulfonylaminocarbonyl and p-cyanophenylsulfonylaminocarbonyl groups,

[0093] (27). tricyclic compounds wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a 1H-tetrazol-5-yl, a formula: —SO3H, methanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, methanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl and p-methylphenylsulfonylaminocarbonyl groups,

[0094] (28). tricyclic compounds wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a formula: —SO3H, methanesulfonylamino, trifluoromethanesulfonylamino, methanesulfonylaminocarbonyl and trifluoromethanesulfonylaminocarbonyl groups,

[0095] (29). tricyclic compounds wherein m in the formula (I) is an integer of 1, 2 or 3,

[0096] (30). tricyclic compounds wherein n in the formula (I) is an integer of 1 or 2,1

[0097] and with regard to R1, a preferred order raises from (1) to (5) in this order, with regard to R2, a preferred order raises from (6) to (8) in this order, with regard to A, a preferred order raises from (9) to (12), from (13) to (16) and from (17) to (20) in this order, with regard to Y, a preferred order raises from (23) to (26) in this order, with regard to Z, a preferred order raises from (27) to (29) in this order.

[0098] Also, as the tricyclic compounds having the above-mentioned formula (I), tricyclic compounds comprising the combination of two or more of the above-mentioned (1) to (30) are also preferred.

[0099] As the preferred compounds in the Compound (I), the compounds shown in the following Table 1 can be specifically exemplified.

TABLE 1
4
No.	A	B	(R2)n	(R1)m	X—Y—Z
1	6, 7-diF-Q	—OCH2—	H	H	—OCH2COOH
2	6, 7-diF-Q	—OCH2—	H	H	—OCH2CH2COOH
3	6, 7-diF-Q	—OCH2—	H	H	—OCH2CH(CH3)COOH
4	6, 7-diF-Q	—OCH2—	H	H	—OCH2C(CH2CH2)CH2COOH
5	6, 7-diF-Q	—OCH2—	H	H	—SCH2COOH
6	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2COOH
7	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
8	6, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
9	6, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH2CH2)COOH
10	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH(CH2CH3)COOH
11	6, 7-diF-Q	—OCH2—	H	H	—SCH(CH3)CH2COOH
12	6, 7-diF-Q	—OCH2—	H	H	—SC(CH3)2CH2COOH
13	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH(CH3)CH2COOH
14	6, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
15	6, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH2)CCOOH
16	6, 7-diF-Q	—OCH2—	H	H	—S(2-COOH—Ph)
17	6, 7-diF-Q	—OCH2—	H	H	—S(3-COOH—Ph)
18	6, 7-diF-Q	—OCH2—	H	H	—S(4-COOH—Ph)
19	6, 7-diF-Q	—OCH2—	H	H	—SCH2-Tet
20	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2-Tet
21	6, 7-diF-Q	—OCH2—	H	H	—SCH2NHSO2CF3
22	6, 7-diF-Q	—OCH2—	H	H	—SCH2CONHSO2CH3
23	6, 7-diF-Q	—OCH2—	H	H	—SCH2CONHSO2CF3
24	6, 7-diF-Q	—OCH2—	H	H	—SCH2CONHSO2Ph
25	6, 7-diF-Q	—OCH2—	H	H	—SCH2CONHSO2(2-CH3—Ph)
26	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2NHSO2CF3
27	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2CONHSO2CH3
28	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2CONHSO2CF3
29	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2CONHSO2Ph
30	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2CONHSO2(2-CH3—Ph)
31	6, 7-diF-Q	—OCH2—	H	H	—SCH2CH2SO3H
32	6, 7-diF-Q	—OCH2—	H	H	—CH2CH2CH2COOH
33	6, 7-diF-Q	—OCH2—	H	H	═CHCH2CH2COOH
34	6, 7-diF-Q	—OCH2—	H	H	═CHCH═CHCOOH
35	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2COOH
36	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2CH2COOH
37	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2CH(CH3)COOH
38	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2CH(CH2CH3)COOH
39	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2C(CH3)2COOH
40	6, 7-diF-Q	—OCH2—	H	7-F	—SC(CH3)2CH2COOH
41	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2CH(CH3)CH2COOH
42	6, 7-diF-Q	—OCH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
43	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2COOH
44	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2CH2COOH
45	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2CH(CH3)COOH
46	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2CH(CH2CH3)COOH
47	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2C(CH3)2COOH
48	6, 7-diF-Q	—OCH2—	H	8-F	—SC(CH3)2CH2COOH
49	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2CH(CH3)CH2COOH
50	6, 7-diF-Q	—OCH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
51	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2COOH
52	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2CH2COOH
53	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2CH(CH3)COOH
54	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2CH(CH2CH3)COOH
55	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2C(CH3)2COOH
56	6, 7-diF-Q	—OCH2—	H	9-F	—SC(CH3)2CH2COOH
57	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2CH(CH3)CH2COOH
58	6, 7-diF-Q	—OCH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
59	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2COOH
60	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2CH2COOH
61	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2CH(CH3)COOH
62	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2CH(CH2CH3)COOH
63	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2C(CH3)2COOH
64	6, 7-diF-Q	—OCH2—	H	7-CN	—SC(CH3)2CH2COOH
65	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2CH(CH3)CH2COOH
66	6, 7-diF-Q	—OCH2—	H	7-CN	—SCH2C(CH2CH2)CH2COOH
67	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2COOH
68	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2CH2COOH
69	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2CH(CH3)COOH
70	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2CH(CH2CH3)COOH
71	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2C(CH3)2COOH
72	6, 7-diF-Q	—OCH2—	H	8-CN	—SC(CH3)2CH2COOH
73	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2CH(CH3)CH2COOH
74	6, 7-diF-Q	—OCH2—	H	8-CN	—SCH2C(CH2CH2)CH2COOH
75	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2COOH
76	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2CH2COOH
77	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2CH(CH3)COOH
78	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2CH(CH2CH3)COOH
79	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2C(CH3)2COOH
80	6, 7-diF-Q	—OCH2—	H	9-CN	—SC(CH3)2CH2COOH
81	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2CH(CH3)CH2COOH
82	6, 7-diF-Q	—OCH2—	H	9-CN	—SCH2C(CH2CH2)CH2COOH
83	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2COOH
84	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2CH2COOH
85	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2CH(CH3)COOH
86	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2CH(CH2CH3)COOH
87	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2C(CH3)2COOH
88	6, 7-diF-Q	—OCH2—	H	7-CF3	—SC(CH3)2CH2COOH
89	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2CH(CH3)CH2COOH
90	6, 7-diF-Q	—OCH2—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
91	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2COOH
92	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2CH2COOH
93	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2CH(CH3)COOH
94	6, 7-diF-Q	—OCH3—	H	8-CF3	—SCH2CH(CH2CH3)COOH
95	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2C(CH3)2COOH
96	6, 7-diF-Q	—OCH2—	H	8-CF3	—SC(CH3)2CH2COOH
97	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2CH(CH3)CH2COOH
98	6, 7-diF-Q	—OCH2—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
99	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2COOH
100	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2CH2COOH
101	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2CH(CH3)COOH
102	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2CH(CH2CH3)COOH
103	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2C(CH3)2COOH
104	6, 7-diF-Q	—OCH2—	H	9-CF3	—SC(CH3)2CH2COOH
105	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2CH(CH3)CH2COOH
106	6, 7-diF-Q	—OCH2—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
107	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2COOH
108	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2CH2COOH
109	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2CH(CH3)COOH
110	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2CH(CH2CH3)COOH
111	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2C(CH3)2COOH
112	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SC(CH3)2CH2COOH
113	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2CH(CH3)CH2COOH
114	6, 7-diF-Q	—OCH2—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
115	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2COOH
116	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2CH2COOH
117	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2CH(CH3)COOH
118	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2CH(CH2CH3)COOH
119	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2C(CH3)2COOH
120	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SC(CH3)2CH2COOH
121	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2CH(CH3)CH2COOH
122	6, 7-diF-Q	—OCH2—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
123	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2COOH
124	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2CH2COOH
125	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2CH(CH3)COOH
126	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2CH(CH2CH3)COOH
127	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2C(CH3)2COOH
128	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SC(CH3)2CH2COOH
129	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2CH(CH3)CH2COOH
130	6, 7-diF-Q	—OCH2—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
131	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2COOH
132	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2CH2COOH
133	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
134	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
135	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
136	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SC(CH3)2CH2COOH
137	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
138	6, 7-diF-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
139	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2COOH
140	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH2COOH
141	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
142	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
143	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
144	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SC(CH3)2CH2COOH
145	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
146	6, 7-diF-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
147	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2COOH
148	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH2COOH
149	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
150	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
151	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
152	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SC(CH3)2CH2COOH
153	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
154	6, 7-diF-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
155	6-F, 7-Cl-Q	—OCH2—	H	H	—SCH2CH2COOH
156	6-F, 7-Cl-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
157	6-F, 7-Cl-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
158	6-F, 7-Cl-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
159	6-F, 7-Cl-Q	—OCH2—	H	7-F	—SCH2CH2COOH
160	6-F, 7-Cl-Q	—OCH2—	H	7-F	—SCH2CH(CH3)COOH
161	6-F, 7-Cl-Q	—OCH2—	H	7-F	—SCH2C(CH3)2COOH
162	6-F, 7-Cl-Q	—OCH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
163	6-F, 7-Cl-Q	—OCH2—	H	8-F	—SCH2CH2COOH
164	6-F, 7-Cl-Q	—OCH2—	H	8-F	—SCH2CH(CH3)COOH
165	6-F, 7-Cl-Q	—OCH2—	H	8-F	—SCH2C(CH3)2COOH
166	6-F, 7-Cl-Q	—OCH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
167	6-F, 7-Cl-Q	—OCH2—	H	9-F	—SCH2CH2COOH
168	6-F, 7-Cl-Q	—OCH2—	H	9-F	—SCH2CH(CH3)COOH
169	6-F, 7-Cl-Q	—OCH2—	H	9-F	—SCH2C(CH3)2COOH
170	6-F, 7-Cl-Q	—OCH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
171	7-F-Q	—OCH2—	H	H	—SCH2CH2COOH
172	7-F-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
173	7-F-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
174	7-F-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
175	7-F-Q	—OCH2—	H	7-F	—SCH2CH2COOH
176	7-F-Q	—OCH2—	H	7-F	—SCH2CH(CH3)COOH
177	7-F-Q	—OCH2—	H	7-F	—SCH2C(CH3)2COOH
178	7-F-Q	—OCH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
179	7-F-Q	—OCH2—	H	8-F	—SCH2CH2COOH
180	7-F-Q	—OCH2—	H	8-F	—SCH2CH(CH3)COOH
181	7-F-Q	—OCH2—	H	8-F	—SCH2C(CH3)2COOH
182	7-F-Q	—OCH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
183	7-F-Q	—OCH2—	H	9-F	—SCH2CH2COOH
184	7-F-Q	—OCH2—	H	9-F	—SCH2CH(CH3)COOH
185	7-F-Q	—OCH2—	H	9-F	—SCH2C(CH3)2COOH
186	7-F-Q	—OCH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
187	7-F-Q	—OCH2—	H	7-C≡CH	—SCH2CH2COOH
188	7-F-Q	—OCH2—	H	7-C≡CH	—SCH2CH(CH3)COOH
189	7-F-Q	—OCH2—	H	7-C≡CH	—SCH2C(CH3)2COOH
190	7-F-Q	—OCH2—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
191	7-F-Q	—OCH2—	H	8-C≡CH	—SCH2CH2COOH
192	7-F-Q	—OCH2—	H	8-C≡CH	—SCH2CH(CH3)COOH
193	7-F-Q	—OCH2—	H	8-C≡CH	—SCH2C(CH3)2COOH
194	7-F-Q	—OCH2—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
195	7-F-Q	—OCH2—	H	9-C≡CH	—SCH2CH2COOH
196	7-F-Q	—OCH2—	H	9-C≡CH	—SCH2CH(CH3)COOH
197	7-F-Q	—OCH2—	H	9-C≡CH	—SCH2C(CH3)2COOH
198	7-F-Q	—OCH2—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
199	7-F-Q	—OCH2—	H	7-CF3	—SCH2CH2COOH
200	7-F-Q	—OCH2—	H	7-CF3	—SCH2CH(CH3)COOH
201	7-F-Q	—OCH2—	H	7-CF3	—SCH2C(CH3)2COOH
202	7-F-Q	—OCH2—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
203	7-F-Q	—OCH2—	H	8-CF3	—SCH2CH2COOH
204	7-F-Q	—OCH2—	H	8-CF3	—SCH2CH(CH3)COOH
205	7-F-Q	—OCH2—	H	8-CF3	—SCH2C(CH3)2COOH
206	7-F-Q	—OCH2—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
207	7-F-Q	—OCH2—	H	9-CF3	—SCH2CH2COOH
208	7-F-Q	—OCH2—	H	9-CF3	—SCH2CH(CH3)COOH
209	7-F-Q	—OCH2—	H	9-CF3	—SCH2C(CH3)2COOH
210	7-F-Q	—OCH2—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
211	7-F-Q	—OCH2—	H	7-C(CH3)2O	—SCH2CH2COOH
212	7-F-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
213	7-F-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
214	7-F-Q	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
215	7-F-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH2COOH
216	7-F-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
217	7-F-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
218	7-F-Q	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
219	7-F-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH2COOH
220	7-F-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
221	7-F-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
222	7-F-Q	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
223	7-Cl-Q	—OCH2—	H	H	—SCH2COOH
224	7-Cl-Q	—OCH2—	H	H	—SCH2CH2COOH
225	7-Cl-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
226	7-Cl-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
227	7-Cl-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
228	TQ	—OCH2—	H	H	—SCH2COOH
229	TQ	—OCH2—	H	H	—SCH2CH2COOH
230	TQ	—OCH2—	H	H	—SCH2CH(CH3)COOH
231	TQ	—OCH2—	H	H	—SCH2CH(CH2CH3)COOH
232	TQ	—OCH2—	H	H	—SCH2C(CH3)2COOH
233	TQ	—OCH2—	H	H	—SC(CH3)2CH2COOH
234	TQ	—OCH2—	H	H	—SCH2CH(CH3)CH2COOH
235	TQ	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
236	TQ	—OCH2—	H	7-F	—SCH2COOH
237	TQ	—OCH2—	H	7-F	—SCH2CH2COOH
238	TQ	—OCH2—	H	7-F	—SCH2CH(CH3)COOH
239	TQ	—OCH2—	H	7-F	—SCH2CH(CH2CH3)COOH
240	TQ	—OCH2—	H	7-F	—SCH2C(CH3)2COOH
241	TQ	—OCH2—	H	7-F	—SC(CH3)2CH2COOH
242	TQ	—OCH2—	H	7-F	—SCH2CH(CH3)CH2COOH
243	TQ	—OCH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
244	TQ	—OCH2—	H	8-F	—SCH2COOH
245	TQ	—OCH2—	H	8-F	—SCH2CH2COOH
246	TQ	—OCH2—	H	8-F	—SCH2CH(CH3)COOH
247	TQ	—OCH2—	H	8-F	—SCH2CH(CH2CH3)COOH
248	TQ	—OCH2—	H	8-F	—SCH2C(CH3)2COOH
249	TQ	—OCH2—	H	8-F	—SC(CH3)2CH2COOH
250	TQ	—OCH2—	H	8-F	—SCH2CH(CH3)CH2COOH
251	TQ	—OCH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
252	TQ	—OCH2—	H	9-F	—SCH2COOH
253	TQ	—OCH2—	H	9-F	—SCH2CH2COOH
254	TQ	—OCH2—	H	9-F	—SCH2CH(CH3)COOH
255	TQ	—OCH2—	H	9-F	—SCH2CH(CH2CH3)COOH
256	TQ	—OCH2—	H	9-F	—SCH2C(CH3)2COOH
257	TQ	—OCH2—	H	9-F	—SC(CH3)2CH2COOH
258	TQ	—OCH2—	H	9-F	—SCH2CH(CH3)CH2COOH
259	TQ	—OCH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
260	TQ	—OCH2—	H	7-C≡CH	—SCH2COOH
261	TQ	—OCH2—	H	7-C≡CH	—SCH2CH2COOH
262	TQ	—OCH2—	H	7-C≡CH	—SCH2CH(CH3)COOH
263	TQ	—OCH2—	H	7-C≡CH	—SCH2CH(CH2CH3)COOH
264	TQ	—OCH2—	H	7-C≡CH	—SCH2C(CH3)2COOH
265	TQ	—OCH2—	H	7-C≡CH	—SC(CH3)2CH2COOH
266	TQ	—OCH2—	H	7-C≡CH	—SCH2CH(CH3)CH2COOH
267	TQ	—OCH2—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
268	TQ	—OCH2—	H	8-C≡CH	—SCH2COOH
269	TQ	—OCH2—	H	8-C≡CH	—SCH2CH2COOH
270	TQ	—OCH2—	H	8-C≡CH	—SCH2CH(CH3)COOH
271	TQ	—OCH2—	H	8-C≡CH	—SCH2CH(CH2CH3)COOH
272	TQ	—OCH2—	H	8-C≡CH	—SCH2C(CH3)2COOH
273	TQ	—OCH2—	H	8-C≡CH	—SC(CH3)2CH2COOH
274	TQ	—OCH2—	H	8-C≡CH	—SCH2CH(CH3)CH2COOH
275	TQ	—OCH2—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
276	TQ	—OCH2—	H	9-C≡CH	—SCH2COOH
277	TQ	—OCH2—	H	9-C≡CH	—SCH2CH2COOH
278	TQ	—OCH2—	H	9-C≡CH	—SCH2CH(CH3)COOH
279	TQ	—OCH2—	H	9-C≡CH	—SCH2CH(CH2CH3)COOH
280	TQ	—OCH2—	H	9-C≡CH	—SCH2C(CH3)2COOH
281	TQ	—OCH2—	H	9-C≡CH	—SC(CH3)2CH2COOH
282	TQ	—OCH2—	H	9-C≡CH	—SCH2CH(CH3)CH2COOH
283	TQ	—OCH2—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
284	TQ	—OCH2—	H	7-CF3	—SCH2COOH
285	TQ	—OCH2—	H	7-CF3	—SCH2CH2COOH
286	TQ	—OCH2—	H	7-CF3	—SCH2CH(CH3)COOH
287	TQ	—OCH2—	H	7-CF3	—SCH2CH(CH2CH3)COOH
288	TQ	—OCH2—	H	7-CF3	—SCH2C(CH3)2COOH
289	TQ	—OCH2—	H	7-CF3	—SC(CH3)2CH2COOH
290	TQ	—OCH2—	H	7-CF3	—SCH2CH(CH3)CH2COOH
291	TQ	—OCH2—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
292	TQ	—OCH2—	H	8-CF3	—SCH2COOH
293	TQ	—OCH2—	H	8-CF3	—SCH2CH2COOH
294	TQ	—OCH2—	H	8-CF3	—SCH2CH(CH3)COOH
295	TQ	—OCH2—	H	8-CF3	—SCH2CH(CH2CH3)COOH
296	TQ	—OCH2—	H	8-CF3	—SCH2C(CH3)2COOH
297	TQ	—OCH2—	H	8-CF3	—SC(CH3)2CH2COOH
298	TQ	—OCH2—	H	8-CF3	—SCH2CH(CH3)CH2COOH
299	TQ	—OCH2—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
300	TQ	—OCH2—	H	9-CF3	—SCH2COOH
301	TQ	—OCH2—	H	9-CF3	—SCH2CH2COOH
302	TQ	—OCH2—	H	9-CF3	—SCH2CH(CH3)COOH
303	TQ	—OCH2—	H	9-CF3	—SCH2CH(CH2CH3)COOH
304	TQ	—OCH2—	H	9-CF3	—SCH2C(CH3)2COOH
305	TQ	—OCH2—	H	9-CF3	—SC(CH3)2CH2COOH
306	TQ	—OCH2—	H	9-CF3	—SCH2CH(CH3)CH2COOH
307	TQ	—OCH2—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
308	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2COOH
309	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2CH2COOH
310	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
311	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
312	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
313	TQ	—OCH2—	H	7-C(CH3)2OH	—SC(CH3)2CH2COOH
314	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
315	TQ	—OCH2—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
316	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2COOH
317	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2CH2COOH
318	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
319	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
320	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
321	TQ	—OCH2—	H	8-C(CH3)2OH	—SC(CH3)2CH2COOH
322	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
323	TQ	—OCH2—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
324	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2COOH
325	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2CH2COOH
326	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
327	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
328	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
329	TQ	—OCH2—	H	9-C(CH3)2OH	—SC(CH3)2CH2COOH
330	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
331	TQ	—OCH2—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
332	Q	—OCH2—	H	H	—SCH2CH2COOH
333	Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
334	Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
335	Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
336	4-Cl-Q	—OCH2—	H	H	—SCH2CH2COOH
337	4-Cl-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
338	4-Cl-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
339	4-Cl-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
340	5-F-Q	—OCH2—	H	H	—SCH2CH2COOH
341	5-F-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
342	5-F-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
343	5-F-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
344	7-CF3-Q	—OCH2—	H	H	—SCH2CH2COOH
345	7-CF3-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
346	7-CF3-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
347	7-CF3-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
348	5, 7-diF-Q	—OCH2—	H	H	—SCH2CH2COOH
349	5, 7-diF-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
350	5, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
351	5, 7-diF-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
352	6-F, 7-CF3-Q	—OCH2—	H	H	—SCH2CH2COOH
353	6-F, 7-CF3-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
354	6-F, 7-CF3-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
355	6-F, 7-CF3-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
356	5, 6, 7-triF-Q	—OCH2—	H	H	—SCH2CH2COOH
357	5, 6, 7-triF-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
358	5, 6, 7-triF-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
359	5, 6, 7-triF-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
360	4-t-Bu-T	—OCH2—	H	H	—SCH2CH2COOH
361	4-t-Bu-T	—OCH2—	H	H	—SCH2CH(CH3)COOH
362	4-t-Bu-T	—OCH2—	H	H	—SCH2C(CH3)2COOH
363	4-t-Bu-T	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
364	5-F-BT	—OCH2—	H	H	—SCH2CH2COOH
365	5-F-BT	—OCH2—	H	H	—SCH2CH(CH3)COOH
366	5-F-BT	—OCH2—	H	H	—SCH2C(CH3)2COOH
367	5-F-BT	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
368	5, 6-diF-BT	—OCH2—	H	H	—SCH2CH2COOH
369	5, 6-diF-BT	—OCH2—	H	H	—SCH2CH(CH3)COOH
370	5, 6-diF-BT	—OCH2—	H	H	—SCH2C(CH3)2COOH
371	5, 6-diF-BT	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
372	5-F-BO	—OCH2—	H	H	—SCH2CH2COOH
373	5-F-BO	—OCH2—	H	H	—SCH2CH(CH3)COOH
374	5-F-BO	—OCH2—	H	H	—SCH2C(CH3)2COOH
375	5-F-BO	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
376	6-t-Bu-Py	—OCH2—	H	H	—SCH2CH2COOH
377	6-t-Bu-Py	—OCH2—	H	H	—SCH2CH(CH3)COOH
378	6-t-Bu-Py	—OCH2—	H	H	—SCH2C(CH3)2COOH
379	6-t-Bu-Py	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
380	5-Me, 6-i-Pr-Py	—OCH2—	H	H	—SCH2CH2COOH
381	5-Me, 6-i-Pr-Py	—OCH2—	H	H	—SCH2CH(CH3)COOH
382	5-Me, 6-i-Pr-Py	—OCH2—	H	H	—SCH2C(CH3)2COOH
383	5-Me, 6-i-Pr-Py	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
384	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2CH2COOH
385	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2CH(CH3)COOH
386	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2C(CH3)2COOH
387	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2C(CH2CH2)CH2COOH
388	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2CH2COOH
389	6-F, 7-Cl-Q	—CH2CH2—	H	H	—SCH2CH(CH3)COOH
390	6-F, 7-Cl-Q	—CH2CH2—	H	H	—SCH2C(CH3)2COOH
391	6-F, 7-Cl-Q	—CH2CH2—	H	H	—SCH2C(CH2CH2)CH2COOH
392	7-F-Q	—CH2CH2—	H	H	—SCH2CH2COOH
393	7-F-Q	—CH2CH2—	H	H	—SCH2CH(CH3)COOH
394	7-F-Q	—CH2CH2—	H	H	—SCH2C(CH3)2COOH
395	7-F-Q	—CH2CH2—	H	H	—SCH2C(CH2CH2)CH2COOH
396	TQ	—CH2CH2—	H	H	—SCH2CH2COOH
397	TQ	—CH2CH2—	H	H	—SCH2CH(CH3)COOH
398	TQ	—CH2CH2—	H	H	—SCH2C(CH3)2COOH
399	TQ	—CH2CH2—	H	H	—SCH2C(CH2CH2)CH2COOH
400	6, 7-diF-Q	—SCH2—	H	H	—SCH2CH2COOH
401	6, 7-diF-Q	—SCH2—	H	H	—SCH2CH(CH3)COOH
402	6, 7-diF-Q	—SCH2—	H	H	—SCH2C(CH3)2COOH
403	6, 7-diF-Q	—SCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
404	6, 7-diF-Q	—CH2O—	H	H	—SCH2CH2COOH
405	6, 7-diF-Q	—CH2O—	H	H	—SCH2CH(CH3)COOH
406	6, 7-diF-Q	—CH2O—	H	H	—SCH2C(CH3)2COOH
407	6, 7-diF-Q	—CH2O—	H	H	—SCH2C(CH2CH2)CH2COOH
408	6, 7-diF-Q	—CH2S—	H	H	—SCH2CH2COOH
409	6, 7-diF-Q	—CH2S—	H	H	—SCH2CH(CH3)COOH
410	6, 7-diF-Q	—CH2S—	H	H	—SCH2C(CH3)2COOH
411	6, 7-diF-Q	—CH2S—	H	H	—SCH2C(CH2CH2)CH2COOH
412	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2COOH
413	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2CH2COOH
414	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2CH(CH3)COOH
415	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2CH(CH2CH3)COOH
416	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2C(CH3)2COOH
417	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SC(CH3)2CH2COOH
418	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2CH(CH3)CH2COOH
419	6, 7-diF-Q	—OCH2—	H	7-CH2OH	—SCH2C(CH2CH2)CH2COOH
420	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2COOH
421	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2CH2COOH
422	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2CH(CH3)COOH
423	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2CH(CH2CH3)COOH
424	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2C(CH3)2COOH
425	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SC(CH3)2CH2COOH
426	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2CH(CH3)CH2COOH
427	6, 7-diF-Q	—OCH2—	H	8-CH2OH	—SCH2C(CH2CH2)CH2COOH
428	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2COOH
429	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2CH2COOH
430	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2CH(CH3)COOH
431	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2CH(CH2CH3)COOH
432	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2C(CH3)2COOH
433	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SC(CH3)2CH2COOH
434	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2CH(CH3)CH2COOH
435	6, 7-diF-Q	—OCH2—	H	9-CH2OH	—SCH2C(CH2CH2)CH2COOH
436	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2COOH
437	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2CH2COOH
438	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2CH(CH3)COOH
439	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2CH(CH2CH3)COOH
440	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2C(CH3)2COOH
441	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SC(CH3)2CH2COOH
442	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2CH(CH3)CH2COOH
443	6, 7-diF-Q	—OCH2—	H	7-CH═CH2	—SCH2C(CH2CH2)CH2COOH
444	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2COOH
445	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2CH2COOH
446	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2CH(CH3)COOH
447	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2CH(CH2CH3)COOH
448	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2C(CH3)2COOH
449	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SC(CH3)2CH2COOH
450	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2CH(CH3)CH2COOH
451	6, 7-diF-Q	—OCH2—	H	8-CH═CH2	—SCH2C(CH2CH2)CH2COOH
452	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2COOH
453	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2CH2COOH
454	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2CH(CH3)COOH
455	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2CH(CH2CH3)COOH
456	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2C(CH3)2COOH
457	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SC(CH3)2CH2COOH
458	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2CH(CH3)CH2COOH
459	6, 7-diF-Q	—OCH2—	H	9-CH═CH2	—SCH2C(CH2CH2)CH2COOH
460	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2COOH
461	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2CH2COOH
462	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2CH(CH3)COOH
463	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2CH(CH2CH3)COOH
464	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2C(CH3)2COOH
465	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SC(CH3)2CH2COOH
466	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2CH(CH3)CH2COOH
467	6, 7-diF-Q	—OCH2—	H	7-OCH3	—SCH2C(CH2CH2)CH2COOH
468	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2COOH
469	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2CH2COOH
470	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2CH(CH3)COOH
471	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2CH(CH2CH3)COOH
472	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2C(CH3)2COOH
473	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SC(CH3)2CH2COOH
474	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2CH(CH3)CH2COOH
475	6, 7-diF-Q	—OCH2—	H	8-OCH3	—SCH2C(CH2CH2)CH2COOH
476	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2COOH
477	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2CH2COOH
478	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2CH(CH3)COOH
479	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2CH(CH2CH3)COOH
480	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2C(CH3)2COOH
481	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SC(CH3)2CH2COOH
482	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2CH(CH3)CH2COOH
483	6, 7-diF-Q	—OCH2—	H	9-OCH3	—SCH2C(CH2CH2)CH2COOH
484	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2COOH
485	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2CH2COOH
486	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2CH(CH3)COOH
487	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2CH(CH2CH3)COOH
488	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2C(CH3)2COOH
489	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SC(CH3)2CH2COOH
490	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2CH(CH3)CH2COOH
491	6, 7-diF-Q	—OCH2—	H	7-OCHF2	—SCH2C(CH2CH2)CH2COOH
492	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2COOH
493	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2CH2COOH
494	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2CH(CH3)COOH
495	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2CH(CH2CH3)COOH
496	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2C(CH3)2COOH
497	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SC(CH3)2CH2COOH
498	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2CH(CH3)CH2COOH
499	6, 7-diF-Q	—OCH2—	H	8-OCHF2	—SCH2C(CH2CH2)CH2COOH
500	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2COOH
501	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2CH2COOH
502	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2CH(CH3)COOH
503	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2CH(CH2CH3)COOH
504	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2C(CH3)2COOH
505	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SC(CH3)2CH2COOH
506	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2CH(CH3)CH2COOH
507	6, 7-diF-Q	—OCH2—	H	9-OCHF2	—SCH2C(CH2CH2)CH2COOH
508	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2COOH
509	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2CH2COOH
510	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2CH(CH3)COOH
511	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2CH(CH2CH3)COOH
512	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2C(CH3)2COOH
513	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SC(CH3)2CH2COOH
514	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2CH(CH3)CH2COOH
515	6, 7-diF-Q	—OCH2—	H	7-OCF3	—SCH2C(CH2CH2)CH2COOH
516	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2COOH
517	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2CH2COOH
518	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2CH(CH3)COOH
519	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2CH(CH2CH3)COOH
520	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2C(CH3)2COOH
521	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SC(CH3)2CH2COOH
522	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2CH(CH3)CH2COOH
523	6, 7-diF-Q	—OCH2—	H	8-OCF3	—SCH2C(CH2CH2)CH2COOH
524	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2COOH
525	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2CH2COOH
526	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2CH(CH3)COOH
527	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2CH(CH2CH3)COOH
528	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2C(CH3)2COOH
529	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SC(CH3)2CH2COOH
530	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2CH(CH3)CH2COOH
531	6, 7-diF-Q	—OCH2—	H	9-OCF3	—SCH2C(CH2CH2)CH2COOH
532	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2COOH
533	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2CH2COOH
534	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2CH(CH3)COOH
535	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2CH(CH2CH3)COOH
536	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2C(CH3)2COOH
537	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SC(CH3)2CH2COOH
538	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2CH(CH3)CH2COOH
539	6, 7-diF-Q	—OCH2—	H	7-SOCH3	—SCH2C(CH2CH2)CH2COOH
540	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2COOH
541	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2CH2COOH
542	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2CH(CH3)COOH
543	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2CH(CH2CH3)COOH
544	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2C(CH3)2COOH
545	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SC(CH3)2CH2COOH
546	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2CH(CH3)CH2COOH
547	6, 7-diF-Q	—OCH2—	H	8-SOCH3	—SCH2C(CH2CH2)CH2COOH
548	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2COOH
549	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2CH2COOH
550	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2CH(CH3)COOH
551	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2CH(CH2CH3)COOH
552	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2C(CH3)2COOH
553	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SC(CH3)2CH2COOH
554	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2CH(CH3)CH2COOH
555	6, 7-diF-Q	—OCH2—	H	9-SOCH3	—SCH2C(CH2CH2)CH2COOH
556	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2COOH
557	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2CH2COOH
558	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2CH(CH3)COOH
559	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2CH(CH2CH3)COOH
560	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2C(CH3)2COOH
561	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SC(CH3)2CH2COOH
562	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2CH(CH3)CH2COOH
563	6, 7-diF-Q	—OCH2—	H	7-SO2CH3	—SCH2C(CH2CH2)CH2COOH
564	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2COOH
565	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2CH2COOH
566	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2CH(CH3)COOH
567	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2CH(CH2CH3)COOH
568	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2C(CH3)2COOH
569	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SC(CH3)2CH2COOH
570	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2CH(CH3)CH2COOH
571	6, 7-diF-Q	—OCH2—	H	8-SO2CH3	—SCH2C(CH2CH2)CH2COOH
572	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2COOH
573	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2CH2COOH
574	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2CH(CH3)COOH
575	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2CH(CH2CH3)COOH
576	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2C(CH3)2COOH
577	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SC(CH3)2CH2COOH
578	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2CH(CH3)CH2COOH
579	6, 7-diF-Q	—OCH2—	H	9-SO2CH3	—SCH2C(CH2CH2)CH2COOH
580	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2COOH
581	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2CH2COOH
582	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2CH(CH3)COOH
583	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2CH(CH2CH3)COOH
584	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2C(CH3)2COOH
585	6, 7-diF-Q	—OCH2—	1-F	H	—SC(CH3)2CH2COOH
586	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2CH(CH3)CH2COOH
587	6, 7-diF-Q	—OCH2—	1-F	H	—SCH2C(CH2CH2)CH2COOH
588	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2COOH
589	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2CH2COOH
590	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2CH(CH3)COOH
591	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2CH(CH2CH3)COOH
592	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2C(CH3)2COOH
593	6, 7-diF-Q	—OCH2—	3-F	H	—SC(CH3)2CH2COOH
594	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2CH(CH3)CH2COOH
595	6, 7-diF-Q	—OCH2—	3-F	H	—SCH2C(CH2CH2)CH2COOH
596	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2COOH
597	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2CH2COOH
598	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2CH(CH3)COOH
599	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2CH(CH2CH3)COOH
600	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2C(CH3)2COOH
601	6, 7-diF-Q	—OCH2—	4-F	H	—SC(CH3)2CH2COOH
602	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2CH(CH3)CH2COOH
603	6, 7-diF-Q	—OCH2—	4-F	H	—SCH2C(CH2CH2)CH2COOH
604	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2COOH
605	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2CH2COOH
606	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2CH(CH3)COOH
607	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2CH(CH2CH3)COOH
608	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2C(CH3)2COOH
609	6, 7-diF-Q	—OCH2—	1-Cl	H	—SC(CH3)2CH2COOH
610	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2CH(CH3)CH2COOH
611	6, 7-diF-Q	—OCH2—	1-Cl	H	—SCH2C(CH2CH2)CH2COOH
612	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2COOH
613	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2CH2COOH
614	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2CH(CH3)COOH
615	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2CH(CH2CH3)COOH
616	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2C(CH3)2COOH
617	6, 7-diF-Q	—OCH2—	3-Cl	H	—SC(CH3)2CH2COOH
618	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2CH(CH3)CH2COOH
619	6, 7-diF-Q	—OCH2—	3-Cl	H	—SCH2O(CH2CH2)CH2COOH
620	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2COOH
621	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2CH2COOH
622	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2CH(CH3)COOH
623	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2CH(CH2CH3)COOH
624	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2C(CH3)2COOH
625	6, 7-diF-Q	—OCH2—	4-Cl	H	—SC(CH3)2CH2COOH
626	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2CH(CH3)CH2COOH
627	6, 7-diF-Q	—OCH2—	4-Cl	H	—SCH2C(CH2CH2)CH2COOH
628	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2COOH
629	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2CH2COOH
630	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2CH(CH3)COOH
631	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2CH(CH2CH3)COOH
632	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2C(CH3)2COOH
633	6, 7-diF-Q	—OCH2—	1-NO2	H	—SC(CH3)2CH2COOH
634	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2CH(CH3)CH2COOH
635	6, 7-diF-Q	—OCH2—	1-NO2	H	—SCH2C(CH2CH2)CH2COOH
636	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2COOH
637	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2CH2COOH
638	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2CH(CH3)COOH
639	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2CH(CH2CH3)COOH
640	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2C(CH3)2COOH
641	6, 7-diF-Q	—OCH2—	3-NO2	H	—SC(CH3)2CH2COOH
642	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2CH(CH3)CH2COOH
643	6, 7-diF-Q	—OCH2—	3-NO2	H	—SCH2C(CH2CH2)CH2COOH
644	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2COOH
645	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2CH2COOH
646	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2CH(CH3)COOH
647	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2CH(CH2CH3)COOH
648	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2C(CH3)2COOH
649	6, 7-diF-Q	—OCH2—	4-NO2	H	—SC(CH3)2CH2COOH
650	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2CH(CH3)CH2COOH
651	6, 7-diF-Q	—OCH2—	4-NO2	H	—SCH2C(CH2CH2)CH2COOH
652	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2COOH
653	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2CH2COOH
654	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2CH(CH3)COOH
655	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2CH(CH2CH3)COOH
656	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2C(CH3)2COOH
657	6, 7-diF-Q	—OCH2—	1-CN	H	—SC(CH3)2CH2COOH
658	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2CH(CH3)CH2COOH
659	6, 7-diF-Q	—OCH2—	1-CN	H	—SCH2C(CH2CH2)CH2COOH
660	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2COOH
661	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2CH2COOH
662	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2CH(CH3)COOH
663	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2CH(CH2CH3)COOH
664	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2C(CH3)2COOH
665	6, 7-diF-Q	—OCH2—	3-CN	H	—SC(CH3)2CH2COOH
666	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2CH(CH3)CH2COOH
667	6, 7-diF-Q	—OCH2—	3-CN	H	—SCH2C(CH2CH2)CH2COOH
668	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2COOH
669	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2CH2COOH
670	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2CH(CH3)COOH
671	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2CH(CH2CH3)COOH
672	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2C(CH3)2COOH
673	6, 7-diF-Q	—OCH2—	4-CN	H	—SC(CH3)2CH2COOH
674	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2CH(CH3)CH2COOH
675	6, 7-diF-Q	—OCH2—	4-CN	H	—SCH2C(CH2CH2)CH2COOH
676	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2COOH
677	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2CH2COOH
678	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2CH(CH3)COOH
679	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2CH(CH2CH3)COOH
680	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2C(CH3)2COOH
681	6, 7-diF-Q	—OCH2—	1-CH3	H	—SC(CH3)2CH2COOH
682	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2CH(CH3)CH2COOH
683	6, 7-diF-Q	—OCH2—	1-CH3	H	—SCH2C(CH2CH2)CH2COOH
684	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2COOH
685	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2CH2COOH
686	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2CH(CH3)COOH
687	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2CH(CH2CH3)COOH
688	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2C(CH3)2COOH
689	6, 7-diF-Q	—OCH2—	3-CH3	H	—SC(CH3)2CH2COOH
690	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2CH(CH3)CH2COOH
691	6, 7-diF-Q	—OCH2—	3-CH3	H	—SCH2C(CH2CH2)CH2COOH
692	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2COOH
693	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2CH2COOH
694	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2CH(CH3)COOH
695	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2CH(CH2CH3)COOH
696	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2C(CH3)2COOH
697	6, 7-diF-Q	—OCH2—	4-CH3	H	—SC(CH3)2CH2COOH
698	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2CH(OHa)CH2COOH
699	6, 7-diF-Q	—OCH2—	4-CH3	H	—SCH2C(CH2CH2)CH2COOH
700	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2COOH
701	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2CH2COOH
702	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2CH(CH3)COOH
703	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2CH(CH2CH3)COOH
704	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2C(CH3)2COOH
705	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SC(CH3)2CH2COOH
706	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2CH(CH3)CH2COOH
707	6, 7-diF-Q	—OCH2—	1-OCH3	H	—SCH2C(CH2CH2)CH2COOH
708	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2COOH
709	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2CH2COOH
710	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2CH(CH3)COOH
711	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2CH(CH2CH3)COOH
712	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2C(CH3)2COOH
713	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SC(CH3)2CH2COOH
714	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2CH(CH3)CH2COOH
715	6, 7-diF-Q	—OCH2—	3-OCH3	H	—SCH2C(CH2CH2)CH2COOH
716	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2COOH
717	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2CH2COOH
718	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2CH(CH3)COOH
719	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2CH(CH2CH3)COOH
720	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2C(CH3)2COOH
721	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SC(CH3)2CH2COOH
722	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2CH(CH3)CH2COOH
723	6, 7-diF-Q	—OCH2—	4-OCH3	H	—SCH2C(CH2CH2)CH2COOH
724	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2COOH
725	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2CH(CH2CH3)COOH
726	6, 7-diF-Q	—CH2CH2—	H	H	—SC(CH3)2CH2COOH
727	6, 7-diF-Q	—CH2CH2—	H	H	—SCH2CH(CH3)CH2COOH
728	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2COOH
729	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2CH2COOH
730	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2CH(CH3)COOH
731	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2CH(CH2CH3)COOH
732	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2C(CH3)2COOH
733	6, 7-diF-Q	—CH2CH2—	H	7-F	—SC(CH3)2CH2COOH
734	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2CH(CH3)CH2COOH
735	6, 7-diF-Q	—CH2CH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
736	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2COOH
737	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2CH2COOH
738	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2CH(CH3)COOH
739	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2CH(CH2CH3)COOH
740	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2C(CH3)2COOH
741	6, 7-diF-Q	—CH2CH2—	H	8-F	—SC(CH3)2CH2COOH
742	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2CH(CH3)CH2COOH
743	6, 7-diF-Q	—CH2CH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
744	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2COOH
745	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2CH2COOH
746	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2CH(CH3)COOH
747	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2CH(CH2CH3)COOH
748	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2C(CH3)2COOH
749	6, 7-diF-Q	—CH2CH2—	H	9-F	—SC(CH3)2CH2COOH
750	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2CH(CH3)CH2COOH
751	6, 7-diF-Q	—CH2CH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
752	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2COOH
753	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2CH2COOH
754	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2CH(CH3)COOH
755	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2CH(CH2CH3)COOH
756	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2C(CH3)2COOH
757	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SC(CH3)2CH2COOH
758	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2CH(CH3)CH2COOH
759	6, 7-diF-Q	—CH2CH2—	H	7-CN	—SCH2C(CH2CH2)CH2COOH
760	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2COOH
761	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2CH2COOH
762	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2CH(CH3)COOH
763	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2CH(CH2CH3)COOH
764	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2C(CH3)2COOH
765	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SC(CH3)2CH2COOH
766	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2CH(CH3)CH2COOH
767	6, 7-diF-Q	—CH2CH2—	H	8-CN	—SCH2C(CH2CH2)CH2COOH
768	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2COOH
769	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2CH2COOH
770	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2CH(CH3)COOH
771	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2CH(CH2CH3)COOH
772	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2C(CH3)2COOH
773	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SC(CH3)2CH2COOH
774	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2CH(CH3)CH2COOH
775	6, 7-diF-Q	—CH2CH2—	H	9-CN	—SCH2C(CH2CH2)CH2COOH
776	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2COOH
777	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2CH2COOH
778	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2CH(CH3)COOH
779	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2CH(CH2CH3)COOH
780	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2C(CH3)2COOH
781	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SC(CH3)2CH2COOH
782	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2CH(CH3)CH2COOH
783	6, 7-diF-Q	—CH2CH2—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
784	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2COOH
785	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2CH2COOH
786	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2CH(CH3)COOH
787	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2CH(CH2CH3)COOH
788	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2C(CH3)2COOH
789	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SC(CH3)2CH2COOH
790	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2CH(CH3)CH2COOH
791	6, 7-diF-Q	—CH2CH2—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
792	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2COOH
793	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2CH2COOH
794	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2CH(CH3)COOH
795	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2CH(CH2CH3)COOH
796	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2C(CH3)2COOH
797	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SC(CH3)2CH2COOH
798	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2CH(CH3)CH2COOH
799	6, 7-diF-Q	—CH2CH2—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
800	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2COOH
801	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2CH2COOH
802	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH3)COOH
803	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH2CH3)COOH
804	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2C(CH3)2COOH
805	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SC(CH3)2CH2COOH
806	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH3)CH2COOH
807	6, 7-diF-Q	—CH2CH2—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
808	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2COOH
809	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2CH2COOH
810	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH3)COOH
811	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH2CH3)COOH
812	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2C(CH3)2COOH
813	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SC(CH3)2CH2COOH
814	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH3)CH2COOH
815	6, 7-diF-Q	—CH2CH2—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
816	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2COOH
817	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2CH2COOH
818	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH3)COOH
819	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH2CH3)COOH
820	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2C(CH3)2COOH
821	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SC(CH3)2CH2COOH
822	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH3)CH2COOH
823	6, 7-diF-Q	—CH2CH2—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
824	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2COOH
825	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH2COOH
826	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
827	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
828	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
829	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SC(CH3)2CH2COOH
830	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
831	6, 7-diF-Q	—CH2CH2—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
832	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2COOH
833	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH2COOH
834	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
835	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
836	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
837	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SC(CH3)2CH2COOH
838	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
839	6, 7-diF-Q	—CH2CH2—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
840	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2COOH
841	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH2COOH
842	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
843	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
844	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
845	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SC(CH3)2CH2COOH
846	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
847	6, 7-diF-Q	—CH2CH2—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
848	6, 7-diF-Q	—CH2O—	H	H	—SCH2COOH
849	6, 7-diF-Q	—CH2O—	H	H	—SCH2CH(CH2CH3)COOH
850	6, 7-diF-Q	—CH2O—	H	H	—SC(CH3)2CH2COOH
851	6, 7-diF-Q	—CH2O—	H	H	—SCH2CH(CH3)CH2COOH
852	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2COOH
853	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2CH2COOH
854	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2CH(CH3)COOH
855	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2CH(CH2CH3)COOH
856	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2C(CH3)2COOH
857	6, 7-diF-Q	—CH2O—	H	7-F	—SC(CH3)2CH2COOH
858	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2CH(CH3)CH2COOH
859	6, 7-diF-Q	—CH2O—	H	7-F	—SCH2C(CH2CH2)CH2COOH
860	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2COOH
861	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2CH2COOH
862	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2CH(CH3)COOH
863	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2CH(CH2CH3)COOH
864	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2C(CH3)2COOH
865	6, 7-diF-Q	—CH2O—	H	8-F	—SC(CH3)2CH2COOH
866	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2CH(CH3)CH2COOH
867	6, 7-diF-Q	—CH2O—	H	8-F	—SCH2C(CH2CH2)CH2COOH
868	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2COOH
869	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2CH2COOH
870	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2CH(CH3)COOH
871	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2CH(CH2CH3)COOH
872	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2C(CH3)2COOH
873	6, 7-diF-Q	—CH2O—	H	9-F	—SC(CH3)2CH2COOH
874	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2CH(CH3)CH2COOH
875	6, 7-diF-Q	—CH2O—	H	9-F	—SCH2C(CH2CH2)CH2COOH
876	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2COOH
877	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2CH2COOH
878	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2CH(CH3)COOH
879	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2CH(CH2CH3)COOH
880	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2C(CH3)2COOH
881	6, 7-diF-Q	—CH2O—	H	7-CN	—SC(CH3)2CH2COOH
882	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2CH(CH3)CH2COOH
883	6, 7-diF-Q	—CH2O—	H	7-CN	—SCH2C(CH2CH2)CH2COOH
884	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2COOH
885	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2CH2COOH
886	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2CH(CH3)COOH
887	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2CH(CH2CH3)COOH
888	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2C(CH3)2COOH
889	6, 7-diF-Q	—CH2O—	H	8-CN	—SC(CH3)2CH2COOH
890	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2CH(CH3)CH2COOH
891	6, 7-diF-Q	—CH2O—	H	8-CN	—SCH2C(CH2CH2)CH2COOH
892	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2COOH
893	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2CH2COOH
894	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2CH(CH3)COOH
895	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2CH(CH2CH3)COOH
896	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2C(CH3)2COOH
897	6, 7-diF-Q	—CH2O—	H	9-CN	—SC(CH3)2CH2COOH
898	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2CH(CH3)CH2COOH
899	6, 7-diF-Q	—CH2O—	H	9-CN	—SCH2C(CH2CH2)CH2COOH
900	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2COOH
901	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2CH2COOH
902	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2CH(CH3)COOH
903	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2CH(CH2CH3)COOH
904	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2C(CH3)2COOH
905	6, 7-diF-Q	—CH2O—	H	7-CF3	—SC(CH3)2CH2COOH
906	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2CH(CH3)CH2COOH
907	6, 7-diF-Q	—CH2O—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
908	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2COOH
909	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2CH2COOH
910	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2CH(CH3)COOH
911	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2CH(CH2CH3)COOH
912	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2C(CH3)2COOH
913	6, 7-diF-Q	—CH2O—	H	8-CF3	—SC(CH3)2CH2COOH
914	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2CH(CH3)CH2COOH
915	6, 7-diF-Q	—CH2O—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
916	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2COOH
917	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2CH2COOH
918	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2CH(CH3)COOH
919	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2CH(CH2CH3)COOH
920	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2C(CH3)2COOH
921	6, 7-diF-Q	—CH2O—	H	9-CF3	—SC(CH3)2CH2COOH
922	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2CH(CH3)CH2COOH
923	6, 7-diF-Q	—CH2O—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
924	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2COOH
925	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2CH2COOH
926	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2CH(CH3)COOH
927	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2CH(CH2CH3)COOH
928	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2C(CH3)2COOH
929	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SC(CH3)2CH2COOH
930	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2CH(CH3)CH2COOH
931	6, 7-diF-Q	—CH2O—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
932	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2COOH
933	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2CH2COOH
934	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2CH(CH3)COOH
935	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2CH(CH2CH3)COOH
936	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2C(CH3)2COOH
937	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SC(CH3)2CH2COOH
938	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2CH(CH3)CH2COOH
939	6, 7-diF-Q	—CH2O—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
940	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2COOH
941	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2CH2COOH
942	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2CH(CH3)COOH
943	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2CH(CH2CH3)COOH
944	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2C(CH3)2COOH
945	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SC(CH3)2CH2COOH
946	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2CH(CH3)CH2COOH
947	6, 7-diF-Q	—CH2O—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
948	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2COOH
949	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2CH2COOH
950	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
951	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
952	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
953	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SC(CH3)2CH2COOH
954	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
955	6, 7-diF-Q	—CH2O—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
956	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2COOH
957	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2CH2COOH
958	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
959	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
960	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
961	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SC(CH3)2CH2COOH
962	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
963	6, 7-diF-Q	—CH2O—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
964	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2COOH
965	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2CH2COOH
966	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
967	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
968	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
969	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SC(CH3)2CH2COOH
970	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
971	6, 7-diF-Q	—CH2O—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
972	6, 7-diCl-Q	—OCH2—	H	H	—SCH2COOH
973	6, 7-diCl-Q	—OCH2—	H	H	—SCH2CH2COOH
974	6, 7-diCl-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
975	6, 7-diCl-Q	—OCH2—	H	H	—SCH2CH(CH2CH3)COOH
976	6, 7-diCl-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
977	6, 7-diCl-Q	—OCH2—	H	H	—SC(CH3)2CH2COOH
978	6, 7-diCl-Q	—OCH2—	H	H	—SCH2CH(CH3)CH2COOH
979	6, 7-diCl-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
980	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2COOH
981	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2CH2COOH
982	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2CH(CH3)COOH
983	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2CH(CH2CH3)COOH
984	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2C(CH3)2COOH
985	6-Cl, 7-F-Q	—OCH2—	H	H	—SC(CH3)2CH2COOH
986	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2CH(CH3)CH2COOH
987	6-Cl, 7-F-Q	—OCH2—	H	H	—SCH2C(CH2CH2)CH2COOH
988	TQ	—CH2CH2—	H	H	—SCH2COOH
989	TQ	—CH2CH2—	H	H	—SCH2CH(CH2CH3)COOH
990	TQ	—CH2CH2—	H	H	—SC(CH3)2CH2COOH
991	TQ	—CH2CH2—	H	H	—SCH2CH(CH3)CH2COOH
996	TQ	—CH2CH2—	H	7-F	—SCH2COOH
997	TQ	—CH2CH2—	H	7-F	—SCH2CH2COOH
998	TQ	—CH2CH2—	H	7-F	—SCH2CH(CH3)COOH
999	TQ	—CH2CH2—	H	7-F	—SCH2CH(CH2CH3)COOH
1000	TQ	—CH2CH2—	H	7-F	—SCH2C(CH3)2COOH
1001	TQ	—CH2CH2—	H	7-F	—SC(CH3)2CH2COOH
1002	TQ	—CH2CH2—	H	7-F	—SCH2CH(CH3)CH2COOH
1003	TQ	—CH2CH2—	H	7-F	—SCH2C(CH2CH2)CH2COOH
1004	TQ	—CH2CH2—	H	8-F	—SCH2COOH
1005	TQ	—CH2CH2—	H	8-F	—SCH2CH2COOH
1006	TQ	—CH2CH2—	H	8-F	—SCH2CH(CH3)COOH
1007	TQ	—CH2CH2—	H	8-F	—SCH2CH(CH2CH3)COOH
1008	TQ	—CH2CH2—	H	8-F	—SCH2C(CH3)2COOH
1009	TQ	—CH2CH2—	H	8-F	—SC(CH3)2CH2COOH
1010	TQ	—CH2CH2—	H	8-F	—SCH2CH(CH3)CH2COOH
1011	TQ	—CH2CH2—	H	8-F	—SCH2C(CH2CH2)CH2COOH
1012	TQ	—CH2CH2—	H	9-F	—SCH2COOH
1013	TQ	—CH2CH2—	H	9-F	—SCH2CH2COOH
1014	TQ	—CH2CH2—	H	9-F	—SCH2CH(CH3)COOH
1015	TQ	—CH2CH2—	H	9-F	—SCH2CH(CH2CH3)COOH
1016	TQ	—CH2CH2—	H	9-F	—SCH2C(CH3)2COOH
1017	TQ	—CH2CH2—	H	9-F	—SC(CH3)2CH2COOH
1018	TQ	—CH2CH2—	H	9-F	—SCH2CH(CH3)CH2COOH
1019	TQ	—CH2CH2—	H	9-F	—SCH2C(CH2CH2)CH2COOH
1020	TQ	—CH2CH2—	H	7-CN	—SCH2COOH
1021	TQ	—CH2CH2—	H	7-CN	—SCH2CH2COOH
1022	TQ	—CH2CH2—	H	7-CN	—SCH2CH(CH3)COOH
1023	TQ	—CH2CH2—	H	7-CN	—SCH2CH(CH2CH3)COOH
1024	TQ	—CH2CH2—	H	7-CN	—SCH2C(CH3)2COOH
1025	TQ	—CH2CH2—	H	7-CN	—SC(CH3)2CH2COOH
1026	TQ	—CH2CH2—	H	7-CN	—SCH2CH(CH3)CH2COOH
1027	TQ	—CH2CH2—	H	7-CN	—SCH2C(CH2CH2)CH2COOH
1028	TQ	—CH2CH2—	H	8-CN	—SCH2COOH
1029	TQ	—CH2CH2—	H	8-CN	—SCH2CH2COOH
1030	TQ	—CH2CH2—	H	8-CN	—SCH2CH(CH3)COOH
1031	TQ	—CH2CH2—	H	8-CN	—SCH2CH(CH2CH3)COOH
1032	TQ	—CH2CH2—	H	8-CN	—SCH2C(CH3)2COOH
1033	TQ	—CH2CH2—	H	8-CN	—SC(CH3)2CH2COOH
1034	TQ	—CH2CH2—	H	8-CN	—SCH2CH(CH3)CH2COOH
1035	TQ	—CH2CH2—	H	8-CN	—SCH2C(CH2CH2)CH2COOH
1036	TQ	—CH2CH2—	H	9-CN	—SCH2COOH
1037	TQ	—CH2CH2—	H	9-CN	—SCH2CH2COOH
1038	TQ	—CH2CH2—	H	9-CN	—SCH2CH(CH3)COOH
1039	TQ	—CH2CH2—	H	9-CN	—SCH2CH(CH2CH3)COOH
1040	TQ	—CH2CH2—	H	9-CN	—SCH2C(CH3)2COOH
1041	TQ	—CH2CH2—	H	9-CN	—SC(CH3)2CH2COOH
1042	TQ	—CH2CH2—	H	9-CN	—SCH2CH(CH3)CH2COOH
1043	TQ	—CH2CH2—	H	9-CN	—SCH2C(CH2CH2)CH2COOH
1044	TQ	—CH2CH2—	H	7-CF3	—SCH2COOH
1045	TQ	—CH2CH2—	H	7-CF3	—SCH2CH2COOH
1046	TQ	—CH2CH2—	H	7-CF3	—SCH2CH(CH3)COOH
1047	TQ	—CH2CH2—	H	7-CF3	—SCH2CH(CH2CH3)COOH
1048	TQ	—CH2CH2—	H	7-CF3	—SCH2C(CH3)2COOH
1049	TQ	—CH2CH2—	H	7-CF3	—SC(CH3)2CH2COOH
1050	TQ	—CH2CH2—	H	7-CF3	—SCH2CH(CH3)CH2COOH
1051	TQ	—CH2CH2—	H	7-CF3	—SCH2C(CH2CH2)CH2COOH
1052	TQ	—CH2CH2—	H	8-CF3	—SCH2COOH
1053	TQ	—CH2CH2—	H	8-CF3	—SCH2CH2COOH
1054	TQ	—CH2CH2—	H	8-CF3	—SCH2CH(CH3)COOH
1055	TQ	—CH2CH2—	H	8-CF3	—SCH2CH(CH2CH3)COOH
1056	TQ	—CH2CH2—	H	8-CF3	—SCH2C(CH3)2COOH
1057	TQ	—CH2CH2—	H	8-CF3	—SC(CH3)2CH2COOH
1058	TQ	—CH2CH2—	H	8-CF3	—SCH2CH(CH3)CH2COOH
1059	TQ	—CH2CH2—	H	8-CF3	—SCH2C(CH2CH2)CH2COOH
1060	TQ	—CH2CH2—	H	9-CF3	—SCH2COOH
1061	TQ	—CH2CH2—	H	9-CF3	—SCH2CH2COOH
1062	TQ	—CH2CH2—	H	9-CF3	—SCH2CH(CH3)COOH
1063	TQ	—CH2CH2—	H	9-CF3	—SCH2CH(CH2CH3)COOH
1064	TQ	—CH2CH2—	H	9-CF3	—SCH2C(CH3)2COOH
1065	TQ	—CH2CH2—	H	9-CF3	—SC(CH3)2CH2COOH
1066	TQ	—CH2CH2—	H	9-CF3	—SCH2CH(CH3)CH2COOH
1067	TQ	—CH2CH2—	H	9-CF3	—SCH2C(CH2CH2)CH2COOH
1068	TQ	—CH2CH2—	H	7-C≡CH	—SCH2COOH
1069	TQ	—CH2CH2—	H	7-C≡CH	—SCH2CH2COOH
1070	TQ	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH3)COOH
1071	TQ	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH2CH3)COOH
1072	TQ	—CH2CH2—	H	7-C≡CH	—SCH2C(CH3)2COOH
1073	TQ	—CH2CH2—	H	7-C≡CH	—SC(CH3)2CH2COOH
1074	TQ	—CH2CH2—	H	7-C≡CH	—SCH2CH(CH3)CH2COOH
1075	TQ	—CH2CH2—	H	7-C≡CH	—SCH2C(CH2CH2)CH2COOH
1076	TQ	—CH2CH2—	H	8-C≡CH	—SCH2COOH
1077	TQ	—CH2CH2—	H	8-C≡CH	—SCH2CH2COOH
1078	TQ	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH3)COOH
1079	TQ	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH2CH3)COOH
1080	TQ	—CH2CH2—	H	8-C≡CH	—SCH2C(CH3)2COOH
1081	TQ	—CH2CH2—	H	8-C≡CH	—SC(CH3)2CH2COOH
1082	TQ	—CH2CH2—	H	8-C≡CH	—SCH2CH(CH3)CH2COOH
1083	TQ	—CH2CH2—	H	8-C≡CH	—SCH2C(CH2CH2)CH2COOH
1084	TQ	—CH2CH2—	H	9-C≡CH	—SCH2COOH
1085	TQ	—CH2CH2—	H	9-C≡CH	—SCH2CH2COOH
1086	TQ	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH3)COOH
1087	TQ	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH2CH3)COOH
1088	TQ	—CH2CH2—	H	9-C≡CH	—SCH2C(CH3)2COOH
1089	TQ	—CH2CH2—	H	9-C≡CH	—SC(CH3)2CH2COOH
1090	TQ	—CH2CH2—	H	9-C≡CH	—SCH2CH(CH3)CH2COOH
1091	TQ	—CH2CH2—	H	9-C≡CH	—SCH2C(CH2CH2)CH2COOH
1092	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2COOH
1093	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH2COOH
1094	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)COOH
1095	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
1096	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2C(CH3)2COOH
1097	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SC(CH3)2CH2COOH
1098	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
1099	TQ	—CH2CH2—	H	7-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
1100	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2COOH
1101	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH2COOH
1102	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)COOH
1103	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
1104	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2C(CH3)2COOH
1105	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SC(CH3)2CH2COOH
1106	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
1107	TQ	—CH2CH2—	H	8-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
1108	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2COOH
1109	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH2COOH
1110	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)COOH
1111	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH2CH3)COOH
1112	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2C(CH3)2COOH
1113	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SC(CH3)2CH2COOH
1114	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2CH(CH3)CH2COOH
1115	TQ	—CH2CH2—	H	9-C(CH3)2OH	—SCH2C(CH2CH2)CH2COOH
1116	TQ	—OCH2—	H	7-COOCH3	—SCH2COOH
1117	TQ	—OCH2—	H	7-COOCH3	—SCH2CH2COOH
1118	TQ	—OCH2—	H	7-COOCH3	—SCH2CH(CH3)COOH
1119	TQ	—OCH2—	H	7-COOCH3	—SCH2CH(CH2CH3)COOH
1120	TQ	—OCH2—	H	7-COOCH3	—SCH2C(CH3)2COOH
1121	TQ	—OCH2—	H	7-COOCH3	—SC(CH3)2CH2COOH
1122	TQ	—OCH2—	H	7-COOCH3	—SCH2CH(CH3)CH2COOH
1123	TQ	—OCH2—	H	7-COOCH3	—SCH2C(CH2CH2)CH2COOH
1124	TQ	—OCH2—	H	8-COOCH3	—SCH2COOH
1125	TQ	—OCH2—	H	8-COOCH3	—SCH2CH2COOH
1126	TQ	—OCH2—	H	8-COOCH3	—SCH2CH(CH3)COOH
1127	TQ	—OCH2—	H	8-COOCH3	—SCH2CH(CH2CH3)COOH
1128	TQ	—OCH2—	H	8-COOCH3	—SCH2C(CH3)2COOH
1129	TQ	—OCH2—	H	8-COOCH3	—SC(CH3)2CH2COOH
1130	TQ	—OCH2—	H	8-COOCH3	—SCH2CH(CH3)CH2COOH
1131	TQ	—OCH2—	H	8-COOCH3	—SCH2C(CH2CH2)CH2COOH
1132	TQ	—OCH2—	H	9-COOCH3	—SCH2COOH
1133	TQ	—OCH2—	H	9-COOCH3	—SCH2CH2COOH
1134	TQ	—OCH2—	H	9-COOCH3	—SCH2CH(CH3)COOH
1135	TQ	—OCH2—	H	9-COOCH3	—SCH2CH(CH2CH3)COOH
1136	TQ	—OCH2—	H	9-COOCH3	—SCH2C(CH3)2COOH
1137	TQ	—OCH2—	H	9-COOCH3	—SC(CH3)2CH2COOH
1138	TQ	—OCH2—	H	9-COOCH3	—SCH2CH(CH3)CH2COOH
1139	TQ	—OCH2—	H	9-COOCH3	—SCH2C(CH2CH2)CH2COOH

[0100] Incidentally, in the above Table 1, the abbreviations mean the following groups

[0101] t-Bu, t-butyl group; BO, 2-benzoxazolyl group; BT, 2-benzothiazolyl group; Tet, a 1H-tetrazol-5-yl group; Me, methyl group; i-Pr, isopropyl group; Ph, phenyl group; Py, 2-pyridyl group; Q, quinolin-2-yl group; T, 2-thiazolyl group; TQ, 5,6,7,8-tetrahydroquinolin-2-yl group.

[0102] In the above Table 1, the numerical value of the formula (I) shows a number of the position.

[0103] More preferred compounds may include Compounds Nos. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 119, 120, 121, 122, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145,146,155,156,157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 187, 188, 189, 190, 191, 192, 193, 194, 199, 200, 201, 202, 203, 204, 205, 206, 211, 212, 213, 214, 215, 216, 217, 218, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 272, 275, 284, 285, 286, 287, 288, 290, 291, 292, 293, 284, 295, 296, 297, 298, 299, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 332, 333, 334, 335, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 404, 405, 406, 407, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 556,557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1003, 1004, 1005, 1006, 1007, 1007, 1009, 1010,1011, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1092, 1093, 1094, 1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106 or 1107,

[0104] more preferably Compounds Nos.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 59, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 107, 108, 109, 110,111, 112, 113, 114, 115, 116, 117, 119, 120, 121, 122, 131, 132, 133, 134, 135, 136, 137, 138, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 187, 188, 189, 190, 191, 192, 193, 194, 199, 200, 201, 202, 203, 204, 205, 206, 211, 212, 213, 214, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 272, 275, 284, 285, 286, 287, 288, 290, 291, 292, 293, 284, 295, 296, 297, 298, 299, 308, 309, 310, 311, 312, 313, 314, 315, 323, 332, 333, 334, 335, 352, 353, 354, 355, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 404, 405, 406, 407, 412, 413, 414, 415, 416, 417, 418, 419, 436, 437, 438, 439, 440, 441, 442, 443, 460, 461, 462, 463, 464, 465, 466, 467, 484, 485, 486, 487, 488, 489, 490, 491, 508, 509, 510, 511, 512, 513, 514, 515, 532, 533, 534, 535, 536, 537, 538, 539, 556, 557, 558, 559, 560, 561, 562, 563, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 752, 753, 754, 755, 756, 757, 758, 759, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 824, 825, 826, 827, 828, 829, 830, 831, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 876, 877, 878, 879, 880, 881, 882, 883, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 948, 949, 950, 951, 952, 953, 954, 955, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1003, 1004, 1005, 1006, 1007, 1007, 1009, 1010, 1011, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082, 1083, 1092, 1093, 1094, 1095, 1096, 1097, 1098 or 1099,

[0105] further more preferably Compounds Nos. 1, 2, 3, 4, 5, 6, 7, 8, 10,11, 12, 13, 14, 15, 16, 21, 22, 23, 26, 27, 28, 31, 32, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 59, 60, 61, 62, 63, 64, 65, 66, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 107, 108, 109, 110,111, 112, 113, 114, 115, 116, 117, 119, 120, 121, 122, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 187, 188, 189, 190, 191, 192, 193, 194, 199, 200, 201, 202, 203, 204, 205, 206, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 272, 275, 284, 285, 286, 287, 288, 290, 291, 292, 293, 284, 295, 296, 297, 298, 299, 323, 332, 333, 334, 335, 352, 353, 354, 355, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 404, 405, 406, 407, 508, 509, 510, 511, 512, 513, 514, 515, 532, 533, 534, 535, 536, 537, 538, 539, 556, 557, 558, 559, 560, 561, 562, 563, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 752, 753, 754, 755, 756, 757, 758, 759, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 848, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 876, 877, 878, 879, 880, 881, 882, 883, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 948, 949, 950, 951, 952, 953, 954, 955, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000, 1001, 1003, 1004, 1005, 1006, 1007, 1007, 1009, 1010,1011, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1044, 1045, 1046, 1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058, 1059, 1068, 1069, 1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082 or 1083,

[0106] particularly preferably

[0107] Compound No. 1;

[0108] [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetic acid,

[0109] Compound No. 5;

[0110] [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioacetic acid,

[0111] Compound No. 6;

[0112] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0113] Compound No. 7;

[0114] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid,

[0115] Compound No. 8;

[0116] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2,2-dimethylpropionic acid,

[0117] Compound No. 10;

[0118] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-ethylpropionic acid,

[0119] Compound No. 12;

[0120] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-3,3-dimethylpropionic acid,

[0121] Compound No. 14;

[0122] {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid,

[0123] Compound No. 16;

[0124] 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoic acid

[0125] Compound No. 22;

[0126] [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylaceticamide

[0127] Compound No. 27;

[0128] 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylpropionamide

[0129] Compound No. 31;

[0130] 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}ethanesulfonic acid

[0131] Compound No. 32;

[0132] 4-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoic acid

[0133] Compound No. 36;

[0134] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0135] Compound No. 42;

[0136] {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid,

[0137] Compound No. 44;

[0138] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-8-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0139] Compound No. 60;

[0140] 3-{[7-cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0141] Compound No. 84;

[0142] 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-trifluoromethyl-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0143] Compound No. 108;

[0144] 3-{[7-ethynyl-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0145] Compound No. 155;

[0146] 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0147] Compound No. 159;

[0148] 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0149] Compound No. 162;

[0150] {1-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]-cyclopropyl}acetic acid,

[0151] Compound No. 171;

[0152] 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0153] Compound No. 172;

[0154] 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid,

[0155] Compound No. 174;

[0156] {1-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid,

[0157] Compound No. 223;

[0158] {2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl}thioacetic acid,

[0159] Compound No. 224;

[0160] 3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0161] Compound No. 225;

[0162] 3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid,

[0163] Compound No. 227;

[0164] {1-[[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid,

[0165] Compound No. 229;

[0166] 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0167] Compound No. 230;

[0168] 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid,

[0169] Compound No. 235;

[0170] {1-[[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid,

[0171] Compound No. 352;

[0172] 3-{[2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid,

[0173] Compound No. 384;

[0174] 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}propionic acid,

[0175] Compound No. 385;

[0176] 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}-2-methylpropionic acid, or

[0177] Compound No. 404;

[0178] 3-{[9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid.

[0179] The compound represented by the formula (I) of the present invention can be produced, for example, by Preparation process A, B, C, D, E, F, G or M shown below.

[0180] Preparation Process A 567 (XXXX)  (Ia)

[0181] In the chemical formulae described in the above-mentioned preparation processes, R1, R2, R3, A, B, X, Y, Z, m and n have the same meanings as defined above, L represents a halogen atom, a C1-C4 alkylsulfonyloxy group, a fluoro C1-C4 alkylsulfonyloxy group or a phenylsulfonyloxy group which may be substituted (said a substituent(s) is a C1-C4 alkyl group or a halogen atom), R4 represents a C1-C4 alkyl group or a phenyl group which may be substituted (said a substituent(s) is a C1-C4 alkyl group or a halogen atom), Tet means a 1H-tetrazol-5-yl group, Hal means a halogen atom, and t-Boc means a t-butoxycarbonyl group.

[0182] Preparation process A is a preparation process of Compound (I).

[0183] Step A1 of Preparation process A is a step of synthesizing Compound (III) by halogenating or sulfonylating Compound (II).

[0184] Halogenation of Compound (II) can be carried out by reacting Compound (II) and a halogenating agent in a solvent or without solvent (preferably in a solvent).

[0185] The solvent to be used is not particularly limited so long as it has no adverse effect and dissolves starting materials with some extends, and there may be mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and dichloroethane; aromatic hydrocarbons such as benzene and toluene; or aliphatic hydrocarbons such as heptane, hexane and cyclohexane, preferably halogenated hydrocarbons.

[0186] As the halogenating agent, there may be mentioned, for example, thionyl chloride, thionyl bromide, phosphorus oxychloride, phosphorus oxybromide or phosphorus pentachloride, etc., preferably thionyl chloride or phosphorus oxychloride. An amount of the halogenating agent to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 2-fold mole based on Compound (II).

[0187] The reaction is usually carried out in the range of −20 to 100° C., preferably −10 to 30° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 10 minutes to 5 hours.

[0188] Sulfonylation of Compound (II) can be carried out by reacting Compound (II) and a sulfonylating agent in the presence of a base in a solvent.

[0189] The solvent to be used is not particularly limited so long as it has no adverse effect and dissolves starting materials with some extends, and there may be mentioned, for example, the same solvent to those used in the above-mentioned halogenating reaction (for example, halogenated hydrocarbons, aromatic hydrocarbons or aliphatic hydrocarbons), preferably halogenated hydrocarbons.

[0190] As the sulfonylating agent, there may be mentioned, for example, methanesulfonyl chloride, trifluoromethanesulfonyl chloride, methanesulfonic anhydride, trifluoromethanesulfonic anhydride, benzenesulfonyl chloride, toluenesulfonyl chloride, benzenesulfonyl bromide or toluenesulfonyl bromide, etc., preferably methanesulfonyl chloride, benzenesulfonyl chloride or toluenesulfonyl chloride. An amount of the sulfonylating agent to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 3-fold mole based on Compound (II).

[0191] As the base, there may be mentioned, for example, amines such as triethylamine, tributylamine, diisopropylethylamine, pyridine, picoline, lutidine and 4-dimethylaminopyridine, preferably triethylamine, diisopropylethylamine or pyridine.

[0192] An amount of the base to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 2-fold mole based on the sulfonylating agent.

[0193] The reaction is usually carried out in the range of −10 to 100° C., preferably 0 to 30° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 30 minutes to 5 hours.

[0194] Incidentally, Compound (III) can be separated and purified from the reaction mixture by the usual method, and a crude product obtained by concentrating the reaction mixture can be used as such to the next step.

[0195] Step A2 can be carried out by reacting Compound (III) and Compound (IV) in the presence of a base in a solvent.

[0196] An amount of Compound (IV) to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (III).

[0197] The solvent to be used is not particularly limited so long as it has no adverse effect and dissolves starting materials with some extends, and there may be mentioned, for example, aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, N,N-dimethylacetamide and hexamethylphosphoric triamide; halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane; ketones such as acetone, methyl ethyl ketone and methyl isobutyl ketone; nitriles such as acetonitrile; esters such as ethyl acetate; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran or dioxane; or a mixed solvent of the above solvents, preferably halogenated hydrocarbons, aprotic polar solvents, ethers or a mixed solvent of the above solvents.

[0198] As the base to be used, there may be mentioned, for example, alkali metal hydrides such as sodium hydroxide or lithium hydroxide; alkali metal amides such as sodium amide, etc.; amines such as triethylamine, tributylamine, diisopropylethylamine, pyridine, picoline, lutidine or 4-dimethylaminopyridine, etc.; or alkali metal carbonates such as sodium carbonate, potassium carbonate and sodium hydrogen carbonate, preferably amines or alkali metal hydrides. An amount of the base to be used may vary depending on the kind of the starting compounds, and it is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (IV).

[0199] The reaction is usually carried out in the range of −50 to 150° C., preferably −10 to 100° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 30 minutes to 5 hours.

[0200] Step A3 is a step to obtain Compound (I) in another method, in particular, it is suitably employed when X is a sulfur atom. This step is carried out by reacting Compound (II) and Compound (IV) in the presence of an acid catalyst in a solvent.

[0201] An amount of Compound (IV) to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 2-fold mole based on Compound (II).

[0202] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane; alcohols such as methanol, ethanol, propanol, isopropanol and butanol; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, N,N-dimethylacetamide and hexamethylphosphoric triamide; or ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane, preferably halogenated hydrocarbons.

[0203] As the acid catalyst to be used, there may be mentioned, for example, mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid; organic acids such as methanesulfonic acid and trifluoroacetic acid; Lewis acids such as boron trifluoride-diethyl ether complex, zinc chloride, tin tetrachloride and aluminum chloride, preferably organic acids or boron trifluoride-diethyl ether complex.

[0204] An amount of the catalyst to be used is usually in an amount of 0.1 to 50-fold mole, preferably 1 to 10-fold mole based on Compound (II), and when organic acids are used, it may be used in a largely excess amount served as a solvent.

[0205] The reaction is usually carried out in the range of −10 to 100° C., preferably 0 to 30° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 10 minutes to 5 hours.

[0206] Incidentally, in Compound (I), the compound wherein Z is a carboxyl group (Compound Ic mentioned below) is directly produced by using Compound (IV) wherein Z is a carboxyl group, or can be synthesized by firstly leading to Compound (I) where Z is a protected carboxyl group using Compound (IV) where Z is a protected carboxyl group (said protective group is preferably C1-C4 alkyl group) and then by hydrolyzing said protective group under acidic or alkaline conditions according to the conventional method.

[0207] Also, in Compound (I), a desired protective group can be easily introduced into Compound (Ic) wherein Z is a carboxyl group according to the conventional method. (for example, written by W. Greene and P. G. H. Wult “Protective Group in Organic Synthesis”, 2nd Ed., John Wiley & Sons, see page 224)

[0208] Preparation process B is a preparation processs of Compound (Ia).

[0209] A method of obtaining Compound (VI) from Compound (II) or Compound (III) and thiocarboxylic acid (V) in Step B1 can be carried out in the same manner as described in the Step A2 or Step A3 of the above-mentioned Preparation process A except for using thiocarboxylic acid (V) in place of Compound (IV).

[0210] In Step B2, Compound (VII) can be synthesized by hydrolyzing Compound (VI) under alkaline conditions according to the conventional method.

[0211] Step B3 is carried out by reacting Compound (VI) and Compound (VIII) in the presence of a base in a solvent. The present reaction is carried out in the same manner as in the above-mentioned Step A2 except for using Compound (VII) in place of Compound (II), and using Compound (VIII) in place of Compound (IV).

[0212] An amount of Compound (VIII) to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (VII)

[0213] Preparation processs C is a preparation processs of Compound (Ib), and in Step C1, the reaction of obtaining Compound (X) from Compound (II) or Compound (III) and Compound (IX) is carried out under the same reaction conditions as those of Preparation process A except for using Compound (IX) in place of Compound (IV).

[0214] In Step C2, Compound (Ib) can be synthesized by reacting Compound (X) and an azide compound in a solvent.

[0215] As the azide compound to be used, there may be mentioned, for example, alkali metal azides such as sodium azide, potassium azide and lithium azide; alkaline earth metal azides such as calcium azide and magnesium azide; or organic tin azides such as trimethyl tin azide, tributyl tin azide and triphenyl tin azide. An amount of the azide compound to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (X). In said reaction, the azide compound can be used singly, or may be used in combination with, for example, Lewis acids such as aluminum chloride, stannic chloride, zinc chloride, titanium chloride and boron trifluoride-diethyl ether complex; ammonium salts such as ammonium chloride and tetramethyl ammonium chloride; sulfonic acids such as methanesulfonic acid and ethanesulfonic acid; alkali metal chlorides such as lithium chloride, and others; or amine salts such as triethylamine hydrochloride, and others.

[0216] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and N,N-dimethylacetamide; ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane, diethoxyethane and dioxane; aromatic hydrocarbons such as benzene, toluene and xylene; or aliphatic hydrocarbons such as hexane and petroleum ether.

[0217] The reaction is usually carried out in the range of 0 to 200° C., preferably 50 to 150° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 1 hour to 72 hours, preferably 3 hours to 48 hours.

[0218] Preparation process D is a preparation processs of Compound (Id), and it is carried out by a method (Step D1a) in which Compound (Ic) and Compound (XI) are reacted in the presence of a condensing agent, or a method (Step D1c) in which Compound (Ic) is once led to its reactive derivative (Step D1b), then, the reactive derivative and Compound (XI) are reacted in the presence of a base.

[0219] As the condensing agent to be used in Step D1a, there may be mentioned, for example, N,N′-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N,N′-carbonyldiimidazole (CDI), diphenylphosphoryl azide, benztriazol-1-yloxy-tris(dimethyamino)phosphonium hexafluorophosphate (BOP), benzotriazol-1-yloxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), or 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU), preferably DCC or EDC.

[0220] An amount of the condensing agent to be used is usually 1 to 5-fold mole, preferably 1 to 3-fold mole based on Compound (IC).

[0221] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane, diethoxyethane and dioxane; nitrites such as acetonitrile; aprotic polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and N,N-dimethylacetamide; or halogenated hydrocarbons such as methylene chloride, chloroform and dichlorodichloroethane, these may be used singly or a mixed solvent.

[0222] The reaction is usually carried out in the range of −20 to 100° C., preferably 0 to 50° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 30 minutes to 24 hours, preferably 1 hour to 10 hours.

[0223] As the reactive derivative of Compound (Ic) in Step D1b, there may be mentioned, for example, acid halide derivatives of Compound (Ic) such as an acid bromide or an acid chloride of Compound (Ic); or reactive amide derivatives of Compound (Ic) obtained from Compound (Ic) and imidazole, dimethylpyrazole or triazole, preferably an acid halide derivative.

[0224] The acid halide of Compound (Ic) can be prepared according to the conventional method, and it can be synthesized by reacting, for example, Compound (Ic) with a halogenating agent (for example, thionyl chloride, thionyl bromide or phosphorus pentachloride) in a solvent (for example, halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane).

[0225] Also, an activated amide derivative of Compound (Ic) can be prepared according to the conventional method, and it can be synthesized by reacting, for example, in the case of an imidazole amide product of Compound (Ic), Compound (Ic) is reacted with 1,1′-carbonyldiimidazole in a solvent.

[0226] The reactive derivative of Compound (Ic) can be used in the next Step D1b as such without separation after formation.

[0227] An amount of Compound (XI) to be used in the reaction of the reactive derivative of Compound (Ic) and Compound (XI) in Step D1c is usually 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (Ic).

[0228] As the base to be used, there may be mentioned, for example, amines such as triethylamine, tributylamine, diisopropylethylamine, pyridine, picoline, lutidine, 4-dimethylaminopyridine, 1,8-diazabicyclo[5.4.0]undecene and 1,5-diazabicyclo[4.3.0]-7-nonene, preferably triethylamine, tributylamine or diisopropylethylamine. An amount of the base to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (Ic).

[0229] The reaction is usually carried out in the range of 0 to 150° C., preferably 10 to 100° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 48 hours, preferably 30 minutes to 24 hours.

[0230] Also, Compound (Id) can be synthesized by a method via Compound (XII).

[0231] Step D2 is a step to obtain Compound (XII) by amidating a carboxyl group of Compound (Ic), and it is carried out by optionally selecting a method from methods conventionally known in the art. For example, Compound (XII) can be easily synthesized by reacting the reactive derivative of the above-mentioned Compound (Ic) and ammonia.

[0232] Step D3 can be carried out by reacting Compound (XII) and Compound (XIII) in a solvent in the presence of a base.

[0233] An amount of Compound (XIII) is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XII).

[0234] The solvent and the base to be used are mentioned those described in the above-mentioned Step D1, and the reaction can be carried out under the same conditions as Step D1.

[0235] Preparation process E is a preparation processs of Compound (Ie).

[0236] In Step E1, the reaction of obtaining Compound (XV) from Compound (II) or Compound (III) and Compound (XIV) can be carried out in the same manner as mentioned above except for using Compound (XIV) in place of Compound (IV).

[0237] Step E2 is carried out by reacting Compound (XV) and Compound (XIII) in a solvent in the presence of a base.

[0238] An amount of Compound (XIII) to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XV).

[0239] As the solvent to be used, the same solvents as those mentioned in the above Step D1 may be mentioned, and preferably halogenated hydrocarbons or aprotic polar solvents.

[0240] As the base to be used, the same base as those mentioned in the above Step D1 may be mentioned, and an amount of the base to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XIV). Also, in the present reaction, the base may be used in a largely excess amount served as a solvent.

[0241] The reaction is usually carried out in the range of −20 to 100° C., preferably 0 to 50° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 30 minutes to 5 hours.

[0242] Preparation process F is another preparation processs of Compound (Ie).

[0243] The reaction of obtaining Compound (XVIII) from Compound (XVI) in Step F1 is carried out by using a conventionally known method which has been known as “Mitsunobu Reaction”. For example, it is carried out by reacting Compound (XVI) and Compound (XVII), with triphenylphosphine and diethyl azodicarboxylate in tetrahydrofuran. An amount of triphenylphosphine to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 3-fold mole based on Compound (XVI). An amount of diethylazodicarboxylate to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XVI).

[0244] The reaction is usually carried out in the range of −50 to 80° C., preferably −10 to 50° C. The reaction time may vary depending on the above-mentioned other conditions, and it is usually for 5 minutes to 24 hours, preferably 30 minutes to 10 hours.

[0245] The reaction of obtaining Compound (Ie) from Compound (XVIII) in Step F2 can be carried out by the conventionally known method, for example, by a method of deprotection by reacting with organic acids such as trifluoroacetic acid in tetrahydrofuran.

[0246] Preparation process G is a preparation processs of Compound (If).

[0247] Step G1 is a step of preparing Compound (XX) by trifrating Compound (XIX).

[0248] Trifration of Compound (XIX) can be carried out by reacting Compound (XIX) and a trifrating agent in the presence of a base in a solvent.

[0249] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and dichloroethane; ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane, diethoxyethane and dioxane; aromatic hydrocarbons such as benzene and toluene; or aliphatic hydrocarbons such as heptane, hexane and cyclohexane, preferably halogenated hydrocarbons or ethers.

[0250] As the trifrating agent, there may be mentioned, for example, trifluoromethanesulfonyl chloride, trifluoromethanesulfonic anhydride and the like, preferably trifluoromethanesulfonic anhydride. An amount of the trifrating agent to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 2-fold mole based on Compound (XIX).

[0251] As the base, there may be mentioned, for example, amines such as triethylamine, tributylamine, diisopropylethylamine, pyridine, picoline, lutidine, 4-dimethylaminopyridine and the like, preferably triethylamine, diisopropylethylamine, pyridine. An amount of the base to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 2-fold mole based on the trifrating agent.

[0252] The reaction is usually carried out in the range of −20 to 100° C., preferably −10 to 50° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 5 minutes to 5 hours.

[0253] Step G2 is carried out by reacting Compound (XX) and Compound (XXI) in an inert gas atmosphere such as nitrogen, helium and argon in the presence of a catalyst (palladium catalyst) and a base in a solvent.

[0254] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, polar solvents such as N,N-dimethylformamide, dimethylsulfoxide, N-methylpyrrolidone and N,N-dimethylacetamide, or acetonitrile, etc., preferably N,N-dimethylformamide.

[0255] As the base, there may be mentioned, for example, amines such as triethylamine, tributylamine, diisopropylethylamine, pyridine, picoline, lutidine and 4-dimethylaminopyridine, preferably triethylamine, diisopropylethylamine or pyridine. An amount of the base to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 2-fold mole based on Compound (XX).

[0256] Also, in place of the amines, a combination of a phase-transfer catalyst such as tetrabutyl ammonium chloride and tetrabutyl ammonium bromide, and alkali metal carbonates such as potassium carbonate, sodium carbonate and sodium hydrogen carbonate may be used.

[0257] As the palladium complex, there may be mentioned, for example, palladium acetate, palladium acetate-triphenylphosphine, dichlorobistriphenylphosphine or tetrakistriphenylphosphine, preferably palladium acetate-triphenylphosphine or tetrakistriphenylphosphine. An amount of the palladium complex to be used is usually in an amount of 0.01 to 1-fold mole, preferably 0.01 to 0.1-fold mole based on Compound (XX).

[0258] Also, lithium chloride or lithium bromide may be copresent in the reaction.

[0259] The reaction is usually carried out in the range of 0 to 150° C., preferably 25 to 80° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 30 minutes to 24 hours, preferably 1 hour to 10 hours.

[0260] Preparation processs M is a preparation processs of Compound (Ia).

[0261] Step M1 is carried out by reacting Compound (XXXX) and Compound (IVa) in the presence of a catalyst in a solvent.

[0262] An amount of Compound (IVa) to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 2-fold mole based on Compound (XXXX).

[0263] The solvent to be used not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane; aromatic hydrocarbons such as benzene and toluene, preferably halogenated hydrocarbons.

[0264] As the catalyst to be used, there maybe used, for example, Lewis acids such as boron trifluoride-diethyl ether complex and others.

[0265] An amount of the catalyst to be used is usually in an amount of 0.1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XXXX).

[0266] The reaction is usually carried out in the range of 0 to 100° C., preferably 0 to 30° C. There action time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 10 hours, preferably 30 minutes to 5 hours.

[0267] In the above-mentioned respective reactions, the desired compound can be isolated from the reaction mixture according to the conventional manner. For example, when insoluble material exists, after optionally removing it by filtration, the solvent is distilled, or the solvent was removed under reduced pressure, water is added to the residue, the mixture is extracted with a water-immiscible organic solvent such as ethyl acetate, etc., and if necessary, after drying over anhydrous sodium sulfate, etc., the solvent is removed to obtain the desired compound, and further necessary, it can be further purified by the conventional method, for example, recrystallization, column chromatography, and others.

[0268] Also, the compound of the general formula (I) according to the present invention can be converted into a pharmaceutically acceptable salt by treating with an acid or a base according to the conventional method. For example, a desired salt can be obtained by reacting with a desired acid or a base in an inert solvent (preferably ethers such as diethyl ether, tetrahydrofuran, dimethoxyethane, diethoxyethane and dioxane; alcohols such as methanol, ethanol, propanol, isopropanol and butanol; halogenated hydrocarbons such as methylene chloride, chloroform; or water), and removing the solvent, or collecting the precipitated crystal by filtration. Also, it can be separated as a salt directly from a reaction mixture at the final reaction step.

[0269] Moreover, in the compound of the formula (I), there exist optical isomer(s) (including diastereomer) due to an asymmetric carbon(s) and/or geometric (E, Z) isomers due to an unsaturated carbon. These respective isomers can be separated by treating the corresponding racemic isomers or geometric isomer mixture by usual optical resolution methods (fractional recrystallization method, optical resolution column chromatography method or diastereimer method, etc.) or separation methods (recrystallization method, column chromatography method, etc.). For example, optical isomers are to be separated, Compound (I) which is racemic mixture is reacted with optically active sulfonic acid compound ((S) or (R)-camphor-10-sulfonic acid, etc.), to obtain one of the diastereomer salts, if necessary, further subjecting to purification, the resulting diastereomer salt is decomposed according to the conventional manner to obtain an optical isomer. Also, when the above reaction is carried out by using the starting compound which has been subjected to optical resolution or separation, desired optical isomer or geometric isomer can be obtained.

[0270] Compound (IV), (V), (VIII), (IX), (XI), (XIII), (XIV), (XVI), (XVII) and other sub-starting materials which are used as starting materials in the above-mentioned Preparation processes A, B, C, D, E, F, G and M are each known compounds, or can be easily produced according to the conventionally known method. Also, Compound (II) can be produced according to Preparation processs H or Preparation processs J as shown below, Compound (XXIVa) can be produced according to Preparation processs I as shown below, Compound (XIXa) can be produced according to Preparation processs K as shown below, Compound (XXI) can be produced, for example, according to Preparation processs L as shown below, Compound (XXXX) can be produced according to Preparation processs N as shown below. 89101112

[0271] In the above formulae, R1, R2, A, B, Hal, m and n have the same meanings as mentioned above, R5 represents a hydrogen atom or a formula: —P(R6)3.Hal group,

[0272] wherein R6 represents a C1-C4 alkyl group or a phenyl group,

[0273] Ac represents an acetyl group, R1 represents a C1-C4 alkyl group, R8 represents a halogen atom with the same meaning as in R1, a nitro group, a cyano group, a C1-C4 alkyl group with the same meaning as in R1, a fluoro C1-C4 alkyl group with the same meaning as in R1, a C1-C4 alkoxy group with the same meaning as in R1, a fluoro C1-C4 alkoxy group with the same meaning as in R1 or a C1-C4 alkylthio group with the same meaning as in R1, r is an integer of 1 to 4, when r is 2 or more, R8s may be different from each other, Et means an ethyl group, THP means a tetrahydropyranyl group, TBS means a t-butyldimethylsilyl group.

[0274] Preparation processs H is a preparation processs of Compound (II).

[0275] In Step H1 of Preparation processs H, as a starting material, there are a method (Step H1a) of using Compound (XXIII, R5=a hydrogen atom) or a method (Step H1b) of using Compound (XXIII), R5=a formula: —P(R6)3.Hal group).

[0276] In the method of using Compound (XXIII, R5=a hydrogen atom) of Step H1a, it is carried out by reacting Compound (XXII) and Compound (XXIII, R5=a hydrogen atom) in acetic anhydride. An amount of Compound (XXIII, R5=a hydrogen atom) to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XXII).

[0277] The reaction is usually carried out in the range of 20 to 200° C., preferably 50 to 150° C. The reaction time may vary depending on the reaction temperature and others, it is usually for 1 hour to 200 hours, preferably 3 hours to 100 hours.

[0278] In the method of using Compound (XXIII, R5=a formula: —P(R6)3.Hal group) of Step H1b, it is carried out by reacting Compound (XXII) and Compound (XXIII, R5=a formula: —P(R6)3.Hal group) in a solvent in the presence of a base. An amount of Compound (XXIII, R5=a formula: —P(R6)3.Hal group) to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 2-fold mole based on Compound (XXII).

[0279] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, dioxane and tetrahydrofuran; halogenated hydrocarbons such as methylene chloride, chloroform and dichloroethane; or aprotic polar solvents such as N,N-dimethylformamide and dimethylsulfoxide, preferably aromatic hydrocarbons or ethers.

[0280] As the base to be used, there may be mentioned, for example, alkali metal hydrides such as sodium hydride, lithium hydride and potassium hydride; alkali metal amides such as sodium amide and lithium diisopropylamide; alkali metal alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide; or alkyl lithiums such as methyl lithium, butyl lithium and t-butyl lithium, preferably sodium hydride, lithium diisopropylamide, potassium t-butoxide, butyl lithium or t-butyl lithium. An amount of the base to be used is usually in an amount of 1 to 3-fold mole, preferably 1 to 1.5-fold mole based on Compound (XXIII, R5=a formula: —P(R6)3.Hal group).

[0281] The reaction is usually carried out in the range of −80 to 100° C., preferably −60 to 50° C. The reaction time may vary depending on the reaction temperature and others, it is usually for 10 minutes to 10 hours, preferably 15 minutes to 6 hours.

[0282] The reduction of Compound (XXIV) to Compound (II) in Step H2 is carried out by using a reducing agent in a solvent.

[0283] As the reducing agent, there may be mentioned, for example, sodium borohydride, lithium borohydride, sodium cyanoborohydride or lithium aluminum hydride, preferably sodium borohydride.

[0284] As the solvent to be used, there may be mentioned, for example, alcohols such as methanol, ethanol, propanol, isopropanol and butanol; ethers such as tetrahydrofuran, dioxane and 1,2-dimethoxyethane; nitriles such as acetonitrile; amides such as N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone; water; or a mixed solvent of the above solvents, preferably methanol, ethanol, tetrahydrofuran, N,N-dimethylformamide, N,N-dimethylacetamide or a mixed solvent of the above solvents.

[0285] The reaction is usually carried out in the range of −10 to 150° C., preferably 0 to 100° C. The reaction time may vary depending on the reaction temperature and other conditions, and it is usually for 10 minutes to 10 hours, preferably 30 minutes to 6 hours.

[0286] Preparation processs I is a preparation processs of Compound (XXIVa).

[0287] Step I1 is carried out by reacting Compound (XXV) and Compound (XXIIIa) in acetic anhydride, and it is carried out by the same method as mentioned in the above Step H1 except for using Compound (XXIIIa) in place of Compound (XXIII, R5=a hydrogen atom).

[0288] In Step I2, Compound (XXVI) is hydrolyzed to Compound (XXVII) according to the conventional manner under alkaline conditions.

[0289] Step I3 is carried out by reacting Compound (XXVII) and Compound (XXIX) in a solvent in the presence of abase. An amount of Compound (XXIX) to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 2-fold mole based on Compound (XXVII).

[0290] As the solvent and the base to be used In Step I3, those mentioned in the above Step A2 may be mentioned, and as the reaction conditions, those mentioned in Step A2 can be employed and carried out.

[0291] Step I4 contains a step (Step I4a) of obtaining a carboxylic acid material by hydrolyzing an ester group of Compound (XXVIII) and a step (Step I4b) of cyclizing said carboxylic acid material to produce Compound (XXIV).

[0292] Hydrolysis of the ester group of Compound (XXVIII) in Step I4a can be easily carried out according to the conventional manner under alkaline or acidic conditions.

[0293] Step I4b is carried out by reacting the carboxylic acid material of Compound (XXVIII) obtained as mentioned above in a solvent in the presence of a catalyst (a dehydrating agent).

[0294] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and dichloroethane; or nitrobenzene or carbon disulfide, preferably halogenated hydrocarbons.

[0295] As the catalyst to be used, there may be mentioned, for example, mineral acids such as sulfuric acid, phosphoric acid and polyphosphoric acid; acid anhydrides such as methanesulfonic anhydride and trifluoroacetic acid anhydride; or Lewis acids such as boron trifluoride-diethyl ether complex, aluminum chloride and zinc chloride, preferably polyphosphoric acid, methanesulfonic anhydride, trifluoroacetic acid anhydride or boron trifluoride-diethyl ether complex. Also, a mixture of trifluoroacetic acid anhydride and boron trifluoride-diethyl ether complex is suitably used.

[0296] An amount of the catalyst to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XXVIII) or its carboxylic acid material.

[0297] The reaction is usually carried out in the range of 0 to 100° C., preferably 0 to 50° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 24 hours, preferably 30 minutes to 18 hours.

[0298] Preparation processs J is another preparation processs of Compound (XXIV).

[0299] Step J1 is a step to obtain Compound (XX) by trifrating Compound (XXX), and it is carried out in the same manner as in the above-mentioned Step G1 except for using Compound (XXX) in place of Compound (XIX).

[0300] Step J2 is a step to obtain Compound (XXIV) by subjecting Compound (XXXI) and Compound (XXI) to coupling reaction, and the present reaction is carried out in the same manner as in the above-mentioned Step G2 except for using Compound (XXXI) in place of Compound (XX).

[0301] Preparation processs K is a preparation processs of Compound (XIXa).

[0302] Step K1 is carried out by the method of reacting Compound (XXXIII) and Compound (XXXII) according to the conventionally known method, for example, by reacting them in ethyl acetate, in the presence of an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid and pyridinium p-toluenesulfonate.

[0303] Step K2 is carried out by reacting Compound (XXXIII) and Compound (XXXIV) in a solvent by using a base. The present reaction is carried out in the same method of obtaining Compound (XXIV) by using Compound (XXIII, R5=a formula: —P(R6)3.Hal group) in the above-mentioned Step H1 except for using Compound (XXXIII) in place of Compound (XXII), and using Compound (XXXIV) in place of Compound (XXIII, R5=a formula: —P(R6)3.Hal group).

[0304] A reaction of producing Compound (XXXVI) from Compound (XXXV) in Step K3 can be carried out by the conventionally known method, for example, by a method of subjecting to deprotecting reaction in tetrahydrofuran using a tetra-n-butyl ammonium fluoride 1.0M tetrahydrofuran solution.

[0305] A reaction of producing Compound (XXXVII) from Compound (XXXVI) in Step K4 can be carried out by subjecting to rearrangement reaction in a solvent in the presence of an acid catalyst.

[0306] The solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, a mixed solvent comprising one or several kinds of organic solvents selected from alcohols such as methanol, ethanol, propanol and butanol; ethers such as tetrahydrofuran, dioxane and 1,2-dimethoxyethane; nitrites such as acetonitrile; and amides such as N,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone; a mixed solvent with water, preferably a mixed solvent comprising one or two organic solvents selected from tetrahydrofuran and N,N-dimethylformamide with water.

[0307] As the acid catalyst to be used, there may be mentioned, for example, mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid; organic acids such as methanesulfonic acid and trifluoroacetic acid. An amount of the catalyst to be used is usually in an amount of 1 to 100-fold mole, preferably 1 to 50-fold mole based on Compound (II).

[0308] The reaction is usually carried out in the range of 0 to 100° C., preferably 0 to 30° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 5 minutes to 48 hours, preferably 30 minutes to 24 hours.

[0309] Step K5 is carried out by reacting Compound (XXXVII) and Compound (XXXVIII) in a solvent in the presence of a base. An amount of Compound (XXXVIII) to be used is usually in an amount of 1 to 10-fold mole, preferably 1 to 5-fold mole based on Compound (XXXVII).

[0310] As the base to be used, there may be mentioned, for example, alkali metal hydrides such as sodium hydride and lithium hydride; alkali metal alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide; alkyl lithiums such as methyl lithium and butyl lithium; or metal amides such as sodium amide and lithium diisopropyl amide, preferably metal hydrides.

[0311] An amount of the base to be used is usually in an amount of 1 to 5-fold mole, preferably 1 to 2-fold mole based on Compound (XXXVIII).

[0312] In Step K5, the solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, aromatic hydrocarbons such as benzene and toluene; ethers such as tetrahydrofuran, dioxane, dimethoxyethane and diethoxyethane; or aprotic polar solvents such as N,N-dimethylformamide, N,N-dimethylacetamide and dimethylsulfoxide, preferably ethers.

[0313] The reaction is usually carried out in the range of −50° C. to 100° C., preferably −10° C. to 50° C.

[0314] The reaction time is usually for 15 minutes to 12 hours, preferably 30 minutes to 5 hours.

[0315] Step K6 is carried out by subjecting Compound (XXXIX) to catalytic reduction by hydrogen in the presence of a catalyst in a solvent.

[0316] In Step K6, the solvent to be used is not particularly limited so long as it has no adverse effect on the reaction and dissolves starting materials with some extends, and there may be mentioned, for example, alcohols such as methanol and ethanol; or ethers such as tetrahydrofuran and dioxane, preferably alcohols.

[0317] The catalyst to be used in Step K6 may be mentioned, for example, palladium-carbon, platinum-carbon, platinum oxide or rhodium-carbon. In the reaction of Step K6, a partial pressure of hydrogen is usually 1 atm to 10 atm, preferably 1 atm to 3 atm.

[0318] The reaction is usually carried out in the range of 0° C. to 100° C., preferably 20° C. to 80° C. The reaction time may vary depending on the reaction temperature and others, and it is usually for 15 minutes to 72 hours, preferably 30 minutes to 48 hours.

[0319] Preparation processs N is a preparation processs of Compound (XXXX).

[0320] Step N1 is a reduction of Compound (XXXa) to Compound (XXXXI), and is carried out by using a reducing agent in a solvent. The present reaction is carried out in the same manner as in the method of obtaining Compound (II) in the above-mentioned Step H2.

[0321] Step N2 is carried out by reacting Compound (XXXXI) according to the conventionally known method, for example, by reacting it in methanol in the presence of an acid catalyst such as hydrochloric acid, p-toluenesulfonic acid and pyridinium p-toluenesulfonate.

[0322] Step N3 is carried out by reacting Compound (XXXXII) and a silylating agent according to the conventionally known method, for example, by reacting it in tetrahydrofuran in the presence of a base catalyst such as imidazole.

[0323] Step N4 is a step of converning Compound (XXXXIII) having a halogen atom into Compound (XXXXIV) having an ester group, and can be carried out by subjecting to lithiation using lithium-halogen exchange reaction between alkyl lithium and an organic halogenated material as described in “Organometallic Chemistry (New Experimental Chemistry Lecture 12)”, Maruzen (1975), and then, {circumflex over (1)} carbon dioxide is reacted for carboxylation, subsequently to treate it with an alkylating agent such as dimethyl sulfate, or {circumflex over (2)} it is treated with a carbonate ester such as dimethyl carbonate.

[0324] A reaction of producing Compound (XXXXV) from Compound (XXXXIV) in Step N5 is carried out by the conventionally known method, for example, by subjecting to deprotection reaction using a tetra-n-butyl ammonium fluoride 1.0M tetrahydrofuran solution in tetrahydrofuran.

[0325] Step N6 is carried out by reacting Compound (XXXXV) and trifluoromethanesulfonic anhydride in a solvent in the presence of a base, and it is carried out in the same manner as the process of obtaining Compound (XX) in the above-mentioned Step G1 except for using Compound (XXXXII) in place of Compound (XIX).

[0326] Step N7 is a coupling reaction of Compound (XXXXVI) and Compound (XXI). The present reaction is carried out by using a palladium catalyst in an inert gas atmosphere in a solvent. The present reaction is carried out in the same manner as the process of obtaining Compound (If) in the above-mentioned Step G2 except for using Compound (XXXXVI) in place of Compound (XX).

[0327] Preparation processs O is a preparation processs of Compound (XXIV).

[0328] Step O1 is a coupling reaction of Compound (XXXXVII) and Compound (XXI). The present reaction is carried out by using a palladium catalyst in an inert gas atmosphere in a solvent. The present reaction is carried out in the same method of obtaining Compound (If) in the above-mentioned Step G2 except for using Compound (XXXXVII) in place of Compound (XX), and copresenting neither lithium chloride nor lithium bromide.

[0329] Preparation processs P is a method of providing Compound (XXIII) to be used in Step H1 of Preparation processs H.

[0330] Step P1 is carried out by using Compound (XXXXVIII) and α,β-unsaturated aldehyde in a solvent in the presence of an acid catalyst as disclosed in J.Org. Chem., 42, 911 (1977).

[0331] Step P2 is carried out, for example, as disclosed in Japanese Provisional Patent Publication No. Hei.9-31059, by using Compound (XXXXIX) in a solvent with a brominating agent such as N-bromosuccin imide, and a radical initiator such as benzoyl peroxide and 2,2′-azobis(isobutyronitrile).

[0332] Step P3 is easily carried out by reacting Compound (XXXXX) with triphenylphosphine according to the conventionally known method in a solvent.

[0333] Preparation processs Q is a method of producing Compound (XXIX) to be used in Step I1 of Preparation processs I, and can be carried out by using Compound (XXXXXII) according to the conventionally known method, for example, with a brominating agent such as N-bromosuccin imide in the presence of a radical initiator such as benzoyl peroxide and 2,2′-azobis(isobutyronitrile).

[0334] In Compound (II), Compound (XIX) and Compound (XXI), there exist optical isomers (including diastereomer) due to an asymmetric carbon(s) and/or geometric (E, Z) isomers due to an unsaturated carbon(s). These respective isomers can be separated by treating the corresponding racemic isomers or geometric isomer mixture by usual optical resolution methods (fractional crystallization method, optical resolution column chromatography method or diastereimer method, etc.) or separation methods (recrystallization method, column chromatography method, etc.). For example, optical isomers are to be separated, Compound (I) which is racemic mixture is reacted with optically active sulfonic acid Compound ((S) or (R)-camphor-10-sulfonic acid, etc.), to obtain one of the diastereomer salts, if necessary, further subjecting to purification, the resulting diastereomer salt is decomposed according to the conventional manner to obtain an optical isomer.

[0335] Incidentally, Compounds (XXII), (XXIII), (XXIIIa), (XXV), (XXIX), (XXX), (XXXII), (XXXIV), (XXXVIII), (XXXa), (XXXXVII), (XXXXVIII), (XXXXXII) and other sub-starting materials which are used as starting materials in Preparation processs H, Preparation processs I, Preparation processs J, Preparation processs K, Preparation processs L, Preparation processs N, Preparation processs O, Preparation processs P and Preparation processs Q are each known compound or can be easily produced according to the conventionally known method.

[0336] Utilizability in Industry

[0337] The compound represented by the formula (I) according to the present invention has potent leukotriene antagonistic action, and is extremely useful as an antiallergic agent and an anti-inflammatory agent.

[0338] As an administration form for the purposes, there may be mentioned, for example, an oral administration such as a tablet, a capsule, a granule, powder or a syrup, or a non-oral administration such as an intravenous injection, an intra-muscular injection, a suppository, an inhalant, an aerosol or an ophthalmic solution. A dose for administration may vary depending on an age, a body weight, symptom and a form of administration as wel as a number of administration, and it is usually administered about 0.1 to 1,000 mg per day once or divided to several times to an adult person.

EXAMPLES

[0339] In the following, the present invention is further explained in more detail by referring to Test examples and Examples, but the scope of the present invention is not limited by these.

Test Example 1

[0340] Leukotriene D4 Receptor Binding Test

[0341] <Preparation of Receptor Sample>

[0342] As a receptor sample, a lung cell membrane fraction from guinea pigs was used. Preparation of the membrane fraction was carried out according to the method of Ahn et al. (Eur. J. Pharmacol., 127, 153-155 (1986)). Lungs of Hartley male guinea pigs (400 to 500 g body weight, Nippon SLC Co.) were extracted, and perfused with a physiological saline, and then, adding 10 mM of PIPES, 10 mM of MgCl2 and 10 mM of CaCl2 buffer (pH 7.5) to the lung tissue and the mixture was homogenized. This homogenate was centrifuged at 70,000 xg for 10 minutes to obtain a membrane fraction.

[0343] <Leukotriene D4 Recepter Binding Test>

[0344] Leukotriene D4 (LTD4) recepter binding test was carried out according to the method of Aharony, et al. (J. Pharmacol. Expl.Ther., 243, 921-926 (1987)). To 0.42 mg of the receptor sample were added 10 mM of PIPES, 10 mM of MgCl2 and 10 mM of CaCl2 buffer (pH 7.5) to make the total amount of 480 μl, and 10 μl of [3H] LTD4 (NEN Life Science Products Co.) and 10 μl of a Test compound in dimethylsulfoxide were added to the mixture, and the resulting mixture was incubated at 25° C. for 30 minutes. The mixtures thus incubated were filtered through a glass fiber filter (Whatman Co., GF/C) using cell harvester (Brandel Co., M-30R). The filter were washed with 10 mM of Tris. and 100 mM of NaCl buffer (pH 7.5), and 5 ml of a liquid scintillator (NACALAI TESQUE INC., clearsol I), and radioactivity was measured by a liquid scintillation analyzer (Packard Co., 2000CA). When a dissociation constant (Kd) of LTD4 was to be obtained, [3H] LTD4 with 0.03 to 0.5 nM was used, and 1 μM of non-radioactive LTD4 was added. When a binding inhibition constant (Ki) of the Test compound is to be meaured, [3H] LTD4 with 0.2 nM was used. Kd and Ki are calculated according to the method of Bennett et al. (Neurotransmitter Receptor Binding, 2nd ed., edited by H. I. Yamamura et al., pp. 61-89, Raven Press (1985)). The results are shown in Table 2.

TABLE 2
Results of leukotriene D4 receptor binding test
		pKi		pKi
	Test compound	value	Test compound	value
	Compound of	9.5	Compound of	9.5
	Example 2 (b)		Example 26
	Compound of	9.8	Compound of	9.1
	Example 3		Example 32 (b)
	Compound of	9.8	Compound of	9.2
	Example 4		Example 34 (b)
	Compound of	9.6	Compound of	9.4
	Example 5 (b)		Example 35 (b)
	Compound of	9.7	Compound of	9.1
	Example 7 (b)		Example 40
	Compound of	9.8	Compound of	9.9
	Example 12		Example 43
	Compound of	9.2	Compound of	9.7
	Example 13 (b)		Example 44
	Compound of	9.2	Compound of	9.8
	Example 14		Example 45
	Compound of	9.8	Compound of	9.8
	Example 15		Example 51 (c)
	Compound of	9.7	Compound of	9.9
	Example 19		Example 54 (b)
	Compound of	9.3	Compound of	9.3
	Example 23		Example 58
	Compound A	9.5

[0345] Compound A: 11-(2-carboxyethyl)thio-2-(7-chloro-6-fluoro-quinolin-2-yl)methoxy-6,11-dihydrodibenz[b,e]oxepine (see WO94/193445 publication)

Test Example 2

[0346] Leukotriene D4 Induced Respiratory Constriction Test

[0347] Respiratory constriction was measured by modifying the method of Konzett and Rossler (Arch. Exp. Pathol. Pharmakol., 195, pp. 71-74 (1940)). Hartley male guinea pigs (400 to 500 g body weight, Nippon SLC Co.) were anesthetized with pentobarbital (50 mg/kg, s.c.), and a cannula was inserted into the trachea to carry out artificial ventilation with an artificial ventilator (manufactured by Harvard Co., Model 683). An inner pressure of the respiratory tract was measured by a differential pressure transducer (Nihon Koden, TP-603T) connected to the respiratory cannula and it is used as an index of respiratory constriction.

[0348] LTD4 (0.03, 0.06, 0.13, 0.25, 0.5, 1 and 2 μg/kg, Sigma Co.) was intravenously administered from a cannula inserted into the right jugular vein from a low dose with an interval of 5 minutes to cause a respiratory constriction reaction and an increased amount of a respiratory inner pressure was measured. Test compound was suspended in 0.5% sodium carboxymethyl cellulose aqueous solution, and orally administered 1 hour before administration of LTD4. Animals were fasted for 24 hours before administration of the Test compound. From a dose-reaction curve of LTD4, 50% reaction dose (ED50) was measured, and a dose (A2) of the Test compound required for shifting two-times of a dose-reaction curve of a control group to a higher dose side was calculated from the formula shown below.

A2=(Dose of Compound administered)/{(ED50 of group to which Compound was added)/(ED50 of control group)−1}

[0349] The results are shown in Table 3.

TABLE 3
Results of leukotriene D4 induced respiratory constriction test
              A2
Test compound (mg/kg p.o. 1 hr)
Compound of   0.0017
Example 2 (b)
Compound of   0.0036
Example 3
Compound of   0.0037
Example 4
Compound of   0.0026
Example 5 (b)
Compound of   0.0035
Example 7 (b)
Compound of   0.0049
Example 12
Compound of   0.0078
Example 13 (b)
Compound of   0.0044
Example 14
Compound of   0.0008
Example 15
Compound of   0.0024
Example 19
Compound of   0.0057
Example 23
Compound of   0.0094
Example 32 (b)
Compound of   0.0077
Example 34 (b)
Compound of   0.0066
Example 35 (b)
Compound of   0.0088
Example 40
Compound of   0.0013
Example 43
Compound of   0.005
Example 44
Compound of   0.0036
Example 51 (c)
Compound of   0.0023
Example 54 (b)
Compound of   0.0064
Example 58
Compound A    0.016

[0350] Compound A: 11-(2-carboxyethyl)thio-2-(7-chloro-6-fluoro-quinolin-2-yl)methoxy-6,11-dihydrodibenz[b,e]oxepine (see WO 94/193445 publication)

Example 1

(a) Methyl [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetate: (Methyl Ester of Exemplary Compound 1)

[0351] In 10 ml of tetrahydrofuran was dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine (1.20 g, 2.99 mmol), and after cooling to 0° C., triethylamine (0.85 ml, 5.98 mmol) and methanesulfonyl chloride (0.30 ml, 3.89 mmol) were added to the solution, and the mixture was stirred at 0° C. for 1 hour, and further at room temperature for 3 hours.

[0352] After completion of the reaction, the solvent was removed under reduced pressure. The resulting residue was dissolved in a mixed solution of 15 ml of N,N-dimethylformamide and 5 ml of tetrahydrofuran, methyl glycolate (0.54 g, 5.98 mmol) was added to the mixture and the mixture was stirred at room temperature overnight.

[0353] Then, water was added to the reaction mixture, the resulting mixture was extracted with chloroform, the organic layer was washed with water, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=2/1(volume ratio)) to obtain 0.38 g of the desired compound as white solid.

(b) [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetic acid: (Exemplary Compound I)

[0354] In a mixed solution comprising 15 ml of methyl alcohol and 5 ml of tetrahydrofuran was dissolved methyl [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetate (0.38 g, 0.81 mmol), an aqueous 1N-sodium hydroxide solution (2.40 ml, 2.40 mmol) was added to the solution, and the mixture was stirred at room temperature for 5 hours.

[0355] After completion of the reaction, the reaction solution was adjusted to pH about 6.5 by using a dil. acetic acid aqueous solution and the mixture was concentrated under reduced pressure. Water was added to the residue and the precipitated solid was collected by filtration. The resulting solid was washed with diethyl ether, and then, dried under reduced pressure to obtain 0.26 g of the desired compound as yellowish solid.

[0356] m.p.; 206 to 208° C.

[0357] FAB-MS(m/z); 460(M++1)

[0358] 1 H-NMR(δ, DMSO-d6); 4.03(s, 1H), 5.02(d, J=12.2 Hz, 1H), 5.49(s, 1H), 6.06(d, J=12.2 Hz, 1H), 6.88(d, J=8.5 Hz, 1H), 7.31-7.50(m, 4H), 7.65(dd, J=8.5, 2.2 Hz, 1H), 7.74(d, J=16.4 Hz, 1H), 7.80(d, J=1.9 Hz, 1H), 7.80(d, J=16.4 Hz, 1H), 7.89(d, J=8.80 Hz, 1H), 7.96(dd, J=12.0, 8.0 Hz, 1H), 8.02(dd, J=11.2, 9.0 Hz, 1H), 8.34(d, J=8.8 Hz, 1H).

(c) Sodium [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetate

[0359] In a mixed solution comprising 15 ml of tetrahydrofuran and 5 ml of methanol was dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetic acid (0.27 g, 0.58 mmol), an aqueous 1.0N-sodium hydroxide solution (5.80 ml, 0.58 mmol) was added to the mixture, and the resulting mixture was stirred at room temperature for 1 hour.

[0360] After completion of the reaction, the reaction solution was concentrated, the residue was washed with a mixed solution of ethyl acetate and diethyl ether, and dried under reduced pressure to obtain 0.10 g of the desired compound as pale yellowish powder.

[0361] m.p.; 202 to 205° C.

[0362] FAB-MS(m/z); 482(M++1)

Example 2

(a) 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 155)

[0363] In a mixed solution comprising 6 ml of trifluoroacetic acid and 40 ml of methylene chloride was dissolved [2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine (0.77 g, 1.90 mmol), and under ice-cooling, 3-mercaptopropionic acid (0.18 ml, 2.09 mmol) was added thereto and then, the mixture was stirred at room temperature for 30 minutes.

[0364] After completion of the reaction, the reaction solution was concentrated, water was added to the residue and the precipitated solid was collected by filtration. The obtained solid was dissolved in a mixed solution of chloroform:methanol=4:1, and the solution was dried over anhydrous sodium sulfate and the solvent was removed. The resulting residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=4/1 (volume ratio)), washed with diethyl ether, and then, dried under reduced pressure to obtain 0.22 g of the desired compound as yellowish solid.

[0365] m.p.; 204 to 207° C.

[0366] FAB-MS(m/z); 506(M++1)

[0367] 1 H-NMR (δ, DMSO-d6); 2.45-2.80(m, 4H), 5.01(d, J=12.9 Hz, 1H), 5.37(s, 1H), 6.18(d, J=12.9 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.35(d, J=16.1 Hz, 1H), 7.30-7.50(m, 4H), 7.56(dd, J=8.5, 2.2 Hz, 1H), 7.71(d, J=2.2 Hz, 1H), 7.77(d, J=16.4 Hz, 1H), 7.93(d, J=8.8 Hz, 1H), 7.99(d, J=9.8 Hz, 1H), 8.19(d, J=7.1 Hz, 1H), 8.35(d, J=8.8 Hz, 1H), 11.50-13.00(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0368] In a mixed solution comprising 10 ml of methanol, 20 ml of chloroform and 5 ml of tetrahydrofuran was dissolved 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid (0.10 g, 0.20 mmol), then, at room temperature, an aqueous 1N-sodium hydroxide solution (0.20 ml, 0.20 mmol) was added to the mixture, and the resulting mixture was stirred at room temperature for 30 minutes.

[0369] After completion of the reaction, the reaction solution was concentrated, the residue was washed with diethyl ether, and dried under reduced pressure to obtain 0.09 g of the desired compound as pale yellowish solid.

[0370] m.p.; 234 to 244° C. (decomposed)

[0371] FAB-MS(m/z); 528(M++1)

Example 3

{1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid trifluoroacetic acid salt: (Trifluoroacetic Acid Salt of Exemplary Compound 42)

[0372] In a mixed solution comprising 1.0 ml of trifluoroacetic acid and 20 ml of methylene chloride was dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine (0.20 g, 0.48 mmol), [1-(mercaptomethyl)cyclopropyl]acetic acid (0.10 g, 0.68 mmol) was added to the solution, and the mixture was stirred at room temperature for 1 hour.

[0373] After completion of the reaction, the reaction solution was concentrated, water was added to the residue and the precipitated solid was collected by filtration. The resulting solid was washed with ethyl acetate, and dried under reduced pressure to obtain 0.17 g of the desired compound as yellowish solid.

[0374] m.p.; 174 to 179° C.

[0375] FAB-MS(m/z); 548(M++1)

[0376] 1 H-NMR(δ, DMSO-d6); 0.30-0.50(m, 4H), 2.20-2.40(m, 2H), 2.58(d, J=12.9 Hz, 1H), 2.81(d, J=12.7 Hz, 1H), 5.31(d, J=13.4 Hz, 1H), 5.31(s, 1H), 6.04(d, J=15.9 Hz, 1H), 6.92(d, J=8.5 Hz, 1H), 7.35(d, J=16.6 Hz, 1H), 7.21-7.38(m, 3H), 7.61(d, J=8.8 Hz, 1H), 7.68(s, 1H), 7.80(d, J=16.4 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.97(dd, J=12.0, 7.8 Hz, 1H), 8.04(dd, J=11.0, 9.0 Hz, 1H), 8.37(d, J=8.9 Hz, 1H), 11.00-13.00(br.s, 1H)

[0377] In the same manner as in Example 2, compounds of the following Examples 4 to 41 were obtained.

Example 4

Sodium [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioacetate: (Exemplary Compound 5)

[0378] Appearance; yellowish solid.

[0379] m.p.; 210 to 225° C.

[0380] FAB-MS(m/z); 498(M++1)

[0381] 1 H-NMR(δ, DMSO-d6); 3.14(d, J=17.8 Hz, 1H), 3.19(d, J=17.5 Hz, 1H), 5.01(d, J=12.9 Hz, 1H), 5.44(s, 1H), 6.16(d, J=12.7 Hz, 1H), 6.87(d, J=8.3 Hz, 1H), 7.31(d, J=16.4 Hz, 1H), 7.35-7.45(m, 4H), 7.58(dd, J=8.5, 2.0 Hz, 1H), 7.68(d, J=2.0 Hz, 1H), 7.77(d, J=16.1 Hz, 1H), 7.88(d, J=8.6 Hz, 1H), 7.94(dd, J=11.9, 7.8 Hz, 1H), 8.00(dd, J=11.0, 9.0 Hz, 1H), 8.32(d, J=8.8 Hz, 1H)

Example 5

(a) 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 6)

[0382] Appearance; yellowish solid

[0383] m.p.; 213 to 216° C.

[0384] FAB-MS(m/z); 490(M++1)

[0385] 1 H-NMR(δ, DMSO-d6); 2.49-2.72(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.87(d, J=3.9 Hz, 1H), 7.34(d, J=16.4 Hz, 1H), 7.36-7.47(m, 4H), 7.57(dd, J=8.5, 2.2 Hz, 1H), 7.71(d, J=2.2 Hz, 1H), 7.79(d, J=16.4 Hz, 1H), 7.90(d, J=9.0 Hz, 1H), 7.95(dd, J=12.0, 7.8 Hz, 1H), 8.04(dd, J=11.2, 9.0 Hz, 1H), 8.37(d, J=8.5 Hz, 1H)

(b) Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0386] Appearance: red brownish solid

[0387] m.p.; 213 to 216° C.

[0388] FAB-MS(m/z); 512(M++1)

Example 6

(a) 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2,2-dimethylpropionic acid: (Exemplary Compound 8)

[0389] Appearance; yellowish solid

[0390] FAB-MS(m/z); 518(M++1)

[0391] 1 H-NMR(δ, DMSO-d6); 1.10(d, J=16.6 Hz, 6H), 2.56(d, J=12.9 Hz, 1H), 2.85(d, J=12.9 Hz, 1H), 5.02(d, J=12.9 Hz, 1H), 5.23(s, 1H), 6.21(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.33(d, J=16.4 Hz, 1H), 7.38-7.45(m, 4H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.66(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.88(d, J=8.8 Hz, 1H), 7.95(dd, J=12.0, 7.8 Hz, 1H), 8.02(dd, J=9.0, 2.2 Hz, 1H), 8.35(d, J=8.8 Hz, 1H), 12.43(br.s, 1H)

(b) Sodium3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2,2-dimethylpropionate

[0392] Appearance; yellowish solid

[0393] m.p.; 181 to 184° C.

[0394] FAB-MS (m/z); 540 (M++1)

Example 7

(a) {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 14)

[0395] Appearance; pale yellowish solid

[0396] m.p.; 170 to 173° C.

[0397] FAB-MS(m/z); 530(M++1)

[0398] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.23(d, J=16.1 Hz, 1H), 2.34(d, J=16.1 Hz, 1H), 2.53(d, J=12.7 Hz, 1H), 2.80(d, J=12.9 Hz, 1H), 5.02(d, J=12.7 Hz, 1H), 5.23(s, 1H), 6.24(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.30-7.50(m, 5H), 7.58(dd, J=8.5, 2.0 Hz, 1H), 7.66(d, J=2.0 Hz, 1H), 7.78(d, J=16.1 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.95(dd, J=12.0, 8.1 Hz, 1H), 8.02(dd, J=11.0, 8.8 Hz, 1H), 8.35(d, J=8.8 Hz, 1H), 11.5-12.5,(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0399] Appearance; yellowish solid

[0400] m.p.; 137 to 139° C.

[0401] FAB-MS(m/z); 552(M++1)

Example 8

(a) 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoic acid: (Exemplary Compound 16)

[0402] Appearance; yellowish solid

[0403] FAB-MS(m/z); 538(M++1)

[0404] 1 H-NMR(δ, DMSO-d6); 5.07(d, J=12.7 Hz, 1H), 6.37(s, 1H), 6.33(d, J=12.7 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 7.16-7.21(m, 2H), 7.25-7.42(m, 5H), 7.52-7.60(m, 2H), 7.66-7.76(m, 3H), 7.86(d, J=8.5 Hz, 1H), 7.95(dd, J=11.7, 7.8 Hz, 1H), 8.03(dd, J=11.0, 9.0 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

(b) Sodium 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoate

[0405] Appearance; pale yellowish solid

[0406] m.p.; 183 to 186° C.

[0407] FAB-MS(m/z); 560(M++1)

Example 9

(a) 3-[(2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiolbenzoic acid: (Exemplary Compound 17)

[0408] Appearance; yellowish solid

[0409] FAB-MS(m/z); 538(M++1)

[0410] 1 H-NMR(δ, DMSO-d6); 5.11(d, J=12.9 Hz, 1H), 5.79(s, 1H), 6.30(d, J=12.9 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 6.99(d, J=6.8 Hz, 1H), 7.15(t, J=6.1 Hz, 1H), 7.24-7.32(m, 2H), 7.40-7.45(m, 2H), 7.56(dd, J=8.5, 2.2 Hz, 1H), 7.63(J=7.8 Hz, 1H), 7.71-7.76(m, 2H), 7.84-7.90(m, 3H), 7.95(dd, J=12.0, 7.8 Hz, 1H), 8.03(dd, J=11.0, 9.1 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

(b) Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoate

[0411] Appearance; pale yellowish solid

[0412] m.p.; 184 to 188° C.

[0413] FAB-MS(m/z); 560(M++1)

Example 10

(a) 4-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoic acid: (Exemplary Compound 18)

[0414] Appearance; yellowish solid

[0415] FAB-MS(m/z); 538(M++1)

[0416] 1 H-NMR(δ, DMSO-d6); 5.11(d, J=13.2 Hz, 1H), 5.93(s, 1H), 6.24(d, J=12.9 Hz, 1H), 6.92(d, J=8.5 Hz, 1H), 7.15-7.33(m, 4H), 7.43(d, J=7.1 Hz, 1H), 7.55-7.59(m, 3H), 7.72-7.77(m, 2H), 7.83-7.88(m, 3H), 7.94(dd, J=12.0, 7.8 Hz, 1H), 8.03(dd, J=11.2, 9.0 Hz, 1H), 8.35(d, J=8.5 Hz, 1H), 13.00(br.s, 1H)

(b) Sodium 4-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoate

[0417] Appearance; pale yellowish solid

[0418] m.p.; 285 to 287° C. (decomposed)

[0419] FAB-MS(m/z); 560(M++1)

Example 11

Sodium 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}ethanesulfonate: (Exemplary Compound 31)

[0420] Appearance; pale brownish solid.

[0421] m.p.; 246 to 254° C.

[0422] FAB-MS(m/z); 548(M++1)

[0423] 1 H-NMR(δ, DMSO-d6); 2.60-2.85(m; 4H), 5.00(d, J=12.7 Hz, 1H), 5.38(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.85(d, J=8.5 Hz, 1H), 7.34-7.46(m, 5H), 7.55(dd, J=8.5, 2.0 Hz, 1H), 7.75(s, 1H), 7.78(d, J=16.1 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.96(dd, J=11.9, 8.0 Hz, 1H), 8.02(dd, J=11.2, 8.9 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

Example 12

3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 36)

[0424] m.p.; 224 to 227° C.

[0425] FAB-MS(m/z); 508(M++1)

[0426] 1 H-NMR(δ, DMSO-d6); 2.54-2.75(m, 4H), 5.31(d, J=13.7 Hz, 1H), 5.44(s, 1H), 5.98(d, J=13.7 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 7.35(d, J=16.4 Hz, 1H), 7.24-7.47(m, 3H), 7.59(dd, J=8.5, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.95(dd, J=11.8, 7.9 Hz, 1H), 8.19(dd, J=11.0, 9.0 Hz, 1H), 8.35(d, J=8.8 Hz, 1H), 11.00-13.00(br.s, 1H)

Example 13

(a) 3-{[7-cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 60)

[0427] Appearance; yellowish solid

[0428] m.p.; 261 to 264° C. (decomposed)

[0429] FAB-MS(m/z); 513(M+−1)

[0430] 1 H-NMR(δ, DMSO-d6); 2.55-2.66(m, 2H), 2.68-2.73(m, 2H), 5.27(d, J=13.7 Hz, 1H), 5.52(s, 1H), 6.24(d, J=13.7 Hz, 1H), 6.95(d, J=8.6 Hz, 1H), 7.36(d, J=16.1 Hz, 1H), 7.61(t, J=7.8 Hz, 1H), 7.62(dd, J=8.6, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.78(dd, J=7.8, 1.5 Hz, 1H), 7.79(d, J=16.1 Hz, 1H), 7.88(dd, J=7.8, 1.5 Hz, 1H), 7.90(d, J=8.8 Hz, 1H), 7.95(dd, J=11.7, 7.8 Hz, 1H), 8.03(dd, J=11.0, 8.8 Hz, 1H), 8.36(d, J=8.8 Hz, 1H), 11.70(br.s, 1H)

(b) Sodium 3-{[7-cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0431] Appearance; yellowish white solid

[0432] m.p.; 179 to 182° C.

[0433] FAB-MS(m/z); 537(M++1)

Example 14

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-trifluoromethyl-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate: (Sodium Salt of Exemplary Compound 84)

[0434] Appearance; yellowish white solid

[0435] FAB-MS(m/z); 580(M++1)

[0436] 1 H-NMR(δ, DMSO-d6); 2.09-2.20(m, 2H), 2.58-2.61(m, 1H), 2.72-2.75(m, 1H), 5.25(d, J=14.2 Hz, 1H), 5.65(s, 1H), 6.28(d, J=13.7 Hz, 1H), 6.88(d, J=8.6 Hz, 1H), 7.37(d, J=16.4 Hz, 1H), 7.55-7.62(m, 2H), 7.76-7.81(m, 4H), 7.90(d, J=8.8 Hz, 1H), 7.97(dd, J=12.0, 7.8 Hz, 1H), 8.02(dd, J=11.0, 9.0 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

Example 15

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-ethynyl-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate: (Sodium Salt of Exemplary Compound 108)

[0437] Appearance; pale orange solid

[0438] m.p.; 186 to 189° C.

[0439] FAB-MS(m/z); 535(M++1)

[0440] 1 H-NMR(δ, DMSO-d6); 2.09-2.25(m, 2H), 2.55-2.61(m, 1H), 2.68-2.78(m, 1H), 5.44(s, 1H), 5.45(d, J=12.9 Hz, 1H), 6.15(d, J=12.9 Hz, 1H), 6.87(d, J=8.6 Hz, 1H), 7.36(d, J=16.4 Hz, 1H), 7.37(t, J=7.6 Hz, 1H), 7.47-7.52(m, 2H), 7.56(dd, J=8.5, 2.2 Hz, 1H), 7.73(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.96(dd, J=12.0, 8.1 Hz, 1H), 8.04(dd, J=11.2 Hz, 9.0 Hz, 1H), 8.34(d, J=8.6 Hz, 1H)

Example 16

3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 159)

[0441] Appearance; yellowish solid

[0442] m.p.; 238 to 241° C.

[0443] FAB-MS(m/z); 524(M++1)

[0444] 1 H-NMR(δ, DMSO-d6); 2.54-2.76(m, 4H), 5.31(d, J=13.4 Hz, 1H), 5.45(s, 1H), 5.99(d, J=13.4 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 7.30(d, J=16.4 Hz, 1H), 7.24-7.47(m, 3H), 7.59(dd, J=8.5, 2.2 Hz, 1H), 7.72(d, J=1.9 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.93(d, J=8.5 Hz, 1H), 8.00(d, J=9.8 Hz, 1H), 8.19(d, J=7.3 Hz, 1H), 8.36(d, J=8.8 Hz, 1H), 12.32(br.s, 1H)

Example 17

{1-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 162)

[0445] Appearance; yellowish solid

[0446] m.p.; 237 to 239° C.

[0447] FAB-MS(m/z); 564(M++1)

[0448] 1 H-NMR(δ, DMSO-d6); 0.30-0.50(m, 4H), 2.23(d, J=15.9 Hz, 1H), 2.31(d, J=15.9 Hz, 1H), 2.58(d, J=12.9 Hz, 1H), 2.82(d, J=12.7 Hz, 1H), 5.31(d, J=13.4 Hz, 1H), 5.31(s, 1H), 6.04(d, J=13.4 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 7.35(d, J=16.4 Hz, 1H), 7.21-7.44((m, 3H), 7.61(dd, J=8.5, 1.9 Hz, 1H), 7.68(d, J=1.9 Hz, 1H), 7.80(d, J=16.4 Hz, 1H), 7.94(d, J=8.5 Hz, 1H), 8.00(d, J=9.8 Hz, 1H), 8.19(d, J=7.3 Hz, 1H), 8.36(d, J=8.8 Hz, 1H), 12.08(br.s, 1H)

Example 18

(a) 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 171)

[0449] Appearance; pale yellowish solid

[0450] 1 H-NMR(δ, DMSO-d6); 2.45-2.80(m, 4H), 5.02(d, J=12.7 Hz, 1H), 5.37(s, 1H), 6.19(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.30-7.55(m, 6H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.70(dd, J=10.3, 2.4 Hz, 1H), 7.72(s, 1H), 7.80(d, J=15.6 Hz, 1H), 7.84(d, J=8.5 Hz, 1H), 8.04(dd, J=9.0, 6.3 Hz, 1H), 8.38(d, J=8.8 Hz, 1H), 12.33(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0451] Appearance; yellowish solid

[0452] m.p.; 160 to 163° C.

[0453] FAB-MS(m/z); 494(M++1)

Example 19

Sodium 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-(R)-methylpropionate: (Sodium Salt of Exemplary Compound 172)

[0454] Appearance; pale yellowish powder

[0455] m.p.; 195 to 205° C.

[0456] FAB-MS(m/z); 508(M++1)

[0457] 1 H-NMR(δ, DMSO-d6); 0.98-1.03(m, 3H), 2.15-2.90(m, 3H), 5.00(d, J=12.7 Hz, 1H), 5.33(d, J=8.6, 1H), 6.23(dd, J=12 7, 6.1 Hz, 1H), 6.85(d, J=8.5 Hz, 1H), 7.33-7.51(m, 6H), 7.56(d, J=8.6 Hz, 1H), 7.69-7.86(m, 4H), 8.03(dd, J=9.0, 6.6 Hz, 1H), 8.38(d, J=8.5 Hz, 1H),

Example 20

(a) {1-[[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 174)

[0458] Appearance; yellowish solid

[0459] FAB-MS(m/z); 512(M++1)

[0460] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.23(d, J=15.9 Hz, 1H), 2.34(d, J=15.9 Hz, 1H), 2.53(d, J=12.7 Hz, 1H), 2.81(d, J=12.9 Hz, 1H), 5.02(d, J=12.9 Hz, 1H), 5.23(s, 1H), 6.24(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.35(d, J=16.1 Hz, 1H), 7.30-7.50(m, 4H), 7.48(dd, J=8.5, 2.7 Hz, 1H), 7.59(dd, J=8.5, 2.0 Hz, 1H), 7.68(d, J=2.2 Hz, 1H), 7.70(dd, J=10.5, 2.7 Hz, 1H), 7.80(d, J=16.8 Hz, 1H), 7.84(d, J=8.8 Hz, 1H), 8.03(dd, J=9.0, 6.6 Hz, 1H), 8.38(d, J=8.5 Hz, 1H), 11.5-12.5(br.s, 1H)

(b) Sodium {1-[(2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0461] Appearance; yellowish solid

[0462] m.p; 149 to 152° C.

[0463] FAB-MS(m/z); 534(M++1)

Example 21

[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioacetic acid: (Exemplary Compound 223)

[0464] Appearance; yellowish red solid

[0465] m.p.; 221 to 231° C. (decomposed)

[0466] FAB-MS(m/z); 474(M++1)

[0467] 1 H-NMR(δ, DMSO-d6); 3.25(s, 2H), 5.04(d, J=12.7 Hz, 1H), 5.40(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.91(d, J=8.5 Hz, 1H), 7.30-7.50(m, 5H), 7.62(dd, J=8.8, 2.0 Hz, 2H), 7.68(d, J=1.7 Hz, 1H), 7.88(d, J=16.4 Hz, 1H), 7.98(d, J=8.5 Hz, 1H), 8.02(d, J=2.9 Hz, 1H)

Example 22

3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 224)

[0468] Appearance; yellowish solid

[0469] m.p.; 195 to 198° C.

[0470] FAB-MS(m/z); 488(M++1)

[0471] 1 H-NMR(δ, DMSO-d6); 2.45-2.75(m, 4H), 5.02(d, J=12.7 Hz, 1H), 5.37(s, 1H), 6.19(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.35(d, J=16.4 Hz, 1H), 7.30-7.50(m, 4H), 7.58(dd, J=8.8, 2.2 Hz, 2H), 7.72(d, J=2.2 Hz, 1H), 7.79(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.99(d, J=9.0 Hz, 1H), 8.01(s, 1H), 8.38(d, J=8.5 Hz, 1H), 12.27(br.s, 1H)

Example 23

Sodium 3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-(R)-methylpropionate: (Sodium Salt of Exemplary Compound 225)

[0472] Appearance; yellowish powder

[0473] m.p.; 207 to 217° C.

[0474] FAB-MS(m/z); 524(M++1)

[0475] 1 H-NMR(δ, DMSO-d6); 0.97-1.04(m, 3H), 2.17-2.90(m, 3H), 4.99(dd, J=12.7, 2.69 Hz, 1H), 5.34(d, J=10.0, 1H), 6.23(dd, J=12.7, 6.8 Hz, 1H), 6.84(d, J=8.6 Hz, 1H), 7.33-7.42(m, 5H), 7.56(d, J=5.6 Hz, 1H), 7.57(dd, J=8.55, 2.2 Hz, 1H), 7.74-7.82(m, 2H), 7.89(dd, J=8.7, 1.8 Hz, 1H), 7.97-8.02(m, 2H), 8.34(d, J=8.6 Hz, 1H)

Example 24

{1-[[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 227)

[0476] Appearance; yellowish solid

[0477] m.p.; 204 to 206° C.

[0478] FAB-MS(m/z); 528(M++1)

[0479] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.22(d, J=16.1 Hz, 1H), 2.33(d, J=16.1 Hz, 1H), 2.53(d, J=12.9 Hz, 1H), 2.80(d, J=12.9 Hz, 1H), 5.02(d, J=12.7 Hz, 1H), 5.23(s, 1H), 6.23(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.30-7.50(m, 5H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.59(dd, J=8.3, 2.2 Hz, 1H), 7.67(d, J=2.2 Hz, 1H), 7.80(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.99(d, J=8.8 Hz, 1H), 8.01(s, 1H), 8.38(d, J=8.5 Hz, 1H), 12.08(br.s, 1H)

Example 25

3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 229)

[0480] Appearance; pale yellowish solid

[0481] m.p.; 150 to 153° C.

[0482] FAB-MS(m/z); 480(M++H)

[0483] 1 H-NMR(δ, DMSO-d6); 1.65-1.95(m, 4H), 2.00-2.25(m, 2H), 2.45-2.95(m, 6H), 4.96(d, J=12.7 Hz, 1H), 5.30(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.79(d, J=8.5 Hz, 1H), 7.11(d, J=16.1 Hz, 1H), 7.25-7.55(m, 8H), 7.60(d, J=2.2 Hz, 1H)

Example 26

Sodium 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-(R)-methylpropionate: (Sodium Salt of Exemplary Compound 230)

[0484] Appearance; pale yellowish powder

[0485] m.p.; 168 to 173° C.

[0486] FAB-MS(m/z); 494(M++1)

[0487] 1 H-NMR(δ, DMSO-d6); 1.02(t, 3H), 1.74-1.84(m, 4H), 2.12-2.26(m, 2H), 2.68-2.88(m, 5H), 4.96(dd, J=12.7, 1.9 Hz, 1H), 5.28(d, J=8.3, 1H), 6.20(dd, J=12.7, 5.4 Hz, 1H), 6.80(d, J=8.5 Hz, 1H), 7.10(dd, J=16.1, 4.6 Hz, 1H), 7.27-7.49(m, 8H), 7.61(d, J=2.9 Hz, 1H)

Example 27

Sodium 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-3-methylbutanoate: (Sodium Salt of Exemplary Compound 234)

[0488] Appearance; yellowish white-tinted powder

[0489] m.p.; 168 to 175° C.

[0490] FAB-MS(m/z); 508(M++1)

[0491] 1 H-NMR(δ, DMSO-d6); 1.35(s, 3H), 1.37(s, 3H), 1.74-1.84(m, 4H), 2.26(d, J=13.2 Hz, 1H), 2.31(d, J=13.2 Hz, 1H), 2.71-2.85(m, 4H), 4.96(d, J=12.7 Hz, 1H), 5.56(s, 1H), 6.20(d, J=12.7 Hz, 1H), 6.74(d, J=8.5 Hz, 1H), 7.09(d, J=16.1 Hz, 1H), 7.28-7.50(m, 9H), 7.66(d, J=2.2 Hz, 1H)

Example 28

(a) {1-[[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 235)

[0492] Appearance; yellow greenish solid

[0493] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 1.70-1.90(m, 4H), 2.22(d, J=15.9 Hz, 1H), 2.32(d, J=15.6 Hz, 1H), 2.45-2.90(m, 6H), 4.99(d, J=12.7 Hz, 1H), 5.18(s, 1H), 6.20(d, J=12.7 Hz, 1H), 6.81(d, J=8.5 Hz, 1H), 7.10(d, J=16.1 Hz, 1H), 7.15-7.45(m, 4H), 7.47(d, J=16.4 Hz, 1H), 7.47(dd, J=8.8, 2.2 Hz, 1H), 7.56(d, J=2.2 Hz, 1H), 11.0-13.0(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0494] Appearance; pale yellowish solid

[0495] m.p.; 142 to 145° C.

[0496] FAB-MS(m/z); 520(M++1)

Example 29

(a) 3-{[2-[(E)-2-(4-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 336)

[0497] Appearance; yellowish solid

[0498] FAB-MS(m/z); 488(M++1)

[0499] 1 H-NMR(δ, DMSO-d6); 2.40-2.75(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.88(d, J=8.5 Hz, 1H), 7.34(d, J=16.4 Hz, 1H), 7.35-7.50(m, 4H), 7.57(dd, J=8.5, 2.2 Hz, 1H), 7.65-7.75(m, 1H), 7.72(d, J=2.4 Hz, 1H), 7.85(d, J=16.8 Hz, 1H), 7.80-7.90(m, 1H), 8.05(d, J=8.5 Hz, 1H), 8.13(s, 1H), 8.16(d, J=8.3 Hz, 1H), 12.29(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(4-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0500] Appearance; yellowish solid

[0501] m.p.; 140 to 142° C.

[0502] FAB-MS(m/z); 510(M++1)

Example 30

(a) 3-{[2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 340)

[0503] Appearance; yellowish solid

[0504] 1 H-NMR(δ, DMSO-d6); 2.45-2.80(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.19(d, J=12.7 Hz, 1H), 7.10-7.50(m, 6H), 7.60(dd, J=8.5, 2.2 Hz, 2H), 7.65-7.80(m, 2H), 7.82(d, J=9.0 Hz, 1H), 7.83(d, J=16.6 Hz, 1H), 7.94(d, J=8.8 Hz, 1H), 8.45(d, J=8.8 Hz, 1H), 12.27(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0505] Appearance; yellowish solid

[0506] m.p.; 150 to 152° C.

[0507] FAB-MS(m/z); 494(M++1)

Example 31

(a) {1-[[2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 343)

[0508] Appearance; yellowish solid

[0509] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.24(d, J=16.1 Hz, 1H), 2.35(d, J=16.1 Hz, 1H), 2.55(d, J=12.7 Hz, 1H), 2.82(d, J=12.9 Hz, 1H), 5.03(d, J=12.7 Hz, 1H), 5.24(s, 1H), 6.26(d, J=12.7 Hz, 1H), 6.89(d, J=8.5 Hz, 1H), 7.10-7.50(m, 6H), 7.62(dd, J=8.5, 2.0 Hz, 1H), 7.71(d, J=2.0 Hz, 1H), 7.47(td, J=7.8, 6.1 Hz, 1H), 7.83(d, J=8.5 Hz, 1H), 7.85(d, J=16.1 Hz, 1H), 7.96(d, J=8.8 Hz, 1H), 8.47(d, J=8.5 Hz, 1H), 12.13(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0510] Appearance; yellowish solid

[0511] m.p.; 142 to 144° C.

[0512] FAB-MS(m/z); 534(M++1)

Example 32

(a) 3-{[2-[(E)-2-(5,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 348)

[0513] Appearance; yellowish solid

[0514] FAB-MS(m/z); 490(M++1)

[0515] 1 H-NMR(δ, DMSO-d6); 2.40-2.80(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.19(d, J=12.7 Hz, 1H), 6.88(d, J=8.5 Hz, 1H), 7.30-7.50(m, 5H), 7.52(td, J=10.0, 2.4 Hz, 1H), 7.55-7.65(m, 1H), 7.59(dd, J=8.5, 2.2 Hz, 1H), 7.73(d, J=2.2 Hz, 1H), 7.85(d, J=16.4 Hz, 1H), 7.91(d, J=8.8 Hz, 1H), 8.45(d, J=8.8 Hz, 1H), 12.0-12.5(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(5,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0516] Appearance; pale yellowish solid

[0517] m.p.; 210 to 213° C.

[0518] FAB-MS(m/z); 512(M++1)

Example 33

(a) {1-[[2-[(E)-2-(5,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 351)

[0519] Appearance; yellowish solid

[0520] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.22(d, J=15.9 Hz, 1H), 2.33(d, J=15.9 Hz, 1H), 2.52(d, J=12.9 Hz, 1H), 2.80(d, J=12.9 Hz, 1H), 5.02(d, J=12.7 Hz, 1H), 5.23(s, 1H), 6.24(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.36(d, J=16.4 Hz, 1H), 7.30-7.50(m, 4H), 7.52(dd, J=10.0, 2.4 Hz, 1H), 7.61(dd, J=8.5, 2.0 Hz, 2H), 7.69(d, J=2.0 Hz, 1H), 7.85(d, J=16.4 Hz, 1H), 7.92(d, J=8.8 Hz, 1H), 8.45(d, J=8.8 Hz, 1H), 11.5-12.5(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(5,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl)cyclopropyl}acetate

[0521] Appearance; yellowish solid

[0522] m.p.; 149 to 152° C.

[0523] FAB-MS(m/z); 552 (M++1)

Example 34

(a) 3-{(2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 356)

[0524] Appearance; yellowish solid

[0525] FAB-MS(m/z); 508(M++1)

[0526] 1 H-NMR(δ, DMSO-d6); 2.45-2.80(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.19(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.36(d, J=16.4 Hz), 7.35-7.50(m, 4H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.84(d, J=16.4 Hz, 1H), 7.87(ddd, J=11.7, 7.1, 2.0 Hz, 1H), 7.97(d, J=8.8 Hz, 1H), 8.49(d, J=8.8 Hz, 1H), 11.5-13.0(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0527] Appearance; pale yellowish solid

[0528] m.p.; 235 to 237° C.

[0529] FAB-MS(m/z); 530(M++1)

Example 35

(a) {1-[[2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 359)

[0530] Appearance; yellowish solid

[0531] FAB-MS(m/z); 570(M++1)

[0532] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.22(d, J=15.9 Hz, 1H), 2.34(d, J=16.1 Hz, 1H), 2.52 (d, J=12.5 Hz, 1H), 2.80(d, J=12.7 Hz, 1H), 5.02(d, J=12.7 Hz, 1H), 5.23(s, 1H), 6.24(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.36(d, J=16.4 Hz, 1H), 7.30-7.50(m, 4H), 7.60(dd, J=8.5, 2.0 Hz, 2H), 7.68(d, J=1.7 Hz, 1H), 7.84(d, J=16.4 Hz, 1H), 7.80-7.95(m, 1H), 7.98(d, J=9.0 Hz, 1H), 8.49(d, J=8.8 Hz, 1H), 12.1(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0533] Appearance; yellowish solid

[0534] m.p.; 195 to 198° C.

[0535] FAB-MS(m/z); 570(M++1)

Example 36

(a) 3-{[2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 364)

[0536] Appearance; yellowish solid

[0537] FAB-MS(m/z); 478(M++1)

[0538] 1 H-NMR(δ, DMSO-d6); 2.45-2.80(m, 4H), 5.03(d, J=12.9 Hz, 1H), 5.32(s, 1H), 6.20(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.33(td, J=9.0, 2.4 Hz, 1H), 7.35-7.50(m, 4H), 7.48(d, J=16.1 Hz, 1H), 7.62(d, J=16.4 Hz, 1H), 7.64(dd, J=8.5, 2.2 Hz, 1H), 7.75(d, J=2.2 Hz, 1H), 7.79(dd, J=10.0, 2.4 Hz, 1H), 8.13(dd, J=9.0, 5.4 Hz, 1H), 12.31(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0539] Appearance; pale yellowish solid

[0540] m.p.;>300° C.

[0541] FAB-MS(m/z); 500(M++1)

Example 37

(a) {1-[[2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid: (Exemplary Compound 367)

[0542] Appearance; yellowish solid

[0543] FAB-MS(m/z); 518(M++1)

[0544] 1 H-NMR(δ, DMSO-d6); 0.30-0.60(m, 4H), 2.22(d, J=16.1 Hz, 1H), 2.34(d, J=15.9 Hz, 1H), 2.53 (d, J=12.7 Hz, 1H), 2.80(d, J=12.9 Hz, 1H), 5.03(d, J=12.7 Hz, 1H), 5.19(s, 1H), 6.25(d, J=12.5 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.10-7.50(m, 5H), 7.47(d, J=16.1 Hz, 1H), 7.63(d, J=15.9 Hz, 1H), 7-64(dd, J=8.8, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.79(dd, J=10.0, 0.4 Hz, 1H), 8.12(dd, J=9.0, 5.4 Hz, 1H), 11.5-12.5(br.s, 1H)

(b) Sodium {1-[[2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetate

[0545] Appearance; yellowish solid

[0546] m.p.; 155 to 157° C.

[0547] FAB-MS(m/z); 540(M++1)

Example 38

(a) 3-{[2-[(E)-2-(5-fluoro-2-benzoxazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 372)

[0548] Appearance; pale brownish solid

[0549] FAB-MS(m/z); 462(M++1)

[0550] 1 H-NMR(δ, DMSO-d6); 2.45-2.75(m, 4H), 5.03(d, J=12.7 Hz, 1H), 5.32(s, 1H), 6.20(d, J=13.2 Hz, 1H), 6.88(d, J=8.3 Hz, 1H), 7.17(d, J=16.1 Hz, 1H), 7.25(ddd, J=9.8, 8.8, 2.4 Hz, 1H), 7.35-7.50(m, 4H), 7.59(dd, J=8.8, 2.9 Hz, 1H), 7.66(dd, J=8.8, 2.0 Hz, 1H), 7.74(dd, J=8.8, 4.4 Hz, 1H), 7.76(d, J=16.6 Hz, 1H), 7.78(d, J=2.4 Hz, 1H), 12.0-13.0(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(5-fluoro-2-benzoxazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0551] Appearance; brownish solid

[0552] m.p.; 247 to 250° C.

[0553] FAB-MS(m/z); 484(M++1)

Example 39

(a) 3-{[2-[(E)-2-(6-isopropyl-5-methyl-2-pyridyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 380)

[0554] Appearance; yellowish solid

[0555] FAB-MS(m/z); 460(M++1)

[0556] 1 H-NMR(δ, DMSO-d6); 1.25(d, J=6.6 Hz, 6H), 2.27(s, 3H), 2.44-2.68(m, 4H), 3.20-3.35(m, 1H), 4.98(d, J=12.9 Hz, 1H), 5.36(s, 1H), 6.17(d, J=12.7 Hz, 1H), 7.10(d, J=15.9 Hz, 1H), 7.24(d, J=7.8 Hz, 1H), 7.37-7.55(m, 7H), 7.59(d, J=2.2 Hz, 1H)

(b) Sodium 3-{[2-[(E)-2-(6-isopropyl-5-methyl-2-pyridyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0557] Appearance; white solid

[0558] m.p.; 137 to 139° C.

[0559] FAB-MS(m/z); 482(M++1)

Example 40

Sodium 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}propionate: (Sodium Salt of Exemplary Compound 384)

[0560] Appearance; yellowish solid

[0561] m.p.; 179 to 182° C.

[0562] FAB-MS(m/z); 509(M+)

[0563] 1 H-NMR(δ, DMSO-d6); 2.00-2.20(m, 2H), 2.52-2.70(m, 2H), 2.80-3.00(m, 2H), 3.50-4.00(m, 2H), 5.33(s, 1H), 7.00-7.60(m, 4H), 7.22(d, J=7.8 Hz, 1H), 7.46(d, J=16.1 Hz, 1H), 7.54(d, J=7.3 Hz, 1H), 7.65-8.20(m, 3H), 7.81(d, J=16.1 Hz, 1H), 7.91(d, J=8.8 Hz, 1H), 8.36(d, J=8.5 Hz, 1H)

Example 41

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]thiepin-11-yl]thio}propionate: (Sodium Salt of Exemplary Compound 400)

[0564] Appearance; pale brownish solid

[0565] m.p.; 144 to 148° C.

[0566] FAB-MS(m/z); 528(M++1)

[0567] 1 H-NMR(δ, DMSO-d6); 2.10-2.30(m, 2H), 2.55-2.65(m, 2H), 3.60-4.10(br.s, 1H), 5.10-6.00 (br.s, 1H), 5.50(s, 1H), 7.09(d, J=8.1 Hz, 1H), 7.20-7.60(m, 5H), 7.43(d, J=15.6, 1H), 7.77(d, J=16.4, 1H), 7.80-8.20(m, 4H), 8.35(d, J=9.0 Hz, 1H)

Example 42

(a) Ethyl 1-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl}cyclopropanecarboxylate: (Ethyl Ester of Exemplary Compound 9)

[0568] In a mixed solution comprising 10 ml of methylene chloride and 3 ml of trifluoroacetic acid was dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine (1.0 g, 2.49 mmol), and ethyl 1-(mercaptomethyl)cycloprpanecarboxylate (0.80 g, 4.98 mmol) was added to the solution and the mixture was stirred at room temperature for 1 hour.

[0569] After completion of the reaction, the reaction solution was concentrated, water was added to the residue, a pH of the mixture was adjusted to about 6.5 with sodium hydrogen carbonate, and then, the mixture was extracted with chloroform. The organic layer was washed with water, dried over anhydrous sodium sulfate and then concentrated, and applied to silica gel chromatography (eluent: hexane/ethyl acetate=2/1 (volume ratio)) to obtain 1.30 g of the desired compound as pale yellowish viscous oily product.

[0570] EI-MS(m/z); 543(M+), CI-MS(m/z); 544(M++1)

(b) 1-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl}cyclopropanecarboxylic acid: (Exemplary Compound 9)

[0571] In a mixed solution comprising 20 ml of methanol and 10 ml of tetrahydrofuran was dissolved ethyl 1-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl}cyclopropanecarboxylate (1.3 g, 2.4 mmol), and an aqueous 1N-sodium hydroxide solution (7.2 ml, 7.2 mmol) was added to the solution and the mixture was stirred at room temperature for 15 hours.

[0572] After completion of the reaction, the reaction solution was adjusted to pH about 6.5 by usig a dil. acetic acid aqueous solution, and the mixture was concentrated under reduced pressure. The residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate =1/1 (volume ratio)) to obtain 0.39 g of the desired compound as pale yellowish solid.

[0573] FAB-MS(m/z); 516(M++1)

[0574] 1 H-NMR(δ, DMSO-d6); 0.53-0.58(m, 1H), 0.82-0.87(m, 1H), 1.02-1.09(m, 1H), 2.60(d, J=13.5 Hz, 1H), 2.98(d, J=13.1 Hz, 1H), 5.02(d, J=12.7 Hz, 1H), 5.33(s, 1H), 6.20(d, J=12.7 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.30-7.47(m, 5H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.67(d, J=2.2 Hz, 1H), 7.78(d, J=16.3 Hz, 1H), 7.90(d, J=8.79 Hz, 1H), 7.95(dd, J=12.0, 8.06 Hz, 1H), 8.03(dd, J=11.0, 8.8 Hz, 1H), 8.34(d, J=8.8 Hz, 1H), 12.4(br.s, 1H)

(c) Sodium 1-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl}cyclopropanecarboxylate

[0575] In a mixed solution comprising 15 ml of tetrahydrofuran and 5 ml of methanol was dissolved 1-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl}cyclopropanecarboxylic acid (0.39 g, 0.76 mmol), an aqueous 0.5N-sodium hydroxide solution (1.52 ml, 0.76 mmol) was added to the solution and the mixture was stirred at room temperature for 2 hours.

[0576] After completion of the reaction, the reaction solution was concentrated, the residue was washed with diethyl ether, and dried under reduced pressure to obtain 0.35 g of the desired compound as pale yellowish powder.

[0577] m.p.; 175 to 185° C.

[0578] FAB-MS(M/Z); 538(M++1)

[0579] In the same manner as in

Example 42, the following Compounds of Examples 43 to 45 were obtained.

Example 43

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-(S)-methyl-propionate: (Sodium Salt of Exemplary Compound 7)

[0580] Appearance; ocherous powder

[0581] m.p.; 193 to 216° C.

[0582] FAB-MS(m/z); 526(M++1)

[0583] 1 H-NMR(δ, DMSO-d6); 0.95-1.00(m, 3H), 2.14-2.89(m, 3H), 4.98(dd, J=12.5, 2.9 Hz, 1H), 5.34(d, J=13.7 Hz, 1H), 6.20(dd, J=12.3, 10.2 Hz, 1H), 6.83(dd, J=8.5, 1.22 Hz, 1H), 7.33-7.41 (m, 5H), 7.53(dd, J=8.5, 2.2 Hz, 1H), 7.75(s, 1H), 7.78(d, J=16.1 Hz, 1H), 7.89(dd, J=8.5, 2.6 Hz, 1H), 7.97(dd, J=12.0, 8.3 Hz, 1H), 8.03(dd, J=11.0, 8.8 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

Example 44

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-(R)-methylpropionate: (Sodium Salt of Exemplary Compound 7)

[0584] Appearance; ocherous powder

[0585] m.p.; 196 to 220° C.

[0586] FAB-MS(m/z); 526(M++1)

[0587] 1 H-NMR(δ, DMSO-d6); 0.96-1.01(m, 3H), 2.20-2.89(m, 3H), 4.98(dd, J=12.7, 2.7 Hz, 1H), 5.34(d, J=11.7 Hz, 1H), 6.21(dd, J=12.5, 8.3 Hz, 1H), 6.83(d, J=8.8 Hz, 1H), 7.33-7.44(m, 5H), 7.46(s, 1H), 7.55(d, J=8.5 Hz, 1H), 7.77(d, J=16.1, 1H), 7.89(d, J=8.5 Hz, 1H), 7.97(dd, J=12.0, 8.1 Hz, 1H), 8.03 (dd, J=11.0,8.8 Hz, 1H), 8.34(d, J=8.8 Hz, 1H)

Example 45

Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-ethylpropionate: (Sodium Salt of Exemplary Compound 10)

[0588] Appearance; pale yellowish powder

[0589] m.p.; 209 to 218° C.

[0590] FAB-MS(m/z); 540(M++1)

[0591] 1 H-NMR(δ, DMSO-d6); 0.78(t, 3H), 1.41(m, 2H), 2.06(m, 1H), 2.54-2.63(m, 2H), 4.97(d, J=12.7 Hz, 1H), 5.31(s, 1H), 6.22(d, J=12.5 Hz, 1H), 6.83(d, J=8.5 Hz, 1H), 7.33-7.41(m, 5H), 7.54(d, J=8.5 Hz, 1H), 7.77(d, J=16.4 Hz, 1H), 7.78(d, J=2.2 Hz, 1H), 7.90(d, J=8.8 Hz, 1H), 7.99(dd, J=12.45, 7.57 Hz, 1H), 8.03(dd, J=11.2, 9.0 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

Example 46

(a) 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-trifluoromethanesulfonylpropionamide: (Exemplary Compound 28)

[0592] In 20 ml of tetrahydrofuran were dissolved 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiopropionic acid (0.54 g, 1.1 mmol) and trifluoromethanesulfonamide (0.24 g, 1.6 mmol), and then, dimethylaminopyridine(0.13 g, 1.1 mmol) and ethyl(dimethylaminopropyl)carbodiimide hydrochloride (0.34 g, 1.8 mmol) were successively added to the solution and the mixture was stirred at room temperature for 23 hours.

[0593] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, the organic layer was washed with a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated, and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=1/1 (volume ratio)) to obtain 0.30 g of the desired compound as yellowish solid.

[0594] m.p.; 152 to 156° C.

[0595] FAB-MS(m/z); 621(M++1)

[0596] 1 H-NMR(δ, DMSO-d6); 2.35-2.70(m, 4H), 5.00(d, J=12.7 Hz, 1H), 5.35(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.85(d, J=8.6 Hz, 1H), 7.35(d, J=16.3 Hz, 1H), 7.35-7.46(m, 4H), 7.56(dd, J=8.6, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.95(dd, J=12.0, 8.2 Hz, 1H), 8.02(dd, J=11.0, 9.03 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

(b) 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-trifluoromethanesulfonylpropionamide hydrochloride

[0597] In 2 ml of tetrahydrofuran was dissolved sodium 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-trifluoromethanesulfonylpropionamide (0.12 g, 0.19 mmol), 1N-hydrochloric acid (0.20 ml, 0.20 mmol) was added to the solution and the mixture was stirred at room temperature for 10 minutes. The formed precipitate was further diluted with distilled water and the formed precipitate was collected by filtration. The obtained solid was washed with distilled water and dried under reduced pressure to obtain 0.10 g of the, desired compound as yellowish solid.

[0598] m.p.; 234 to 238° C.

[0599] FAB-MS(m/z); 621(M++1)

[0600] 1 H-NMR(δ, DMSO-d6); 2.44-2.67(m, 4H), 5.02(d, J=12.7 Hz, 1H), 5.36(s, 1H), 6.18(d, J=12.7 Hz, 1H), 6.89(d, J=8.5 Hz, 1H), 7.35(d, J=16.1 Hz, 1H), 7.36(m, 4H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.74(d, J=2.2 Hz, 1H), 7.90(d, J=16, 1 Hz, 1H), 7.99(dd, J=11.5, 7.6 Hz, 1H), 8.04(d, J=9.3 Hz, 1H), 8.13(dd, J=11.0, 8.8 Hz, 1H), 8.52(d, J=8.8 Hz, 1H)

Example 47

(a) [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylacetamide: (Exemplary Compound 22)

[0601] In 20 ml of tetrahydrofuran were dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioacetic acid (0.66 g, 1.33 mmol) and trifluoromethanesulfonamide (0.20 g, 2.10 mmol), and then, dimethylaminopyridine (0.39 g, 4.42 mmol) and ethyl(dimethylaminopropyl) carbodiimide hydrochloride (0.37 g, 1.93 mmol) were successively added to the solution, and the mixture was stirred at room temperature for 1.5 hours.

[0602] After completion of the reaction, water was added to the reaction solution, and the mixture was adjusted to pH about 5.0 with 1N-hydrochloric acid. The mixture was extracted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=2/3 (volume ratio)) to obtain 0.23 g of the desired compound as yellowish solid.

[0603] m.p.; 228 to 234° C. (decomposed)

[0604] FAB-MS(m/z); 553(M++1)

[0605] 1 H-NMR(δ, DMSO-d6); 3.25(s, 3H), 3.30-3.39(m, 2H), 5.04(d, J=12.9 Hz, 1H), 5.37(s, 1H), 6.16(d, J=12.9 Hz, 1H), 6.90(d, J=8.3 Hz, 1H), 7.34(d, J=16.1 Hz, 1H), 7.37-7.48(m, 4H), 7.61(dd, J=8.6, 2.0 Hz, 1H), 7.64(d, J=2.0 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.87(d, J=8.5 Hz, 1H), 7.96(dd, J=12.0, 7.8 Hz, 1H), 8.02(dd, J=11.0, 9.0 Hz, 1H), 8.35(d, J=8.6 Hz, 1H), 11.93(br.s, 1H)

(b) [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylacetamide sodium salt

[0606] In 4 ml of tetrahydrofuran was dissolved under heating [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylacetamide (0.11 g, 0.20 mmol), and an aqueous 1N-sodium hydroxide solution (0.2 ml, 0.20 mmol) was added to the solution and the mixture was stirred at room temperature for 1 hour.

[0607] After completion of the reaction, the solvent was removed under reduced pressure, diethyl ether was added to the resulting residue to form crystal, and the crystal was collected by filtration, washed with diethyl ether and dried under reduced pressure to obtain 0.07 g of the desired compound as beige color solid.

[0608] m.p.; 178 to 183° C.

[0609] FAB-MS(m/z); 575(M++1)

[0610] In the same manner as in Example 47, the compounds of the following Examples 48 to 49 were obtained.

Example 48

[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-trifluoromethanesulfonylacetamide sodium salt: (Sodium Salt of Exemplary Compound 23)

[0611] Appearance; orange solid.

[0612] m.p.; 182 to 186° C.

[0613] FAB-MS(m/z); 629(M++1)

[0614] 1 H-NMR(δ, DMSO-d6); 2.96(d, J=14.4 Hz, 1H), 3.06(d, J=14.7 Hz, 1H), 5.01(d, J=12.7 Hz, 1H), 5.53(s, 1H), 6.11(d, J=12.9 Hz, 1H), 6.87(d, J=8.3 Hz, 1H), 7.34(d, J=16.4 Hz, 1H), 7.33-7.45(m, 4H), 7.57(dd, J=8.5, 2.0 Hz, 1H), 7.7l(d, J=2.0 Hz, 1H), 7.77(d, J=16.4 Hz, 1H), 7.84(d, J=8.6 Hz, 1H), 7.96(dd, J=12.0, 8.05 Hz, 1H), 8.01(dd, J=11.2, 8.8 Hz, 1H), 8.35(d, J=8.6 Hz, 1H)

Example 49

(a) 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylpropionamide: (Exemplary Compound 27)

[0615] Appearance; orange solid.

[0616] FAB-MS(m/z); 567(M++1)

[0617] 1 H-NMR(δ, DMSO-d6); 2.65-2.72(m, 4H), 3.25(s, 3H), 5.02(d, J=12.9 Hz, 1H), 5.35(s, 1H), 6.15(d, J=12.7 Hz, 1H), 6.87(d, J=8.3 Hz, 1H), 7.35(1H, J=16.4 Hz, 1H), 7.39-7.46(m, 4H), 7.57(dd, J=8.6, 2.2 Hz, 1H), 7.71(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.87(d, J=8.5 Hz, 1H), 7.94(dd, J=12.0, 7.8 Hz, 1H), 8.03(dd, J=11.0, 8.8 Hz, 1H), 8.36(d, J=8.5 Hz, 1H), 11.83(s, 1H)

(b) 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylpropionamide sodium salt

[0618] Appearance; brownish solid

[0619] m.p.; 187 to 192° C.

[0620] FAB-MS(m/z); 589(M++1)

Example 50

(a) N-t-butoxycarbonyl-N-{2-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioethyl}trifluoromethanesulfonamide

[0621] In 10 ml of tetrahydrofuran was dissolved [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-(2-hydroxyethyl)thio-6,11-dihydrodibenz[b,e]oxepine (0.29 g, 0.63 mmol), and then, N-t-butoxycarbonyltrifluoromethanesulfonamide (0.26 g, 1.04 mmol) and triphenylphosphine (0.26 g, 0.99 mmol) were added to the solution successively, and further a diethyl azodicarboxylate 2.2M toluene solution (0.40 ml, 0.88 mmol) was added to the mixture and the mixture was stirred at room temperature for 5 hours.

[0622] After completion of the reaction, the reaction solution was concentrated as such and the residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=9/1 (volume ratio)) to obtain 0.39 g of the desired compound as orange solid.

[0623] FAB-MS(m/z); 693(M++1)

[0624] 1 H-NMR(δ, DMSO-d6); 1.46(s, 9H), 2.71-2.75(m, 2H), 3.94-4.07(m, 2H), 5.04(d, J=12.9 Hz, 1H), 5.39(s, 1H), 6.18(d, J=12.9 Hz, 1H), 6.90(d, J=8.3 Hz, 1H), 7.36(d, J=15.9 Hz, 1H), 7.39-7.49 (m, 4H), 7.59(dd, J=8.6, 2.2 Hz, 1H), 7.78(d, J=2.2 Hz, 1H), 7.85(d, J=16.1 Hz, 1H), 7.95(dd, J=11.5, 7.8 Hz, 1H), 7.96(d, J=8.5 Hz, 1H), 8.09(dd, J=11.0, 8.8 Hz, 1H), 8.46(d, J=8.8 Hz, 1H)

(b) N-{2-(2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioethyl}trifluoromethanesulfonamide: (Exemplary Compound 26)

[0625] In 5 ml of tetrahydrofuran was dissolved N-t-butoxycarbonyl-N-{2-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioethyl}trifluoromethanesulfonamide (0.14 g, 0.20 mmol), and 7 ml of trifluoroacetic acid was added to the solution and the mixture was stirred at room temperature for 2 hours until the mixture becomes uniform solution.

[0626] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, the organic layer was washed successively with a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=9/1 (volume ratio)) to obtain 0.06 g of the desired compound as pale yellowish solid.

[0627] m.p.; 84 to 87° C.

[0628] FAB-MS(m/z); 593(M++1)

[0629] 1 H-NMR(δ, DMSO-d6); 2.63(t, J=7.1 Hz, 2H), 3.29-3.36(m, 2H), 5.02(d, J=12.7 Hz, 1H), 5.40(s, 1H), 6.20(d, J=12.9 Hz, 1H), 6.88(d, J=8.6 Hz, 1H), 7.35(d, J-16.4 Hz, 1H), 7.38-7.47(m, 4H), 7.58(dd, J=8.3, 2.2 Hz, 1H), 7.75(d, J=2.2 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.86(d, J-8.8 Hz, 1H), 7.93(dd, J=11.7, 7.8 Hz, 1H), 8.03(dd, J=11.0, 9.0 Hz, 1H), 8.36(d, J=8.8 Hz, 1H), 9.57(br.s, 1H)

Example 51

(a) Ethyl 4-[2-trifluoromethanesulfonyloxy-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate

[0630] In 4 ml of methylene chloride was dissolved ethyl 4-[2-hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate (0.34 g, 1.0 mmol), and then, triethylamine (0.6 ml, 4.3 mmol) and trifluoromethanesulfonic anhydride (0.4 ml, 2.6 mmol) were successively added to the solution and the mixture was stirred at room temperature for 20 minutes.

[0631] After completion of the reaction, the reaction solution was concentrated, and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=92/8 (volume ratio)) to obtain 0.37 g of the desired compound as pale yellowish liquid.

[0632] CI-MS(m/z); 459(M++1), EI-MS(m/z); 458(M+)

[0633] 1 H-NMR(δ, CDCl3); 1.22(t, J=7.1 Hz, 3H), 1.55(quintet, J=7.7 Hz, 2H), 2.06-2.17(m, 2H), 2.28(t, J=7.3 Hz, 2H), 3.79(t, J=7.8 Hz, 1H), 4.10(q, J=7.1 Hz, 2H), 4.98(d, J=14.4 Hz, 1H), 5.52(d, J=14.4 Hz, 1H), 6.99-7.12(m, 4H), 7.18-7.25(m, 3H)

(b) Ethyl 4-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate

[0634] In 5 ml of N,N-dimethylformamide was dissolved ethyl 4-[2-trifluoromethanesulfonyloxy-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate (0.36 g, 0.79 mmol), and then, tetra-n-butyl ammonium chloride (0.27 g, 0.97 mmol), sodium hydrogen carbonate (0.33 g, 3.11 mmol), lithium bromide (0.12 g, 1.38 mmol), 6,7-difluoro-2-vinylquinoline (0.30 g, 1.57 mmol) and tetrakis(triphenylphosphine)palladium (0) (70 mg, 0.06 mmol) were successively added to the solution and the mixture was stirred at room temperature for 6 hours under argon atmosphere.

[0635] After completion of the reaction, water was added to the reaction solution, the mixture was extracted with toluene, and the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=9/1 (volume ratio)) to obtain 91 mg of the desired compound as yellowish solid.

[0636] CI-MS(m/z); 500(M++1), EI-MS(m/z); 499(M+)

[0637] 1 H-NMR(δ, CDCl3); 1.23(t, J=7.1 Hz, 3H), 1.61(quintet, J=7.3 Hz, 2H), 2.05-2.27(m, 2H), 2.30(t, J=7.1 Hz, 2H), 3.85(t, J=7.8 Hz, 1H), 4.10(q, J=7.1 Hz, 2H), 5.00(d, J=14.4 Hz, 1H), 5.56(d, J=14.2 Hz, 1H), 6.99(d, J=8.8 Hz, 1H), 7.11-7.14(m, 1H), 7.19-7.24(m, 4H), 7.43-7.45(m, 2H), 7.50(dd, J=10.3, 8.3 Hz, 1H), 7.61(d, J=8.6 Hz, 1H), 7.64(d, J=15.9 Hz, 1H), 7.80(dd, J=11.2, 7.8 Hz, 1H), 8.04(d, J=8.8 Hz, 1H)

(c) Sodium 4-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate: (Sodium Salt of Exemplary Compound 32)

[0638] In 2 ml of dioxane was dissolved ethyl 4-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate (133 mg, 0.27 mmol), and 2 ml of an aqueous 2N-sodium hydroxide solution was added to the solution and the mixture was stirred at room temperature for 2 hours.

[0639] After completion of the reaction, 4 ml of 1N-hydrochloric acid was added to the reaction solution, the mixture was extracted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. Then, the resulting concentrated residue was dissolved in 2 ml of tetrahydrofuran, and an aqueous 1N-sodium hydroxide solution (0.25 ml, 0.25 mmol) was added to the mixture and the mixture was concentrated. To the obtained residue was added diethyl ether, and the formed precipitate was collected by filtration and washed with diethyl ether and dried under reduced pressure to obtain 87 mg of the desired compound as gray solid.

[0640] m.p.; 211 to 220° C.

[0641] FAB-MS(m/z); 494(M++1)

[0642] 1 H-NMR(δ, DMSO-d6); 1.30-1.51(m, 2H), 1.92(t, J=7.4 Hz, 2H), 2.05(q, J=7.3 Hz, 2H), 4.01(t, J=7.3 Hz, 1H), 5.01(d, J=13.9 Hz, 1H), 5.57(d, J=13.9 Hz, 1H), 6.90(d, J=8.3 Hz, 1H), 7.23-7.27(m, 4H), 7.35(d, J=16.4 Hz, 1H), 7.51(dd, J=8.3, 2.0 Hz, 1H), 7.61(d, J=2.0 Hz, 1H), 7.78(d, J=16.4 Hz, 1H), 7.88(d, J=8.8 Hz, 1H), 7.95(dd, J=12.0, 7.8 Hz, 1H), 8.02(dd, J=11.2, 9.0 Hz, 1H), 8.34(d, J=8.8 Hz, 1H)

Example 52

(a) 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Optical Resolution of Exemplary Compound 6)

[0643] (+)-(S)-Camphor-10-sulfonic acid monohydrate (167 mg, 0.67 mmol) was added to a mixed solution comprising 10 ml of N,N-dimethylformamide and 40 ml of acetonitrile containing 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid (730 mg, 1.49 mmol) obtained in Example 5(a), and the mixture was stirred at room temperature for 1 hour. The precipitated crystal was filtered off, and after adding (−)-(R)-camphor-10-sulfonic acid monohydrate (167 mg, 0.67 mmol) to the filtrate, and after the mixture was stirred at room temperature for 1 hour, precipitated crystal was collected by filtration. The resulting crystal was dissolved in 2.5 ml of dimethylsulfoxide, and then, 7.5 ml of water and sodium hydrogen carbonate (45 ml, 0.54 mmol) were added to the solution, and the mixture was stirred at room temperature for 30 minutes. The formed slurry liquid was adjusted to pH about 4.0 with an aqueous 10% acetic acid solution, and precipitated crystal was collected by filtration. The obtained crystal was dissolved in a mixed solution comprising 3 ml of N,N-dimethylformamide and 12 ml of acetonitrile, and then, (−)-(R)-camphor-10-sulfonic acid monohydrate (167 mg, 0.67 mmol) was added to the solution and the mixture was stirred at room temperature for 30 minutes, and the precipitated crystal was collected by filtration. The obtained crystal was dissolved in 1.5 ml of dimethylsulfoxide, 4.5 ml of water and sodium hydrogen carbonate (33 mg, 0.39 mmol) were added to the solution and the mixture was stirred at room temperature for 1 hour. The formed slurry liquid was adjusted to pH about 4.0 with an aqueous 10% acetic acid solution, and after collecting the crystal, it was dried under reduced pressure to obtain 159 mg of yellowish solid. This solid was subjected to HPLC analysis (Column CHIRAL-CEL OJ-R 0.46 φ×15 cm, eluent: CH3CN/2.0 mM H3PO4—KH2PO4 buffer (pH=4.0)=70/30(v/v), flow rate: 1.0 ml/min, measurement wavelength: 254 nm, measurement temperature: 40° C.), it was detected peaks at retension times of 6.8 and 13.2 minutes with a ratio of 95.5:4.5, and optical purity was 91.0% ee.

Example 53

3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-8-methoxycarbonyl-6,11-dihydrodibenz[b,e]oxepin-11-yl]-thio}propionic acid: (Exemplary Compound 1125)

[0644] In 40 ml of methylene chloride was dissolved [2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-11-methoxy-8-methoxycarbonyl-6,11-dihydrodibenz[b,e]oxepine (0.20 g, 0.45 mmol), and then, 3-mercaptopropionic acid (0 14 ml, 0.54 mmol) and boron trifluoride-diethyl ether complex (0.047 ml, 1.10 mmol) were successively added to the solution and the mixture was stirred at room temperature for 4 hours.

[0645] After completion of the reaction, water was added to the reaction solution, and the mixture was adjusted to pH about 6.0 with a saturated aqueous sodium hydrogen carbonate solution and extracted with chloroform. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. To the resulting residue was added diethyl ether to form crystal, and then, the mixture was filtered. The obtained crystal was washed with diethyl ether and dried under reduced pressure to obtain 0.17 g of the desired compound as yellowish solid.

[0646] m.p.; 121 to 123° C.

[0647] FAB-MS(m/z); 516(M++1)

[0648] 1 H-NMR(δ, DMSO-d6); 1.60-1.90(m, 4H), 2.60-2.90(m, 4H), 3.87(s, 3H), 5.15(d, J=12.9 Hz, 1H), 5.43(s, 1H), 6.09(d, J=12.7 Hz, 1H), 6.84(d, J=8.3 Hz, 1H), 7.10(d, J=15.9 Hz, 1H), 7.28(d, J=8.1 Hz, 1H), 7.43 (d, J=8.3 Hz, 1H), 7.47(d, J=16.1 Hz, 1H), 7.48(dd, J=8.5, 2.2 Hz, 1H), 7.54(d, J=7.8 Hz, 1H), 7.62(d, J=2.2 Hz, 1H), 7.95(dd, J=7.8, 2.0 Hz, 1H), 8.04(d, J=1.7 Hz, 1H)

[0649] In the same manner as in Example 2, compounds of the following Examples 54 to 58 were obtained.

Example 54

(a) 3-{[9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 404)

[0650] Appearance; yellow greenish solid

[0651] 1 H-NMR(δ, DMSO-d6); 2.63-2.73(m, 4H), 5.00(d, J=13.2 Hz, 1H), 5.33(s, 1H), 6.10(d, J=12.9 Hz, 1H), 6.83(d, J=8.2 Hz, 1H), 6.96(t, J=7.0 Hz, 1H), 7.19(t, J=7.6 Hz, 1H), 7.33 (d, J=7.9 Hz, 1H), 7.48(d, J=10.7 Hz, 1H), 7.52(d, J=19.2 Hz, 1H), 7.69(d, J=7.8 Hz, 1H), 7.82-8.08(m, 5H), 8.38(d, J=8.8 Hz, 1H)

(b) Sodium 3-{[9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0652] Appearance; yellowish white-tinted solid

[0653] m.p.; >300° C.

[0654] FAB-MS(m/z); 512(M++1)

Example 55

(a) 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}-2-(S)-methylpropionic acid: (Exemplary Compound 385)

[0655] Appearance; yellow greenish solid

[0656] 1 H-NMR(δ, DMSO-d6); 1.05(d, J=6.8 Hz, 3H), 2.41-2.73(m, 3H), 2.87(m, 2H), 3.70-3.74(m, 2H), 5.33(s, 1H), 7.15-7.25(m, 4H), 7.33(d, J=6.4 Hz, 1H), 7.46(d, J=16.4 Hz, 1H), 7.57(d, J=7.8 Hz, 1H), 7.72(s, 1H), 7.81(d, J=16.6 Hz, 1H), 7.91(dd, J=8.6, 2.7 Hz, 1H), 7.96(dd, J=9.2, 3.7 Hz, 1H), 8.04(dd, J=11.1, 8.9 Hz, 1H), 8.34(d, J=8.8 Hz, 1H)

(b) Sodium 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}-2-(S)-methylpropionate

[0657] Appearance; white powder

[0658] m.p.; 211 to 220° C.

[0659] FAB-MS(m/z); 524(M++1)

Example 56

(a) 3-{[2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 352)

[0660] Appearance; pale yellowish solid

[0661] FAB-MS(m/z); 540(M++1)

[0662] 1 H-NMR(δ, DMSO-d6); 2.45-2.80(m, 4H), 5.02(d, J=12.9 Hz, 1H), 5.37(s, 1H), 6.19(d, J=12.7 Hz, 1H), 6.88(d, J=8.5 Hz, 1H), 7.30-7.50(m, 5H), 7.58(dd, J=8.5, 2.2 Hz, 1H), 7.72(d, J=2.2 Hz, 1H), 7.84(d, J=16.4 Hz, 1H), 8.06(d, J=8.5 Hz, 1H), 8.08(d, J=11.2 Hz, 1H), 8.35(d, J=6.8 Hz, 1H), 8.44(d, J=8.8 Hz, 1H), 12.0-12.7(br.s, 1H)

(b) Sodium 3-{[2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0663] Appearance; yellowish solid

[0664] m.p.; 221 to 224° C. (decomposed)

[0665] FAB-MS(m/z); 494(M++1)

Example 57

(a) 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-8-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid: (Exemplary Compound 44)

[0666] Appearance; yellowish solid

[0667] 1 H-NMR(δ, DMSO-d6); 8.35(d, J=8.6 Hz, 1H), 8.06-7.31(m, 9H), 7.22(td, J=9.0 Hz, J=2.7 Hz, 1H), 6.89(d, J=8.6 Hz, 1H), 6.13(d, J=12.9 Hz, 1H), 5.42(s, 1H), 5.03(d, J=12.9 Hz, 1H), 2.66(t, J=5.9 Hz, 2H), 2.53(t, J=6.1 Hz, 2H)

(b) Sodium 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-8-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionate

[0668] Appearance; pale yellowish glossy solid

[0669] m.p.; 243 to 250° C.

Example 58

3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-3-methylbutanoic acid: (Sodium Salt of Exemplary Compound 12)

[0670] Appearance; pale yellowish solid

[0671] FAB-MS(m/z); 540(M++1)

[0672] 1 H-NMR(δ, DMSO-d6); 1.36(s, 3H), 1.39(s, 3H), 2.29(d, J=18.7 Hz, 1H), 2.34(d, J=18.7 Hz, 1H), 4.99(d, J=12.8 Hz, 1H), 5.64(s, 1H), 6.24(d, J=12.8 Hz, 1H), 6.80(d, J=8.5 Hz, 1H), 7.30-7.80(m, 8H), 7.90(d, J=8.8 Hz, 1H), 7.97(dd, J=8.1, 7.8 Hz, 1H), 8.02(dd, J=11.2, 9.0 Hz, 1H), 8.34(d, J=8.8 Hz, 1H)

Reference Example 1

(a) 2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0673] A 20 ml of acetic anhydride solution containing 7-chloro-6-fluoroquinaldine (0.82 g, 4.20 mmol) and 2-formyl-6,11-dihydrodibenz[b,e]oxepin-11-one (1.00 g, 4.20 mmol) was stirred at 125° C. for 72 hours.

[0674] After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and a saturated aqueous sodium hydrogen carbonate solution was added to the residue and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated. The obtained residue was applied to silica gel chromatography (eluent: toluene to toluene/ethyl acetate=25/1 (volume ratio)) to obtain 1.40 g of the desired compound as yellowish brown solid.

[0675] 1 H-NMR(δ, DMSO-d6); 5.36(s, 2H), 7.20(d, J=8.5 Hz, 1H), 7.49(d, J=8.5 Hz, 1H), 7.50-7.75(m, 5H), 7.73(dd, J=8.5, 2.4 Hz, 1H), 7.80(d, J=7.8 Hz, 1H), 7.96(d, J=9.8 Hz, 1H), 8.14(d, J=7.3 Hz, 1H), 8.23(d, J=2.0 Hz, 1H), 8.26(d, J=8.5 Hz, 1H)

(b) [2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0676] After suspending [2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one (1.40 g, 3.47 mmol) in a mixed solution comprising 40 ml of tetrahydrofuran and 40 ml of methanol, sodium borohydride (0.16 g, 4.16 mmol) was added to the suspension, and the mixture was stirred at room temperature overnight.

[0677] After completion of the reaction, the reaction mixture was concentrated, and the obtained residue was applied to silica gel chromatography (eluent: toluene to toluene/ethyl acetate=9/1 (volume ratio)) to obtain 0.77 g of the desired compound as yellowish solid.

[0678] FAB-MS(m/z); 418(M++1)

[0679] 1 H-NMR(δ, DMSO-d6); 5.30(d, J=12.2 Hz, 1H), 5.77(d, J=14.2 Hz, 1H), 5.97(d, J=3.9 Hz, 1H), 6.27(d, J=3.9 Hz, 1H), 6.83(d, J=8.5 Hz, 1H), 7.25-7.60(m, 5H), 7.70(dd, J=8.5, 2.2 Hz, 1H), 7.80(d, J=15.6 Hz, 1H), 7.92(d, J=8.8 Hz, 1H)

Reference Example 2

(a) [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0680] To 15 ml of tetrahydrofuran suspension containing [(6,7-difluoro-2-quinolinyl)methyl]triphenylphosphonium bromide (1.35 g, 2.59 mmol) suspended therein was added 1.7 ml of n-butyl lithium 1.57M hexane solution at −78° C., and the mixture was stirred at the same temperature for 30 minutes. Then, a solution of 2-formyl-6,11-dihydrodibenz[b,e]oxepin-11-one (0.59 g, 2.48 mmol) dissolved in 15 ml of tetrahydrofuran was added to the above mixture at −78° C. over 15 minutes, and the mixture was stirred at the same temperature for 1 hour.

[0681] After completion of the reaction, a saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated. The obtained residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=97/3 (volume ratio)) to obtain 0.31 g of the desired compound as yellowish solid.

[0682] CI-MS(m/z); 399(M+), EI-MS(m/z); 399(M+)

[0683] 1 H-NMR(δ, DMSO-d6); 5.37(s, 2H), 7.19(d, J=8.8 Hz, 1H), 7.44(d, J=15.9 Hz, 1H), 7.54-7.62 (m, 2H), 7.68(d, J=7.3 Hz, 1H), 7.82(d, J=7.8 Hz, 1H), 7.97-8.07(m, 5H), 8.36-8.39(m, 2H)

(b) 2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0684] The reaction was carried out in the same manner as in Reference example 1(b) except for using 2-[2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one (0.31 g, 0.77 mmol) in place of [2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one to obtain 0.10 g of the desired compound as yellowish solid.

[0685] CI-MS (m/z); 401(M+), EI-MS (m/z); 401(M+)

[0686] 1 H-NMR(δ, DMSO-d6); 5.38(d, J=12.4 Hz, 1H), 5.76(d, J=12.2 Hz, 1H), 5.94(s, 1H), 6.24(s, 1H), 6.82(d, J=8.5 Hz, 1H), 7.28-7.50(m, 5H), 7.56(dd, J=8.5, 2.2 Hz, 1H), 7.76-7.82(m, 2H), 7.88(d, J=8.8 Hz, 1H), 7.93(dd, J=12.0, 8.0 Hz, 1H), 8.01(dd, J=11.2, 9.0 Hz, 1H), 8.33(d, J=8.5 Hz, 1H)

[0687] In the same manner as in Reference example 2, compounds shown in the following Reference examples 3 to 13 were obtained.

Reference Example 3

(a) 2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0688] Appearance; pale yellowish solid

[0689] CI-MS(m/z); 382(M++1), EI-MS(m/z); 381(M+)

[0690] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.19(d, J=8.5 Hz, 1H), 7.45(d, J=16.4 Hz, 1H), 7.49(td, J=8.8, 2.7 Hz, 1H), 7.57(t, J=7.6 Hz, 1H), 7.61(d, J=6.6 Hz, 1H), 7.65-7.75(m, 2H), 7.82(d, J=7.6 Hz, 1H), 7.91(d, J=8.5 Hz, 1H), 7.94(d, J=16.4 Hz, 1H), 8.00-8.15(m, 2H), 8.37(d, J=2.2 Hz, 1H), 8.40(d, J=8.5 Hz, 1H)

(b) 2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0691] Appearance; yellow brownish solid

[0692] CI-MS(m/z); 384(M++1), EI-MS(m/z); 383(M+)

[0693] 1 H-NMR(δ, DMSO-d6); 5.29(d, J=12.5 Hz, 1H), 5.78(d, J=12.2 Hz, 1H), 5.96(d, J=3.7 Hz, 1H), 6.26(d, J=3.9 Hz, 1H), 6.83(d, J=8.3 Hz, 1H), 7.25-7.55(m, 5H), 7.33(d, J=16.4 Hz, 1H), 7.57(dd, J=8.5, 2.2 Hz, 1H), 7.69(dd, J=10.7, 2.7 Hz, 1H), 7.81(d, J=10.7 Hz, 1H), 7.82(d, J=2.0 Hz, 1H), 7.84(d, J=8.8 Hz, 1H), 8.02(dd, J=8.8, 6.6 Hz, 1H), 8.37(d, J=8.5 Hz, 1H)

Reference Example 4

(a) 2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0694] Appearance; pale yellowish solid

[0695] CI-MS(m/z); 398(M++1), EI-MS(m/z); 397(M+)

[0696] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.19(d, J=8.5 Hz, 1H), 7.45(d, J=16.4 Hz, 1H), 7.50-7.75 (m, 4H), 7.82(d, J=7.6 Hz, 1H), 7.94(d, J=16.1 Hz, 1H), 7.96(d, J=8.5 Hz, 1H), 8.00(d, J=8.8 Hz, 1H), 8.02(d, J=1.7 Hz, 1H), 8.06(dd, J=8.5, 2.4 Hz, 1H), 8.36(d, J=2.2 Hz, 1H), 8.40(d, J=8.8 Hz, 1H)

(b) 2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0697] Appearance; yellowish solid

[0698] CI-MS(m/z); 399(M+), EI-MS(m/z); 399(M+)

[0699] 1 H-NMR(δ, DMSO-d6); 5.28(d, J=12.4 Hz, 1H), 5.76(d, J=12.2 Hz, 1H), 5.95(d, J=3.7 Hz, 1H), 6.24(d, J=3.9 Hz, 1H), 6.82(d, J=8.5 Hz, 1H), 7.25-7.55(m, 5H), 7.57(dd, J=8.8, 2.2 Hz, 2H), 7.81(d, J=16.4 Hz, 1H), 7.81(d, J=2.0 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.98(d, J=8.8 Hz, 1H), 8.00(d, J=1.7 Hz, 1H), 8.36(d, J=8.8 Hz, 1H)

Reference Example 5

(a) 2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0700] Appearance; yellowish solid

[0701] CI-MS(m/z); 368(M++1), EI-MS(m/z); 367(M+)

[0702] 1 H-NMR(δ, DMSO-d6); 5.34(s, 2H), 7.14(d, J=8.5 Hz, 1H), 7.20(d, J=16.1 Hz, 1H), 7.34(d, J=8.1 Hz, 1H), 7.43(d, J=8.1 Hz, 1H), 7.50-7.75(m, 3H), 7.59(d, J=16.1 Hz, 1H), 7.81(d, J=7.1 Hz, 1H), 7.93(dd, J=8.5, 2.2 Hz, 1H), 7.26(d, J=2.2 Hz, 1H)

(b) 2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0703] Appearance; pale yellowish solid

[0704] CI-MS(m/z); 370(M++1), EI-MS(m/z); 369(M+)

[0705] 1 H-NMR(δ, DMSO-d6); 2.70-2.90(m, 4H), 2.73(t, J=6.3 Hz, 2H), 2.82(t, J=6.3 Hz, 2H), 5.23(d, J=12.5 Hz, 1H), 5.75(d, J=12.2 Hz, 1H), 5.89(s, 1H), 6.17(d, J=3.4 Hz, 1H), 6.77(d, J=8.5 Hz, 1H), 7.07(d, J=16.1 Hz, 1H), 7.20-7.55(m, 8H), 7.69(d, J=2.2 Hz, 1H)

Reference Example 6

(a) 2-[(E)-2-(4-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0706] Appearance; yellowish solid

[0707] CI-MS(m/z); 398(M++1), EI-MS(m/z); 397(M+)

[0708] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.19(d, J=8.8 Hz, 1H), 7.42(d, J=16.4 Hz, 1H), 7.57(td, J=7.6, 1.2 Hz, 1H), 7.61(d, J=6.6 Hz, 1H), 7.65-7.75(m, 2H), 7.83(dd, J=7.3, 1.5 Hz, 1H), 7.86(ddd, J=8.5, 7.1, 1.5 Hz, 1H), 7.99(d, J=16.6 Hz, 1H), 8.05(dd, J=8.5, 2.4 Hz, 1H), 8.07(d, J=7.8 Hz, 1H), 8.16(dd, J=8.5, 1.5 Hz, 1H), 8.20(s, 1H), 8.38(d, J=2.2 Hz, 1H)

(b) 2-[(E)-2-(4-chloro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0709] Appearance; yellowish solid

[0710] CI-MS(m/z); 400(M++1), EI-MS(m/z); 399(M+)

[0711] 1 H-NMR(δ, DMSO-d6); 5.29(d, J=12.5 Hz, 1H), 5.76(d, J=12.5 Hz, 1H), 5.95(d, J=3.4 Hz, 1H), 6.24(d, J=3.9 Hz, 1H), 6.82(d, J=8.3 Hz, 1H), 7.30(d, J=16.4 Hz, 1H), 7.30-7.45(m, 3H), 7.48(dd, J=6.8, 2.0 Hz, 1H), 7.57(dd, J=8.5, 2.2 Hz, 1H), 7.69(ddd, J=8.3, 6.8, 1.2 Hz, 1H), 7.82(d, J=2.2 Hz, 1H), 7.85(ddd, J=8.3, 6.8, 1.2 Hz, 1H), 7.86(d, J=16.4 Hz, 1H), 8.04(d, J=8.1 Hz, 1H), 8.12(s, 1H), 8.15(d, J=8.3 Hz, 1H)

Reference Example 7

(a) 2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0712] Appearance; yellowish solid

[0713] CI-MS(m/z); 382(M++1), EI-MS(m/z); 381(M+)

[0714] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.19(d, J=8.5 Hz, 1H), 7.38(ddd, J=10.0, 7.8, 1.0 Hz, 1H), 7.47(d, J=16.4 Hz, 1H), 7.57(td, J=7.3, 1.2 Hz, 1H), 7.61(d, J=7.3 Hz, 1H), 7.70(td, J=7.3, 1.5 Hz, 1H), 7.75(td, J=7.8, 6.1 Hz, 1H), 7.83(dd, J=7.8, 1.2 Hz, 1H), 7.85(d, J=8.5 Hz, 1H), 7.96(d, J=15.6 Hz, 1H), 8.00(d, J=8.5 Hz, 1H), 8.05(dd, J=8.8, 2.4 Hz, 1H), 8.38(d, J=2.2 Hz, 1H), 8.46(d, J=9.0 Hz, 1H)

(b) 2-[(E)-2-(5-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0715] Appearance; yellowish solid

[0716] CI-MS(m/z); 384(M++1), EI-MS(m/z); 383(M+)

[0717] 1 H-NMR(δ, DMSO-d6); 5.28(d, J=12.2 Hz, 1H), 5.78(d, J=12.5 Hz, 1H), 5.94(s, 1H), 6.83(d, J=8.3 Hz, 1H), 7.25-7.55(m, 5H), 7.58(dd, J=8.3, 2.2 Hz, 1H), 7.30-7.60(m, 11H), 7.75-7.90 (m, 3H), 7.94(d, J=8.8 Hz, 1H), 8.44(d, J=8.8 Hz, 1H)

Reference Example 8

(a) 2-[(E)-2-(5,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0718] Appearance; pale yellowish solid

[0719] CI-MS(m/z); 400(M++1), EI-MS(m/z); 399(M+)

[0720] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.20(d, J=8.5 Hz, 1H), 7.46(d, J=16.4 Hz, 1H), 7.45-7.65 (m, 4H), 7.70(td, J=7.6, 1.5 Hz, 1H), 7.82(dd, J=7.8, 1.2 Hz, 1H), 7.97(d, J=9.0 Hz, 1H), 7.98 (d, J=15.4 Hz, 1H), 8.05(dd, J=8.8.2.4 Hz, 1H), 8.37(d, J=2.2 Hz, 1H), 8.46(d, J=8.5 Hz, 1H)

(b) 2-[(E)-2-(5,7-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0721] Appearance; yellowish solid

[0722] CI-MS(m/z); 402(M++1), EI-MS(m/z); 401(M+)

[0723] 1 H-NMR(δ, DMSO-d6); 5.29(d, J=12.5 Hz, 1H), 5.77(d, J=12.5 Hz, 1H), 5.94(s, 1H), 6.26(d, J=3.9 Hz, 1H), 6.83(d, J=8.3 Hz, 1H), 7.25-7.65(m, 6H), 7.82(d, J=2.2 Hz, 1H), 7.87(d, J=17.3 Hz, 1H), 7.91(d, J=9.0 Hz, 1H), 8.43(d, J=9.0 Hz, 1H)

Reference Example 9

(a) 2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0724] Appearance; yellowish solid

[0725] CI-MS(m/z); 450(M++1), EI-MS(m/z); 449(M+)

[0726] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.20(d, J=8.5 Hz, 1H), 7.47(d, J=16.4 Hz, 1H), 7.57(t, J=7.6 Hz, 1H), 7.61(d, J=7.8 Hz, 1H), 7.70(t, J=7.3 Hz, 1H), 7.82(d, J=7.6 Hz, 1H), 7.99(d, J=16.4 Hz, 1H), 8.07(d, J=8.1 Hz, 1H), 8.10(d, J=10.3 Hz, 1H), 8.13(d, J=8.1 Hz, 1H), 8.30-8.45(m, 1H), 8.37(d, J=2.4 Hz, 1H), 8.47(d, J=8.8 Hz, 1H)

(b) 2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0727] Appearance; yellowish solid

[0728] CI-MS(m/z); 452(M++1), EI-MS(m/z); 451(M+)

[0729] 1 H-NMR(δ, DMSO-d6); 5.30(d, J=12.5 Hz, 1H), 5.76(d, J=12.5 Hz, 1H), 5.96(br.s, 1H), 6.25(br.s, 1H), 6.83(d, J=8.5 Hz, 1H), 7.30-7.55(m, 4H), 7.34(d, J=16.1 Hz, 1H), 7.57(dd, J=8.5, 2.2 Hz, 1H), 7.82(d, J=2.4 Hz, 1H), 7.86(d, J=16.6 Hz, 1H), 8.05(d, J=8.8 Hz, 1H), 8.07(d, J=11.2 Hz, 1H), 8.34(d, J=6.8 Hz, 1H), 8.42(d, J=8.8 Hz, 1H)

Reference Example 10

(a) 2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0730] Appearance; yellowish solid

[0731] CI-MS(m/z); 418(M++1), EI-MS(m/z); 417(M+)

[0732] 1 H-NMR(δ, DMSO-d6); 5.37(s, 2H), 7.18(d, J=8.5 Hz, 1H), 7.44(d, J=16.4 Hz, 1H), 7.57(td, J=7.6, 1.5 Hz, 1H), 7.60(d, J=7.8 Hz, 1H), 7.69(td, J=7.6, 1.5 Hz, 1H), 7.81(dd, J=7.6, 1.0 Hz, 1H), 7.80-7.95(m, 1H), 7.96(d, J=16.1 Hz, 1H), 8.03(d, J=8.8 Hz, 1H), 8.04(dd, J=8.5, 2.4 Hz, 1H), 8.36(d, J=2.2 Hz, 1H), 8.50(d, J=8.8 Hz, 1H)

(b) 2-[(E)-2-(5,6,7-trifluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0733] Appearance; yellowish solid

[0734] CI-MS(m/z); 420(M++1), EI-MS(m/z); 419(M+)

[0735] 1 H-NMR(δ, DMSO-d6); 5.29(d, J=12.5 Hz, 1H), 5.76(d, J=12.2 Hz, 1H), 5.94(d, J=3.7 Hz, 1H), 6.25(d, J=3.9 Hz, 1H), 6.82(d, J=8.3 Hz, 1H), 7.33(d, J=16.4 Hz, 1H), 7.30-7.45(m, 3H), 7.48(dd, J=6.8, 2.0 Hz, 1H), 7.57(dd, J=8.3, 2.2 Hz, 1H), 7.82(d, J=2.7 Hz, 1H), 7.85(d, J=16.6 Hz, 1H), 7.86(ddd, J=11.5, 7.1, 2.2 Hz, 1H), 7.97(d, J=8.8 Hz, 1H), 8.47(d, J=9.0 Hz, 1H)

Reference Example 11

(a) 2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0736] Appearance; yellowish solid

[0737] CI-MS(m/z); 388(M++1), EI-MS(m/z); 387(M+)

[0738] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.19(d, J=8.5 Hz, 1H), 7.34(td, J=9.0, 2.4 Hz, 1H), 7.50-7.65(m, 2H), 7.58(d, J=16.1 Hz, 1H), 7.70(td, J=7.3, 1.2 Hz, 1H), 7.75-7.80(m, 1H), 7.78(d, J=16.1 Hz, 1H), 7.81(dd, J=9.8, 2.4 Hz, 1H), 8.09(dd, J=8.5, 2.2 Hz, 1H), 8.14(dd, J=8.8, 5.4 Hz, 1H), 8.38(d, J=2.4 Hz, 1H)

(b) 2-[(E)-2-(5-fluoro-2-benzothiazolyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0739] Appearance; yellowish solid

[0740] CI-MS(m/z); 390(M++1), EI-MS(m/z); 389(M+)

[0741] 1 H-NMR(δ, DMSO-d6); 5.28(d, J=12.5 Hz, 1H), 5.80(d, J=12.2 Hz, 1H), 5.91(d, J=3.4 Hz, 1H), 6.25(d, J=3.7 Hz, 1H), 6.82(d, J=8.5 Hz, 1H), 7.25-7.50(m, 5H), 7.44(d, J=16.1 Hz, 1H), 7.62(dd, J=8.5, 2.2 Hz, 1H), 7.63(d, J=16.4 Hz, 1H), 7.79(d, J=10.0, 2.4 Hz, 1H), 7.84(d, J=2.2 Hz, 1H), 8.11(dd, J=8.8, 5.4 Hz, 1H)

Reference Example 12

(a) 2-[(E)-2-(5-fluoro-2-benzoxazolyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0742] Appearance; yellowish solid

[0743] CI-MS(m/z); 372(M++1), EI-MS(m/z); 731(M+)

[0744] 1 H-NMR(δ, DMSO-d6); 5.38(s, 2H), 7.20(d, J=8.8 Hz, 1H), 7.26(ddd, J=9.8, 9.0, 2.7 Hz, 1H), 7.28(d, J=16.4 Hz, 1H), 7.57(td, J=7.6, 1.5 Hz, 1H), 7.55-7.65(m, 1H), 7.61(dd, J=8.8, 2.7 Hz, 1H), 7.70(td, J=7.3, 1.5 Hz, 1H), 7.76(dd, J=9.0, 4.4 Hz, 1H), 7.80(dd, J=7.6, 1.2 Hz, 1H), 7.90(d, J=16.4 Hz, 1H), 8.13(dd, J=8.8, 2.4 Hz, 1H), 8.38(d, J=2.4 Hz, 1H)

(b) 2-[(E)-2-(5-fluoro-2-benzoxazolyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0745] Appearance; yellowish brown solid

[0746] CI-MS(m/z); 374(M++1), EI-MS(m/z); 373(M+)

[0747] 1 H-NMR(δ, DMSO-d6); 5.27(d, J=12.2 Hz, 1H), 5.82(d, J=12.2 Hz, 1H), 5.89(d, J=3.2 Hz, 1H), 6.24(d, J=3.9 Hz, 1H), 6.83(d, J=8.3 Hz, 1H), 7.13(d, J=16.4 Hz, 1H), 7.24(ddd, J=9.8, 9.0, 2.7 Hz, 1H), 7.30-7.50(m, 4H), 7.58(dd, J=8.8, 2.7 Hz, 1H), 7.65(dd, J=8.5, 2.2 Hz, 1H), 7.73(dd, J=8.8, 4.4 Hz, 1H), 7.77(d, J=16.6 Hz, 1H), 7.85(d, J=2.2 Hz, 1H)

Reference Example 13

(a) 2-[(E)-2-(6-isopropyl-5-methyl-2-pyridyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0748] Appearance; yellowish solid

[0749] CI-MS (m/z); 370(M++1), EI-MS(m/z); 369(M+)

[0750] 1 H-NMR(δ, DMSO-d6); 7.14(d, J=8.5 Hz, 1H), 7.21(d, J=16.1 Hz, 1H), 7.31(d, J=7.8 Hz, 1H), 7.50(d, J=8.3 Hz, 1H), 7.54-7.71(m, 4H), 7.80(dd, J=7.6 Hz, 1H), 7.94(dd, J=8.5, 2.4 Hz, 1H), 8.25(d, J=2.2 Hz, 1H)

(b) 2-[(E)-2-(6-isopropyl-5-methyl-2-pyridyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0751] Appearance; yellowish solid

[0752] CI-MS (m/z); 371(M+), EI-MS(m/z); 371(M+)

[0753] 1 H-NMR (δ, DMSO-d6); 1.24(d, J=6.6 Hz, 6H), 2.30(s, 3H), 3.24-3.36(m, 1H), 5.24(d, J=12.2 Hz, 1H), 5.75(d, J=12.4 Hz, 1H), 5.90 (s, 1H), 6.18(s, 1H), 6.77(d, J=8.3 Hz, 1H), 7.08(d, J=16.1 Hz, 1H), 7.24(d, J=7.8 Hz, 1H), 7.32-7.56(m, 7H), 7.68(d, J=2.0 Hz, 1H)

Reference Example 14

(a) 2-[(E)-2-(4-acetoxyphenyl)ethenyl]-6,7-difluoroquinoline

[0754] In 150 ml of acetic anhydride were dissolved 6,7-difluoro-2-quinaldine (17.4 g, 96.8 mmol) and 4-hydroxybenzaldehyde (11.7 g, 95.6 mmol), and the mixture was stirred at 140° C. for 31 hours under nitrogen atmosphere.

[0755] After completion of the reaction, the reaction solution was allowed to cool and diluted with 50 ml of toluene, and then, precipitated crystal was collected by filtration and washed with toluene twice, and dried under reduced pressure to obtain 16.9 g of the desired compound as white solid.

[0756] CI-MS(m/z); 326(M++1), EI-MS(m/z); 325(M+)

[0757] 1 H-NMR(δ, CDCl3); 2.32(s, 3H), 7.12-7.17(m, 2H), 7.29(d, J=16.1 Hz, 1H), 7.51(dd, J=10.3, 8.5 Hz, 1H), 7.62(d, J=8.6 Hz, 1H), 7.62-7.65(m, 2H), 7.69(d, J=16.1 Hz, 1H), 7.81(dd, J=11.5, 7.81 Hz, 1H), 8.05(d, J=8.6 Hz, 1H)

(b) 6,7-difluoro-2-[(E)-2-(4-hydroxyphenyl)ethenyl]quinoline

[0758] In a mixed solution comprising 30 ml of dimethylsulfoxide and 20 ml of methanol was suspended 2-[(E)-2-(4-acetoxyphenyl)ethenyl]-6,7-difluoroquinoline (5.21 g, 16.0 mmol), and a solution in which sodium hydroxide (1.13 g, 28.3 mmol) had been dissolved in 10 ml of water was added to the suspension and the mixture was stirred at room temperature for 20 minutes.

[0759] After completion of there action, 30 ml of 1N-hydrochloric acid was added to the reaction mixture to make the mixture acidic, and the precipitated crystal was extacted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and then, concentrated to obtain 4.20 g of the desired compound as yellowish solid.

[0760] CI-MS(m/z); 284(M++1), EI-MS(m/z); 282(M+−1)

[0761] 1 H-NMR(δ, DMSO-d6); 6.81-6.84(m, 2H), 7.23(d, J=16.1 Hz, 1H), 7.55-7.58(m, 2H), 7.75(d, J=16.1 Hz, 1H), 7.84(d, J=8.8 Hz, 1H), 7.92(dd, J=12.0, 8.0 Hz, 1H), 8.00(dd, J=11.0, 8.8 Hz, 1H), 8.32(d, J=8.8 Hz, 1H), 9.81(br.s, 1H)

(c) Methyl 2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]-3-cyano-benzoate

[0762] To 5 ml of dimethylsulfoxide solution containing 6,7-difluoro-2-[(E)-2-(4-hydroxyphenyl)ethenyl]quinoline (0.40 g, 1.41 mmol) was added a methyl 2-bromomethyl-3-cyano-benzoate (0.29 g, 1.14 mmol) solution dissolved in 5 ml of dimethylsulfoxide, and further potassium carbonate (0.38 g, 2.75 mmol) was added to the mixture and the mixture was stirred at 70° C. for 1 hour under nitrogen atmosphere.

[0763] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=99/1 (volume ratio)) to obtain 0.52 g of the desired compound as yellowish solid.

[0764] CI-MS(m/z); 457(M++1), EI-MS(m/z); 456(M+)

[0765] 1 H-NMR(δ, CDCl3); 3.85(s, 3H), 5.59(s, 2H), 7.01-7.04(m, 2H), 7.22(d, J=16.4 Hz, 1H), 7.49(dd, J=10.0, 8.3 Hz, 1H), 7.54-7.63(m, 4H), 7.66(d, J=16.1 Hz, 1H), 7.80(dd, J=11.5, 7.8 Hz, 1H), 7.87(dd, J=7.8, 1.5 Hz, 1H), 8.03(d, J=8.6 Hz, 1H), 8.10(dd, J=8.1, 1.5 Hz, 1H)

(d) 3-Cyano-2-[4-((E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]benzoic acid

[0766] In 30 ml of dioxane was suspended methyl 3-cyano-2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]benzoate (0.52 g, 1.14 mmol), and a sodium hydroxide (0.48 g, 12.0 mmol) solution dissolved in 1 ml of water was added to the suspension and the mixture was stirred at room temperature for 30 minutes util the solution became uniform.

[0767] After completion of the reaction, the reaction solution was made acidic with 1 ml of trifluoroacetic acid, and then, 100 ml of water was added thereto and the formed precipitate was collected by filtration, washed with water and dried under reduced pressure to obtain 0.41 g of the desired compound as yellowish solid.

(e) 7-Cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0768] In 10 ml of methylene chloride was suspended 3-cyano-2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]benzoic acid (0.41 g, 0.93 mmol), trifluoroacetic acid anhydride (3.0 ml, 21.2 mmol) was added to the suspension to make the solution uniform, and then, boron trifluoride-diethyl ether complex (2.0 ml, 16.3 mmol) was added to the mixture and the mixture was stirred at room temperature for 15 hours.

[0769] After completion of the reaction, the reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution into which sodium hydroxide (1.60 g, 40.0 mmol) had been dissolved therein. The mixture was extracted with ethyl acetate, the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated to obtain 0.38 g of the desired compound as yellowish solid.

[0770] CI-MS(m/z); 425(M++1), EI-MS(m/z); 424(M+)

[0771] 1 H-NMR(δ, DMSO-d6); 5.29(s, 2H), 7.24(d, J=8.5 Hz, 1H), 7.44(d, J=16.4 Hz, 1H), 7.78(t, J=7.81 Hz, 1H), 7.91(d, J=16.4 Hz, 1H), 7.93-7.98(m, 2H), 8.02(dd, J=11.0, 9.0 Hz, 1H), 8.06-8.10(m, 2H), 8.20(dd, J=8.0, 1.2 Hz, 1H), 8.32(d, J=2.4 Hz, 1H), 8.37(d, J=8.5 Hz, 1H)

(f) 7-Cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0772] The same reaction was carried out as in (b) of Reference example 1 except for using 7-cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one (0.37 g, 0.87 mmol) in place of 2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one to obtain 0.37 g of the desired compound as yellowish solid.

[0773] CI-MS(m/z); 427(M++1), EI-MS(m/z); 426(M+)

[0774] 1 H-NMR(δ, DMSO-d6); 5.56(d, J=13.2 Hz, 1H), 5.83(d, J=13.4 Hz, 1H), 6.12(d, J=3.9 Hz, 1H), 6.56(d, J=4.4 Hz, 1H), 6.91(d, J=8.3 Hz, 1H), 7.33(d, J=16.4 Hz, 1H), 7.60(t, J=7.8 Hz, 1H), 7.60-7.62(m, 1H), 7.78-7.91(m, 5H), 7.94(dd, J=12.0, 8.1 Hz, 1H), 8.02(dd, J=11.0, 9.0 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

[0775] In the same manner as in Reference example 14(a), compounds of the following Reference example 15 was obtained.

Reference Example 15

2-[(E)-2-(4-acetoxyphenyl)ethenyl]-7-chloro-6-fluoro-quinoline

[0776] Appearance; pale brownish solid

[0777] CI-MS(m/z); 342(M++1), EI-MS(m/z); 341(M+)

[0778] 1 H-NMR(δ, CDCl3); 2.30(s, 3H), 7.21(dd, J=6.6, 2.0 Hz, 2H), 7.44(d, J=16.4 Hz, 1H), 7.78(d, J=8.5 Hz, 2H), 7.85(d, J=16.4 Hz, 1H), 7.93(d, J=8.5 Hz, 1H), 7.99(d, J=9.5 Hz, 1H), 8.20(d, J=7.3 Hz, 1H), 8.37(d, J=8.5 Hz, 1H)

[0779] In the same manner as in Reference example 14(b), compound of the following Reference example 16 was obtained.

Reference Example 16

7-chloro-6-fluoro-2-((E)-2-(4-hydroxyphenyl)ethenyl]quinoline

[0780] Appearance; yellowish solid

[0781] CI-MS(m/z); 300(M++1), EI-MS(m/z); 298(M+−1)

[0782] 1 H-NMR(δ, DMSO-d6); 6.83(d, J=8.5 Hz, 2H), 7.23(d, J=16.4 Hz, 1H), 7.57(d, J=8.8 Hz, 2H), 7.76(d, J=16.4 Hz, 1H), 7.89(d, J=8.8 Hz, 1H), 7.97(d, J=10.0 Hz, 1H), 8.17(d, J=7.3 Hz, 1H), 8.32(d, J=8.8 Hz, 1H), 9.84(br.s, 1H)

Reference Example 17

Methyl 2-methyl-3-trimethylsilylethynylbenzoate

[0783] In 10 ml of tetrahydrofuran were suspended methyl 3-iodo-2-methylbenzoate (1.20 g, 4.35 mmol) and copper (I) iodide (0.21 g, 1.10 mmol), and then, triethylamine (3.0 ml, 21.5 mmol) and trimethylacetylene (1.5 ml, 10.8 mmol) were added to the suspension to form a uniform solution. Then, to the mixture was added tetrakistriphenylphosphinepalladium (0) (0.72 g, 0.62 mmol), and the mixture was stirred at room temperature for 5 hours under argon atmosphere.

[0784] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, and the organic layer was washed successively with a saturated aqueous ammonium chloride solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=99/1 (volume ratio)) to obtain 1.05 g of the desired compound as black brownish oily product.

[0785] CI-MS(m/z); 247(M++1), EI-MS(m/z); 246(M+)

[0786] 1 H-NMR(δ, CDCl3); 0.27(s, 9H), 2.70(s, 3H), 3.89(s, 3H), 7.17(t, J=7.8 Hz, 1H), 7.58(dd, J=7.8, 1.5 Hz, 1H), 7.78(dd, J=7.8, 1.5 Hz, 1H)

Reference Example 18

Methyl 2-methyl-3-trifluoromethylbenzoate

[0787] In 5 ml of dimethylformamide were suspended methyl 3-iodo-2-methylbenzoate (0.80 g, 2.90 mmol) and copper (I) iodide (0.12 g, 0.63 mmol), and methyl fluorosulfonyl(difluoro)acetate (1.0 ml, 7.91 mmol) was added to the suspension and the mixture was stirred at 80° C. for 6 hours under argon atmosphere. After allowing to coll, copper (I) iodide (0.18 g, 0.95 mmol) and methyl fluorosulfonyl(difluoro)acetate (2.0 ml, 15.8 mmol) were further added to the mixture and stirred at 80° C. for 10 hours.

[0788] After completion of the reaction, pentane was added to the reaction solution, and after removing the precipitates, the filtrate was washed twice with water and once with a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated to obtain 0.62 g of the desired compound as colorless transparent oily product.

[0789] CI-MS(m/z); 219(M++1), EI-MS(m/z); 218(M+)

[0790] 1 H-NMR(δ, CDCl3); 2.64(s, 3H), 3.93(s, 3H), 7.34(dd, J=7.8, 8.1 Hz, 1H), 7.77(d, J=8.1 Hz, 1H), 7.91(d, J=7.8 Hz, 1H)

Reference Example 19

Methyl 2-bromomethyl-3-trimethylsilylethynylbenzoate

[0791] In 15 ml of acetonitrile was dissolved methyl 2-methyl-3-trimethylsilylethynylbenzoate (1.05 g, 4.26 mmol), and N-bromosuccinimide (0.87 g, 4.89 mmol), and benzoyl peroxide (0.22 g, 0.68 mmol) was added to the solution and the mixture was refluxed for 6 hours under argon atmosphere.

[0792] After completion of the reaction, hexane was added to the reaction mixture, and the mixture was washed successively with water, a saturated aqueous sodium hydrogen carbonate solution and a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=99.5/0.5 (volume ratio)) to obtain to obtain 1.02 g of the desired compound as pale yellowish oily product.

[0793] CI-MS(m/z); 325(M++1), EI-MS(m/z); 324(M+)

[0794] 1 H-NMR(δ, CDCl3); 3.95(s, 3H), 5.19(s, 2H), 7.31(t, J=7.87 Hz, 1H), 7.63(dd, J=7.8, 1.5 Hz, 1H), 7.89(dd, J=7.8, 1.5 Hz, 1H)

[0795] In the same manner as in Reference example 19, a compound of the following Reference example 20 was obtained.

Reference Example 20

Methyl 2-bromomethyl-3-trifluoromethylbenzoate

[0796] Appearance; colorless transparent oily product

[0797] CI-MS(m/z); 297(M++1), EI-MS(m/z); 217(M+−Br)

[0798] 1 H-NMR(δ, CDCl3); 3.99(s, 3H), 5.11(s, 2H), 7.49(dd, J=8.1, 7.6 Hz, 1H), 7.82(d, J=8.1 Hz, 1H), 8.05(d, J=7.6 Hz, 1H)

[0799] In the same manner as in Reference example 14(c), compounds of the following Reference examples 21 to 24 were obtained.

Reference Example 21

Methyl 2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]-3-ethynylbenzoate

[0800] Appearance; yellowish solid

[0801] CI-MS(m/z); 456(M++1), EI-MS(m/z); 455(M+)

[0802] 1 H-NMR(δ, CDCl3); 3.33(s, 1H), 3.80(s, 3H), 5.59(s, 2H), 6.99-7.02(m, 2H), 7.21(d, J=16.4 Hz, 1H), 7.40(t, J=7.8 Hz, 1H), 7.49(dd, J=10.0, 8.3 Hz, 1H), 7.56-7.59(m, 2H), 7.60(d, J=8.8 Hz, 1H), 7.70(dd, J=7.8, 1.2 Hz, 1H), 7.76-7.83(m, 2H), 8.02(d, J=8.8 Hz, 1H)

Reference Example 22

Methyl 2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]-3-trifluoromethylbenzoate

[0803] Appearance; yellowish solid

[0804] CI-MS(m/z); 500(M++1), EI-MS(m/z); 499(M+)

[0805] 1 H-NMR(δ, CDCl3); 3.77(s, 3H), 5.46(s, 2H), 6.97-7.00(m, 2H), 7.22(d, J=16.4 Hz, 1H), 7.50 (dd, J=10.0, 8.3 Hz, 1H), 7.57-7.60(m, 2H), 7.61(dd, J=8.1, 7.8 Hz, 1H), 7.68(d, J=16.1 Hz, 1H), 7.80(dd, J=11.5, 7.8 Hz, 1H), 7.86(d, J=8.1 Hz, 1H), 7.95(d, J=7.8 Hz, 1H), 8.03(d, J=8.5 Hz, 1H)

Reference Example 23

Ethyl 3-fluoro-2-[4-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]phenoxymethyl]benzoate

[0806] Appearance; yellowish solid

[0807] CI-MS(m/z); 464(M++1), EI-MS(m/z); 463(M+)

[0808] 1 H-NMR(δ, CDCl3); 1.18(t, J=7.1 Hz, 3H), 4.23(q, J=7.1 Hz, 2H), 5.37(s, 2H), 7.06(d, J=8.8 Hz, 2H), 7.34(d, J=16.4 Hz, 1H), 7.51-7.72(m, 5H), 7.81(d, J=16.4 Hz, 1H), 7.86-8.05(m, 3H), 8.34(d, J=8.8 Hz, 1H)

Reference Example 24

Ethyl 3-fluoro-2-[4-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]phenoxymethyl]benzoate

[0809] Appearance; yellowish solid

[0810] CI-MS(m/z); 480(M++1), EI-MS(m/z); 479(M+)

[0811] 1 H-NMR(δ, CDCl3); 1.18(t, J=7.1 Hz, 3H), 4.23(q, J=7.1 Hz, 2H), 5.37(s, 2H), 7.06(d, J=8.8 Hz, 2H), 7.34(d, J=16.1 Hz, 1H), 7.55-7.72(m, 5H), 7.81(d, J=16.4 Hz, 1H), 7.91(d, J=8.8 Hz, 1H), 7.98(d, J=9.8 Hz, 1H), 8.19(d, J=7.3 Hz, 1H), 8.35(d, J=8.8 Hz, 1H)

[0812] In the same manner as in Reference example 14(d), compounds of the following Reference examples 25 to 28 were obtained.

Reference Example 25

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-ethynyl-6,11-dihydrodibenz[b,e]oxepin-11-one

[0813] Appearance; yellowish solid

[0814] CI-MS(m/z); 424(M++1), EI-MS(m/z); 423(M+)

[0815] 1 H-NMR(δ, DMSO-d6); 3.47(s, 1H), 5.56(s, 2H), 7.21(d, J=8.5 Hz, 1H), 7.44(d, J=16.4 Hz, 1H), 7.58(t, J=7, 8 Hz, 1H), 7.79(dd, J=7.8, 1.5 Hz, 1H), 7.84 (dd, J=7.8, 1.5 Hz, 1H), 7.92 (d, J=16.4 Hz, 1H), 7.94-8.09(m, 3H), 8.31(d, J=2.4 Hz, 1H), 8.38(d, J=8.6 Hz, 1H)

Reference Example 26

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydro-7-trifluoromethyldibenz[b,e]oxepin-11-one

[0816] Appearance; yellowish solid

[0817] CI-MS(m/z); 468(M++1), EI-MS(m/z); 467(M+)

[0818] 1 H-NMR(δ, CDCl3); 5.41(s, 2H), 7.14(d, J=8.54 Hz, 1H), 7.33(d, J=16.4 Hz, 1H), 7.51(dd, J=10.3, 8.3 Hz, 1H), 7.59(t, J=7.8 Hz, 1H), 7.62 (d, J=8.8 Hz, 1H), 7.73 (d, J=16.4 Hz, 1H), 7.81(dd, J=8.5, 2.4 Hz, 1H), 7.82(dd, J=11.5, 7.6 Hz, 1H), 7.91(d, J=7.8 Hz, 1H), 8.00(d, J=7.81 Hz, 1H), 8.07(d, J=8.6 Hz, 1H), 8.39(d, J=2.4 Hz, 1H)

Reference Example 27

7-Fluoro-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0819] Appearance; yellowish solid

[0820] CI-MS(m/z); 418(M++1), EI-MS(m/z); 417(M+)

[0821] 1 H-NMR(δ, CDCl3); 5.45(s, 2H), 7.22(d, J=8.5 Hz, 1H), 7.45(d, J=16.4 Hz, 1H), 7.57-7.64(m, 3H), 7.95(d, J=16.1 Hz, 1H), 8.00-8.09(m, 4H), 8.34(d, J=2.2 Hz, 1H), 8.42(d, J=8.8 Hz, 1H)

Reference Example 28

7-Fluoro-2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0822] Appearance; yellowish solid

[0823] CI-MS(m/z); 434(M++1), EI-MS(m/z); 433(M+)

[0824] 1 H-NMR(δ, CDCl3); 5.45(s, 2H), 6.83(d, J=8.5 Hz, 1H), 7.24(d, J=16.4 Hz, 1H), 7.42-7.78(m, 3H), 7.76(d, J=16.6 Hz, 1H), 7.88-8.32(m, 4H), 8.34(d, J=2.9 Hz, 1H), 8.39(d, J=8.3 Hz, 1H)

[0825] In the same manner as in Reference example 14(e), compounds of the following Reference examples 29 to 32 were obtained.

Reference Example 29

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-ethynyl-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0826] Appearance; yellowish solid

[0827] CI-MS(m/z); 426(M++1), EI-MS(m/z); 425(M+)

[0828] 1 H-NMR(δ, CDCl3); 2.83(d, J=4.4 Hz, 1H), 3.36(s, 1H), 5.55(d, J=13.7 Hz, 1H), 5.76(d, J=4.6 Hz, 1H), 5.95(d, J=13.9 Hz, 1H), 7.01(d, J=8.3 Hz, 1H), 7.23(d, J=15.4 Hz, 1H), 7.30(d, J=7.6 Hz, 1H), 7.43-7.68(m, 7H), 7.79(dd, J=11.2, 7.6 Hz, 1H), 8.04(d, J=8.6 Hz, 1H)

Reference Example 30

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydro-7-trifluoromethyldibenz[b,e]oxepine

[0829] Appearance; yellowish solid

[0830] CI-MS(m/z); 470(M++1), EI-MS(m/z); 469(M+)

[0831] 1 H-NMR(δ, CDCl3); 2.82(s, 1H), 5.43(d, J=13.9 Hz, 1H), 5.86(s, 1H), 6.12(d, J=13.7 Hz, 1H), 6.97(d, J=8.5 Hz, 1H), 7.23(d, J=15.1 Hz, 1H), 7.41-7.71(m, 8H), 7.78(dd, J=11.2, 7.8 Hz, 1H), 8.04(d, J=8.6 Hz, 1H)

Reference Example 31

7-Fluoro-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0832] Appearance; yellowish solid

[0833] CI-MS(m/z); 420(M++1), EI-MS(m/z); 419(M+)

[0834] 1 H-NMR(δ, CDCl3); 5.46(d, J=13.2 Hz, 1H), 5.71(d, J=14.6 Hz, 1H), 6.03(d, J=4.2 Hz, 1H), 6.42(d, J=4.2 Hz, 1H), 6.87(d, J=8.5 Hz, 1H), 7.21-7.42(m, 3H), 7.32(d, J=16.1 Hz, 1H), 7.59(d, J=8.5 Hz, 1H), 7.77-7.83(m, 1H), 7.89(d, J=9.0 Hz, 1H), 7.97(d, J=9.0 Hz, 1H), 8.03(d, J=11.0 Hz, 1H), 8.34(d, J=8.8 Hz, 1H)

Reference Example 32

7-Fluoro-2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0835] Appearance; yellowish solid

[0836] CI-MS(m/z); 436(M++1), EI-MS(m/z); 435(M+)

[0837] 1 H-NMR(δ, CDCl3); 5.47(d, J=12.7 Hz, 1H), 5.68(d, J=12.7 Hz, 1H), 6.05(s, 1H), 6.88(d, J=8.5 Hz, 1H), 7.21-7.42(m, 4H), 7.39(d, J=16.1 Hz, 1H), 7.57(m, 1H), 7.82(s, 1H), 7.98(d, J=8.8 Hz, 1H), 8.02(d, J=9.8 Hz, 1H), 8.21(d, J=7.3 Hz, 1H), 8.40(d, J=8.5 Hz, 1H)

Reference Example 33

2-[(tetrahydropyran-2-yl)oxy]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0838] In 100 ml of ethyl acetate was dissolved 2-hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-one (9.95 g, 44.0 mmol), and dihydropyrane (25.0 ml, 274.0 mmol) and pyridinium p-toluenesulfonate (2.11 g, 8.4 mmol) were added to the solution and the mixture was stirred at room temperature for 21 hours.

[0839] After completion of the reaction, ethyl acetate was added to the reaction solution, and the mixture was washed successively with a saturated aqueous sodium hydrogen carbonate solution, and then, with a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=9 5/5 (volume ratio)) to obtain 12.45 g of the desired compound as pale yellowish solid.

[0840] CI-MS(m/z); 311(M++1), EI-MS(m/z); 226(M+−THP)

[0841] 1 H-NMR(δ, CDCl3); 1.59-1.73(m, 3H), 1.84-2.04(m, 3H), 3.64(dt, J=11.5, 4.4 Hz, 1H), 3.93(ddd, J=11.5, 9.0, 3.2 Hz, 1H), 5.15(s, 2H), 5.42(t, J=3.3 Hz, 1H), 9.98(d, J=8.8 Hz, 1H), 7.22(dd, J=8.8, 3.2 Hz, 1H), 7.33(dd, J=7.3, 1.5 Hz, 1H), 7.45(dt, J=7.6, 1.5 Hz, 1H), 7.54(dt, J=7.6, 1.5 Hz, 1H), 7.89(d, J=3.2 Hz, 1H), 7.92(dd, J=7.8, 1.5 Hz, 1H)

Reference Example 34

11-Hydroxy-2-[(tetrahydropyran-2-yl)oxy]-11-[(2-trimethylsilyl)ethynyl]-6,11-dihydrodibenz[b,e]oxepine

[0842] Under argon atmosphere, n-butyl lithium 1.6M-hexane solution (80.0 ml, 128.0 mmol) was added dropwise over 20 minutes to 50 ml of a diethyl ether solution containing trimethylacetylene (20.0 ml, 142.0 mmol) which had been cooled to −78° C. by an acetone-dry ice bath. After stirring for 10 minutes, a solution of 2-[(tetrahydropyran-2-yl)oxy]-6,11-dihydrodibenz[b,e]oxepin-11-one (29.1 g, 93.8 mmol) dissolved in 200 ml of tetrahydrofuran was added to the mixture and the mixture was stirred at the same temperature for 1 hour and further at room temperature for 2 hours.

[0843] After completion of the reaction, a saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated to obtain 38.3 g of the desired compound as yellowish white solid (diastereomer mixture).

[0844] CI-MS(m/z); 409(M++1), EI-MS(m/z); 408(M+), 324(M+−THP)

[0845] 1 H-NMR(δ, CDCl3); 0.30(s, 3H), 1.59-1.67(m, 3H), 1.79-2.03(m, 3H), 3.55-3.59(m, 1H), 3.86-3.93(m, 1H), 4.26(s, 0.5H), 4.30(s, 0.5H), 5.24(d, J=14.4 Hz, 0.5H), 5.25(d, J=14.7 Hz, 1H), 5.31-5.35(m, 1H), 5.67(d, J=14.4 Hz, 0.5H), 5.69(d, J=14.7 Hz, 0.5H), 6.93-6.95(m, 2H), 7.05-7.08(m, 1H), 7.25-7.30(m, 2H), 7.66-7.69(m, 1H), 8.09-8.12(m, 1H)

Reference Example 35

11-Ethynyl-11-hydroxy-2-[(tetrahydropyran-2-yl)oxy]-6,11-dihydrodibenz[b,e]oxepine

[0846] In 200 ml of tetrahydrofuran was dissolved 11-hydroxy-2-[(tetrahydropyran-2-yl)oxy]-11-[(2-trimethylsilyl)ethynyl]-6,11-dihydrodibenz[b,e]oxepine (38.3 g, 93.8 mmol), and tetra-n-butyl ammonium fluoride 1.0 M-tetrahydrofuran solution (95.0 ml, 95.0 mmol) was added to the solution and the mixture was stirred at room temperature for 40 minutes.

[0847] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, and the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=99.5/0.5 (volume ratio)) to obtain 26.2 g of the desired compound as white solid (diastereomer mixture).

[0848] CI-MS (m/z); 319 (M+−OH), 252 (M+−THP), EI-MS (m/z); 252 (M+−THP)

[0849] 1 H-NMR(δ, CDCl3); 1.57-1.71(m, 3H), 1.81-2.01(m, 3H), 3.06(s, 0.5H), 3.07(s, 0.5H), 3.56-3.60(m, 1H), 3.86-3.90(m, 1H), 4.21(br.s, 1H), 5.29(d, J=14.7 Hz, 0.5H), 5.30(d, J=14.9 Hz, 0.5H), 5.33-5.34(m, 1H), 5.47(d, J=14.9 Hz, 0.5H), 5.53(d, J=14.9 Hz, 0.5H), 6.96-6.98(m, 2H), 7.04-7.07(m, 1H), 7.25-7.31(m, 2H), 7.60-7.62(m, 1H), 8.09-8.12(m, 1H)

Reference Example 36

2-[2-Hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-ylidene]acetaldehyde

[0850] In 10 ml of tetrahydrofuran was dissolved 11-ethynyl-11-hydroxy-2-[(tetrahydropyran-2-yl)oxy]-6,11-dihydrodibenz[b,e]oxepine (0.80 g, 2.4 mmol), and 2 ml of distilled water was added to the solution. To the mixture was added trifluoroacetic acid (0.4 ml, 5.2 mmol), and the mixture was stirred at room temperature for 18 hours.

[0851] After completion of the reaction, a saturated aqueous sodium hydrogen carbonate solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=9/1 (volume ratio)) to obtain 0.42 g of the desired compound as yellowish solid (geometric isomer mixture).

[0852] CI-MS(m/z); 253(M++1), EI-MS(m/z); 252(M+)

[0853] 1 H-NMR(δ, CDCl3); 4.91(br, 1H), 5.18(s, 2H), 6.32(d, J=7.8 Hz, 0.67H), 6.58(d, J=8.3 Hz, 0.33H), 6.71-6.89(m, 3H), 7.24-7.45(m, 4H), 9.57(d, J=8.1 Hz, 0.33H), 9.88(d, J=7.8 Hz, 0.67H)

Reference Example 37

Ethyl 4-[2-hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-ylidene-2-butenoic acid

[0854] Triethyl phosphonoacetate (11.0 ml, 55.4 mmol) was added to a mixture comprising 60% oily sodium hydride (2.04 g, 51.0 mmol) and 20 ml of tetrahydrofuran, and the mixture was stirred at room temperature for 15 minutes. To the solution was added 2-[2-hydroxy-6,11-dihydrodibenz[b,e]oxepine-11-ylidene]acetaldehyde (3.57 g, 14.2 mmol) dissolved in 20 ml of tetrahydrofuran, and the mixture was further stirred at room temperature for 15 minutes.

[0855] After completion of the reaction, a saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=85/15 (volume ratio)) to obtain 3.71 g of the desired compound as yellowish solid (geometric isomer mixture).

[0856] CI-MS(m/z); 323(M++1), EI-MS(m/z); 322(M+)

[0857] 1 H-NMR(δ, CDCl3); 1.26(t, J=7.1 Hz, 0.33H), 1.29(t, J=7.1 Hz, 0.66H), 4.18(q, J=7.08 Hz, 0.33H), 4.22(q, J=7.1 Hz, 0.66H), 5.13(s, 2H), 5.27(br, 0.33H), 5.61(br, 0.66H), 6.06(dd, J=15.4, 0.7 Hz, 0.33H), 6.08(dd, J=15.4, 1.0 Hz, 0.66H), 6.45(dd, J=11.7, 1.0 Hz, 0.66H), 6.68-6.85 (m, 3.33H), 7.22-7.45(m, 4H), 7.41(dd, J=15.4, 11.7 Hz, 0.33H), 7.76(dd, J=15.4, 11.7 Hz, 0.66H)

Reference Example 38

Ethyl 4-[2-hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoate

[0858] 10 mg of platinum oxide (IV) suspended in 2 ml of ethanol was added to ethyl 4-[2-hydroxy-6,11-dihydrodibenz]b,e]oxepin-11-ylidene-2-butenoate (0.50 g, 1.6 mmol) dissolved in 5 ml of ethanol, and the mixture was stirred at room temperature for 42 hours under hydrogen atmosphere.

[0859] After completion of the reaction, insoluble material was removed from the reaction solution, and the filtrate was concentrated to obtain 0.51 g of the desired compound as colorless transparent oily product.

[0860] CI-MS(m/z); 327(M++1), EI-MS(m/z); 326(M+)

[0861] 1 H-NMR(δ, CDCl3); 1.22(t, J=7.1 Hz, 3H), 1.55(quintet, J=7.8 Hz, 2H), 1.96-2.08(m, 1H), 2.17-2.30(m, 1H), 2.26(t, J=7.6 Hz, 2H), 3.64(t, J=7.7 Hz, 1H), 4.09(q, J=7.1 Hz, 2H), 4.96(d, J=15.1 Hz, 1H), 5.04(br, 1H), 5.39(d, J=15.1 Hz, 1H), 6.61-6.65(m, 2H), 6.90-6.93 (m, 1H), 6.97-7.00(m, 1H), 7.13-7.18(m, 3H)

Reference Example 39

6,7-Difluoro-2-vinylquinoline

[0862] In a mixed solution comprising 8 ml of ethanol and triethylamine (0.2 ml, 1.4 mmol) was dissolved 6,7-difluoro-2-methylquinoline (10.64 g, 59.4 mmol), and 37% formaldehyde (4.72 g, 59.4 mmol) was added to the solution and the mixture was stirred at 60° C. for 2 hours. Then, a mixed solution comprising diethylamine hydrochloride (6.60 g, 59.4 mmol), 3 ml of ethanol, 3 ml of water and triethylamine (0.4 ml, 2.8 mmol) was added to the mixture over 30 minutes, and then, the mixture was stirred at 60° C. for 12 hours.

[0863] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous magnesium sulfate. The solvent was concentrated and the resulting residue was applied to silica gel chromatography (eluent: hexane/ethyl acetate=9/1 (volume ratio)) to obtain 2.89 g of the desired compound as pale yellowish solid.

[0864] CI-MS(m/z); 192(M++1), EI-MS(m/z); 191(M+)

[0865] 1 H-NMR(δ, DMSO-d6); 5.69(dd, J=11.0, 1.0 Hz, 1H), 6.39(dd, J=17.6, 1.0 Hz, 1H), 6.95(dd, =17.6, 11.0 Hz, 1H), 7.82(d, J=8.8 Hz, 1H), 6.93(dd, J=8.1, 3.9 Hz, 1H), 8.00(dd, J=9.0, 2.2 Hz, 1H), 8.33(d, J=8.5 Hz, 1H)

Reference Example 40

11-Oxo-2-trifluoromethanesulfonyloxy-6,11-dihydrodibenz[b,e]thiepine

[0866] In 20 ml of methylene chloride was dissolved 2-hydroxy-6,11-dihydrodibenz[b,e]thiepin-11-one (1.12 g, 4.6 mmol), and under ice-cooling, trifluoromethanesulfonic anhydride (2.32 ml, 13.8 mmol) and triethylamine (1.84 ml, 13.8 mmol) were added to the solution and the mixture was stirred at the same temperature for 6 hours.

[0867] After completion of the reaction, the reaction solution was concentrated and the obtained residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=9/1 (volume ratio)) to obtain 0.95 g of the desired compound as black oily product.

[0868] CI-MS(m/z); 375(M++1), EI-MS(m/z); 374(M+)

[0869] 1 H-NMR(δ, DMSO-d6); 4.35(s, 2H), 7.40-7.50(m, 2H), 7.53(d, J=7.8 Hz, 1H), 7.58(d, J=7.3 Hz, 1H), 7.60-7.70(m, 2H), 8.08(d, J=2.2 Hz, 1H)

[0870] In the same manner as in Reference example 40, a compound of the following Reference example 41 was obtained.

Reference Example 41

5-Oxo-3-trifluoromethanesulfonyloxy-10,11-dihydro-5H-dibenzo[a,d]cycloheptene

[0871] Appearance; brownish oily product

[0872] CI-MS(m/z); 357(M++1), EI-MS(m/z); 356(M+)

[0873] 1 H-NMR(δ, DMSO-d6); 3.00-3.30(m, 4H), 7.30-7.50(m, 3H), 7.51-7.65(m, 2H), 7.70(dd, J=8.5, 2.7 Hz, 1H), 7.88(d, J=2.9 Hz, 1H)

Reference Example 42

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]thiepin-11-one

[0874] In 7 ml of N,N-dimethylformamide were dissolved 11-oxo-2-trifluoromethanesulfonyloxy-6,11-dihydrodibenz[b,e]thiepin-2-yl (0.67 g, 1.8 mmol) and 6,7-difluoro-2-vinylquinoline (0.31 g, 1.6 mmol), and then, palladium acetate (0.04 g, 0.2 mmol), triphenylphosphine (0.16 g, 0.6 mmol) and lithium bromide (0.84 g, 4.8 mmol) were added to the solution. Then, under nitrogenatmosphere, triethylamine(2.0 ml, 14.0 mmol) was added to the mixture and the mixture was stirred at 100° C. for 4 hours.

[0875] After completion of the reaction, the reaction solution was concentrated, and the obtained residue was applied to silica gel chromatography (eluent: toluene/ethyl acetate=9/1 (volume ratio)) to obtain 0.62 g of the desired compound as dark brownish solid.

[0876] CI-MS(m/z); 416(M++1), EI-MS(m/z); 415(M+)

[0877] 1 H-NMR(δ, DMSO-d6); 4.31(s, 2H), 7.30-8.20(m, 11H), 8.32(d, J=7.8 Hz, 1H), 8.39(d, J=8.5 Hz, 1H)

[0878] In the same manner as in Reference example 42, a compound of the following Reference example 43 was obtained.

Reference Example 43

3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-one

[0879] Appearance; brownish solid

[0880] CI-MS(m/z); 398(M++1), EI-MS(m/z); 397(M+)

[0881] 1 H-NMR(δ, DMSO-d6); 3.21(s, 4H), 7.20-7.55(m, 7H), 7.85-8.25(m, 5H), 8.38(d, J=8.5 Hz, 1H)

[0882] In the same manner as in Reference example 1(b), compounds of the following Reference examples 44 to 45 were obtained.

Reference Example 44

2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]thiepine

[0883] Appearance; dark brownish solid

[0884] CI-MS(m/z); 418(M++1), EI-MS(m/z); 417(M+)

[0885] 1 H-NMR(δ, DMSO-d6); 4.38(d, J=13.7, 1H), 4.68(d, J=13.7 Hz, 1H), 6.21(s, 1H), 7.06(d, J=8.3 Hz, 1H), 7.20-7.50(m, 5H), 7.34(d, J=14.9, 1H), 7.84(d, J=14.4, 1H), 7.90-8.15(m, 4H), 8.40(d, J=8.8 Hz, 1H)

Reference Example 45

3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-5-hydroxy-10,11-dihydro-5H-dibenz[a,d]cycloheptene

[0886] Appearance; dark brownish solid

[0887] CI-MS(m/z); 400(M++1), EI-MS(m/z); 399(M+)

[0888] 1 H-NMR(δ, DMSO-d6); 3.00-3.30(m, 4H), 5.90-6.05(br.s, 1H), 6.13(s, 1H), 7.10-7.60(m, 6H), 7.39(d, J=16.4 Hz, 1H), 7.65-8.10(m, 5H), 8.35(d, J=8.8 Hz, 1H)

Reference Example 46

8-Bromo-2,11-dihydroxy-6,11-dihydrodibenz[b,e]oxepine

[0889] In a mixed solution comprising 400 ml of tetrahydrofuran and 200 ml of methanol was dissolved 8-bromo-2-hydroxy-6,11-dihydrodibenz[b,e]oxepin-11-one (48.41 g, 0.159 mol), and then, sodium borohydride (6.00 g, 0.159 mol) was added to the solution and the mixture was stirred at room temperature for 2 hours.

[0890] After completion of the reaction, the solvent was removed under reduced pressure, water was added to the residue, and after a pH of the mixture was adjusted to about 6.0 with 1N-hydrochloric acid, the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain 55.95 g of the desired compound as dark brownish oily product. This product was used as such for the next reaction of Reference example 47 without further purification.

[0891] CI-MS(m/z); 307(M++1), EI-MS(m/z); 306(M+)

[0892] 1 H-NMR(δ, DMSO-d6); 5.52(d, J=13.7 Hz, 1H), 5.30(d, J=13.7 Hz, 1H), 5.91(d, J=4.4 Hz, 1H), 6.12(d, J=4.6 Hz, 1H), 6.57(dd, J=8.8, 2.9 Hz, 1H), 6.68(d, J=8.8 Hz, 1H), 6.84(d, J=2.9 Hz, 1H), 7.40-7.60(m, 3H), 9.01(s, 1H)

Reference Example 47

8-Bromo-2-hydroxy-11-methoxy-6,11-dihydrodibenz[b,e]oxepine

[0893] In 500 ml of methanol was dissolved 8-bromo-2,11-dihydroxy-6,11-dihydrodibenz[b,e]oxepine (55.95 g), and then, p-toluenesulfonic acidmonohydrate (3.02 g, 15.9 mmol) was added to the solution and the mixture was refluxed for 1.5 hours.

[0894] After completion of the reaction, the solvent was removed under reduced pressure, the obtained residue was applied to silica gel chromatography (gradient eluent: hexane to hexane/ethyl acetate=9/1 (volume ratio)) to obtain 45.85 g of the desired compound as brownish oily product.

[0895] CI-MS(m/z); 321(M++1), EI-MS(m/z); 320(M+)

[0896] 1 H-NMR(δ, DMSO-d6); 3.25(s, 3H), 4.95(d, J=12.9 Hz, 1H), 5.16(s, 1H), 5.57(d, J=12.9 Hz, 1H), 6.67(dd, J=8.8, 2.2 Hz, 1H), 6.69(d, J=8.1 Hz, 1H), 6.74(d, J=2.0 Hz, 1H), 7.39(d, J=8.3 Hz, 1H), 7.52(dd, J=8.1, 2.2 Hz, 1H), 7.61(d, J=2.0 Hz, 1H)

Reference Example 48

8-Bromo-2-t-butyldimethylsilyloxy-11-methoxy-6,11-dihydrodibenz[b,e]oxepine

[0897] In 400 ml of methylene chloride was dissolved 8-bromo-2-hydroxy-11-methoxy-6,11-dihydrodibenz[b,e]oxepine (41.75 g, 0.130 mol), and then, t-butyldimethylsilyl chloride (29.78 g, 0.198 mol), imidazole (17.88 g, 0.263 mol) and N,N-dimethylaminopyridine (1.59 g, 0.013 mol) were added to the solution and the mixture was stirred at room temperature for 1.5 hours.

[0898] After completion of the reaction, the solvent was removed under reduced pressure, the obtained residue was applied to silica gel chromatography (gradient eluent: hexane to hexane/ethyl acetate=50/1 (volume ratio)) to obtain 51.26 g of the desired compound as reddish oily product.

[0899] CI-MS(m/z); 435(M++1), EI-MS(m/z); 434(M+)

[0900] 1 H-NMR(δ, DMSO-d6); 0.16(s, 6H), 0.94(s, 9H), 3.24(s, 3H), 4.96(d, J=12.7 Hz, 1H), 5.20(s, 1H), 5.66(d, J=12.5 Hz, 1H), 6.65-6.75(m, 1H), 6.76(d, J=8.8 Hz, 1H), 6.84(d, J=2.0 Hz, 1H), 7.38(d, J=8.3 Hz, 1H), 7.55(dd, J=8.1, 2.2 Hz, 1H), 7.66(d, J=2.0 Hz, 1H)

Reference Example 49

11-Methoxy-8-methoxycarbonyl-2-t-butyldimethylsilyloxy-6,11-dihydrodibenz[b,e]oxepine

[0901] n-Butyl lithium 2.52 M-hexane solution (6.83 ml, 17.22 mmol) was added dropwise to 8-bromo-11-methoxy-2-t-butyldimethylsilyloxy-6,11-dihydrodibenz[b,e]oxepine (5.00 g, 11.48 mmol) solution dissolved in 60 ml of tetrahydrofuran at −78° C., and the mixture was stirred at the same temperature for 30 minutes. Then, dry ice (65.0 g) was gradually added to the mixture, the mixture was gradually raised to room temperature. Then, dimethylsulfate (1.30 ml, 13.78 mmol) was added to the mixture and the mixture was refluxed for 8.5 hours.

[0902] After completion of the reaction, ethyl acetate was added to the reaction mixture, and the mixture was washed with a saturated aqueous sodium hydrogen carbonate solution, and then, with a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain 5.44 g of the desired compound as red brownish oily product. This product was used as such for the next reaction of Reference example 50 without effecting further purification.

[0903] CI-MS(m/z); 415(M++1), EI-MS(m/z); 414(M+)

[0904] 1 H-NMR(δ, DMSO-d6); 0.16(s, 6H), 0.94(s, 9H), 3.28(s, 3H), 3.87(s, 3H), 5.11(d, J=12.5 Hz, 1H), 5.34(s, 1H), 5.70(d, J=12.7 Hz, 1H), 6.72(d, J=8.8 Hz, 1H), 6.76(d, J=8.8 Hz, 1H), 6.87(d, J=2.0 Hz, 1H), 7.58(d, J=7.8 Hz, 1H), 7.94(dd, J=7.8, 1.7 Hz, 1H), 8.00(d, J=2.0 Hz, 1H)

Reference Example 50

2-Hydroxy-11-methoxy-8-methoxycarbonyl-6,11-dihydrodibenz[b,e]oxepine

[0905] Tetra-n-butylammonium fluoride (6.00 ml, 20.66 mmol) was added to 11-methoxy-8-methoxycarbonyl-2-t-butyldimethylsilyloxy-6,11-dihydrodibenz[b,e]oxepine (5.44 g) solution dissolved in 250 ml of tetrahydrofuran under ice-cooling, and the mixture was stirred at the same temperature for 1 hour.

[0906] After completion of the reaction, a saturated aqueous ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the obtained residue was applied to silica gel chromatography (gradient eluent: toluene to toluene/ethyl acetate=7/3 (volume ratio)) to obtain 2.47 g of the desired compound as yellowish oily product.

[0907] CI-MS(m/z); 301(M++1), EI-MS(m/z); 300(M+)

[0908] 1 H-NMR(δ, DMSO-d6); 3.29(s, 3H), 3.86(s, 3H), 5.10(d, J=12.9 Hz, 1H), 5.31(s, 1H), 5.61(d, J=12.7 Hz, 1H), 6.66(dd, J=8.8, 2.4 Hz, 1H), 6.70(d, J=8.1 Hz, 1H), 6.77(d, J=2.4 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.92(dd, J=7.8, 1.7 Hz, 1H), 7.95(d, J=1.7 Hz, 1H), 9.06(Br.s. 1H)

[0909] In the same manner as in Example 51(a), a compound of the following Reference example 51 was obtained.

Reference Example 51

11-Methoxy-8-methoxycarbonyl-2-trifluoromethanesulfonyloxy-6,11-dihydrodibenz[b,e]oxepine

[0910] CI-MS(m/z); 433(M++1), EI-MS(m/z); 432(M+)

[0911] 1 H-NMR(δ, DMSO-d6); 3.32(s, 3H), 3.88(s, 3H), 5.30(d, J=12.5 Hz, 1H), 5.56(s, 1H), 5.80 (d, J=12.5 Hz, 1H), 6.98(d, J=9.0 Hz, 1H), 7.38(dd, J=9.0, 3.2 Hz, 1H), 7.58(d, J=2.9 Hz, 1H), 7.58(d, J=8.3 Hz, 1H), 7.99(dd, J=7.8, 1.7 Hz, 1H), 8.08(d, J=1.7 Hz, 1H)

[0912] In the same manner as in Example 51(b), a compound of the following Reference example 52 was obtained.

Reference Example 52

2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-11-methoxy-8-methoxycarbonyl-6,11-dihydrodibenz[b,e]oxepine

[0913] CI-MS(m/z); 442(M++1), EI-MS(m/z); 441(M+)

[0914] 1 H-NMR(δ, DMSO-d6); 1.60-1.90(m, 2H), 2.72(t, J=6.1 Hz, 1H), 2.81(t, J=6.3 Hz, 1H), 3.29(s, 3H), 3.86(s, 3H), 5.16(d, J=12.5 Hz, 1H), 5.36(s, 1H), 5.86(d, J=12.2 Hz, 1H), 6.82(d, J=8.5 Hz, 1H), 7.10(d, J=16.1 Hz, 1H), 7.26(d, J=8.1 Hz, 1H), 7.41(d, J=8.1 Hz, 1H), 7.48(d, J=16.1 Hz, 1H), 7.53(dd, J=8.5, 2.2 Hz, 1H), 7.58(d, J=8.1 Hz, 1H), 7.68(d, J=2.0 Hz, 1H), 7.96(dd, J=7.8, 1.7 Hz, 1H), 8.05(d, J=1.7 Hz, 1H)

Reference Example 53

9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-one

[0915] Palladium acetate (0.67 g, 3.0 mmol) and triphenylphosphine (0.33 g, 13 mmol) were added to 40 ml of N,N-dimethylformamide solution containing 9-bromo-6,11-dihydrodibenz[b,e]oxepin-11-one (2.0 g, 6.9 mmol) and 6,7-difluoro-2-vinylquinoline (1.58 g, 8.3 mmol), and then, under nitrogen atmosphere, triethylamine (6.0 ml, 42 mmol) was added to the solution and the mixture was stirred at 100° C. for 4 hours.

[0916] After completion of the reaction, water was added to the reaction mixture, the resulting mixture was extracted with ethyl acetate, the organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate. The residue obtained by concentrating the solvent was applied to silica gel column chromatography (eluent: hexane/ethyl acetate=3/1 (volume ratio)) to obtain 0.97 g of the desired compound as ocherous solid.

[0917] CI-MS(m/z); 400(M++1), EI-MS(m/z); 399(M+)

[0918] 1 H-NMR(δ, DMSO-d6); 5.34(s, 2H), 7.14(d, J=9.0 Hz, 1H), 7.20(t, J=8.1 Hz, 1H), 7.57-7.67 (m, 3H), 7.91-8.08(m, 6H), 8.14(dd, J=8.1, 1.7 Hz, 1H), 8.40(d, J=8.6 Hz, 1H)

[0919] In the same manner as in Reference example 1(b), a compound of the following Reference example 54 was obtained.

Reference Example 54

9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0920] Appearance; ocherous solid

[0921] CI-MS(m/z); 402(M++1), EI-MS(m/z); 401(M+)

[0922] 1 H-NMR(δ, DMSO-d6); 5.24(d, J=12.7 Hz, 1H), 5.71(d, J=12.5 Hz, 1H), 5.92(s, 1H), 6.21(br.s, 1H), 6.39(d, J=9.3 Hz, 1H), 6.93(t, J=7.6 Hz, 1H), 7.18(t, J=8.3 Hz, 1H), 7.42-7.52(m, 3H), 7.66(d, J=7.8 Hz, 1H), 7.84-8.27(m, 5H), 8.38(d, J=8.6 Hz, 1H)

Reference Example 55

5-Fluoroquinaldine

[0923] Croton aldehyde (23.5 ml, 0.28 mol) was added dropwise over 50 minutes to a mixed solution comprising 40 ml of water and 145 ml of conc. hydrochloric acid dissolved therein 3-fluoroaniline (30.0 g, 0.27 mol) under reflux, and the mixture was refluxed for 2 hours.

[0924] After completion of the reaction, the reaction mixture was cooled, and washed with methylene chloride. Then, toluene was added to the aqueous layer, and a pH of the layer was adjusted to about 9.0 by a 30% aqueous sodium hydroxide solution and the mixture was extracted with toluene. The organic layer was washed with a saturated aqueous sodium chloride solution and dried over anhydrous sodium sulfate, and the mixture was concentrated. The obtained residue was applied to silica gel column chromatography (gradient eluent: toluene to toluene/ethyl acetate=10/1 (volume ratio)) to obtain 1.04 g of the desired compound as yellowish oily product.

[0925] CI-MS(m/z); 162(M++1), EI-MS(m/z); 161(M+)

[0926] 1 H-NMR(δ, DMSO-d6); 2.69(s, 3H), 7.37(ddd, J=10.0, 7.8, 1.0 Hz, 1H), 7.52(d, J=8.8 Hz, 1H), 7.71(td, J=7.8, 6.1 Hz, 1H), 7.80(d, J=8.5 Hz, 1H), 8.37(d, J=8.5 Hz, 1H)

Reference Example 56

2-Bromomethyl-5-fluoroquinoline

[0927] To 40 ml of ethyl acetate solution containing 5-fluoroquinaldine (2.03 g, 12.6 mmol) were added N-bromosuccinimide (4.05 g, 22.8 mmol) and 2,2′-azobis(isobutyronitrile) (0.37 g, 2.25 mmol) divided into several times while refluxing for 12 hours.

[0928] After completion of the reaction, the reaction solution was cooled, and the mixture was washed successively with a saturated aqueous sodium hydrogen carbonate solution, an aqueous sodium thiosulfate solution, and then, with a saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. A residue obtained by concentration was applied to silica gel column chromatography (eluent: hexane/ethyl acetate=50/1 (volume ratio)) to obtain 2.20 g of the desired compound as yellowish solid.

[0929] CI-MS(m/z); 240(M++1), EI-MS(m/z); 239(M+)

[0930] 1 H-NMR(δ, DMSO-d6); 4.89(s, -2H), 7.47(ddd, J=10.0, 7.8, 1.0 Hz, 1H), 7.79(d, J=8.8 Hz, 1H), 7.75-7.85(m, 1H), 7.88(d, J=8.5 Hz, 1H), 8.54(d, J=8.5 Hz, 1H)

Reference Example 57

(5-Fluoroquinolin-2-yl)triphenylphosphonium bromide

[0931] Triphenylphosphine (3.36 g, 12.8 mmol) was added to 15 ml of acetonitrile solution containing 2-bromomethyl-5-fluoroquinoline (2.20 g, 9.2 mmol), and the mixture was stirred at 60° C. for 5 hours.

[0932] After completion of the reaction, the solvent was removed from the reaction solution under reduced pressure, and diethyl ether was added to the residue to crystallize the product. The crystal was obtained by filtration, washed with diethyl ether, and dried under reduced pressure to obtain 5.46 g of the desired compound as brownish solid.

[0933] CI-MS(m/z); 421(M+−HBr), EI-MS(m/z); 421(M+−HBr)

[0934] In the same manner as in Reference example 55, compounds of the following Reference examples 58 to 60 were obtained.

Reference Example 58

5,7-Difluoroquinaldine

[0935] Appearance; brownish solid

[0936] CI-MS(m/z); 180(M++1), EI-MS(m/z); 179(M+)

[0937] 1 H-NMR(δ, DMSO-d6); 2.69(s, 3H), 7.40-7.60(m, 3H), 8.34(d, J=8.8 Hz, 1H)

Reference Example 59

5,6,7-Trifluoroquinaldine

[0938] Appearance; brownish solid

[0939] CI-MS(m/z); 198(M++1), EI-MS(m/z); 197(M+)

[0940] 1 H-NMR(δ, DMSO-d6); 2.68(s, 3H), 7.56(d, J=8.5 Hz, 1H), 7.81(ddd, J=11.7, 7.1, 2.4 Hz, 1H), 8.38(d, J=8.8 Hz, 1H)

Reference Example 60

6-Fluoro-7-trifluoromethylquinaldine

[0941] Appearance; brownish solid

[0942] CI-MS(m/z); 230(M++1), EI-MS(m/z); 229(M+)

[0943] 1 H-NMR(δ, DMSO-d6); 2.87(s, 3H), 7.89(d, J=8.8 Hz, 1H), 8.28(d, J=11.2 Hz, 1H), 8.66(d, J=6.8 Hz, 1H), 8.70(d, J=8.5 Hz, 1H)

[0944] In the same manner as in Reference example 56, a compound of the following Reference examples 61 to 63 were obtained.

Reference Example 61

2-Bromomethyl-5,7-difluoroquinoline

[0945] Appearance; brownish solid

[0946] CI-MS(m/z); 258(M++1), EI-MS(m/z); 257(M+)

[0947] 1 H-NMR(δ, DMSO-d6); 4.87(s, 2H), 7.55-7.75(m, 2H), 7.76(d, J=8.8 Hz, 1H), 8.53(d, J=8.5 Hz, 1H)

Reference Example 62

2-Bromomethyl-5,6,7-trifluoroquinoline

[0948] Appearance; brownish solid

[0949] CI-MS(m/z); 180(M++1), EI-MS(m/z); 179(M+)

[0950] 1 H-NMR(δ, DMSO-d6); 4.88(s, 2H), 7.82(d, J=8.8 Hz, 1H), 7.95(ddd, J=11.5, 7.1, 2.4 Hz, 1H), 8.56(d, J=8.8 Hz, 1H)

Reference Example 63

2-Bromomethyl-6-fluoro-7-trifluoromethylquinaldine

[0951] Appearance; brownish solid

[0952] CI-MS(m/z); 308(M++1), EI-MS(m/z); 307(M+)

[0953] 1 H-NMR(δ, DMSO-d6); 4.90(s, 2H), 7.90(d, J=8.5 Hz, 1H), 8.15(d, J=11.5 Hz, 1H), 8.42(d, J=7.1 Hz, 1H), 8.52(d, J=8.5 Hz, 1H)

[0954] In the same manner as in Reference example 57, compounds of the following Reference examples 64 to 66 were obtained.

Reference Example 64

(5,7-Difluoroquinolin-2-yl)triphenylphosphonium bromide

[0955] Appearance; pale brownish solid

[0956] CI-MS (m/z); 439 (M+−HBr), EI-MS(m/z); 439 (M+−HBr)

Reference Example 65

(5,6,7-Trifluoroquinolin-2-yl)triphenylphosphonium bromide

[0957] Appearance; brownish solid

[0958] CI-MS(m/z); 458(M+−HBr), EI-MS(m/z); 458(M+−HBr)

Reference Example 66

(6-Fluoro-7-trifluoromethylquinolin-2-yl)triphenylphosphonium bromide

[0959] Appearance; brownish solid

[0960] In the same manner as in Reference example 2, a compound of the following Reference example 67 was obtained.

Reference Example 67

(a) 2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-one

[0961] Appearance; pale yellowish solid

[0962] 1 H-NMR(δ, DMSO-d6); 8.39-8.36(m, 2H), 8.05-7.90(m, 5H), 7.53(dd, J=9.0, 2.4 Hz, 1H), 7.47-7.38(m, 3H), 7.21(d, J=8.6 Hz, 1H), 5.37(s, 2H)

(b) 2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-11-hydroxy-6,11-dihydrodibenz[b,e]oxepine

[0963] Appearance; pale yellowish solid

[0964] 1 H-NMR(δ, DMSO-d6); 8.35(d, J=8.6 Hz, 1H), 8.05-7.29(m, 9H), 7.18(td, J=9.0, 2.7 Hz, 1H), 6.84(d, J=8.5 Hz, 1H), 6.25(br.s, 1H), 5.93(s, 1H), 5.73(d, J=12.5 Hz, 1H), 5.27(d, J=12.5 Hz, 1H)

[0965] In the same manner as in Reference example 19, a compound of the following Reference Example 68 was obtained.

Reference Example 68

Ethyl 2-bromomethyl-4-fluorobenzoate

[0966] Appearance; red brownish oily product

[0967] CI-MS(m/z); 261(M++1)

[0968] 1 H-NMR(δ, CDCl3); 8.02(dd, J=4.3, 2.7 Hz, 1H), 7.19(dd, J=9.3, 2.7 Hz, 1H), 7.05(td, J=7.8, 2.7 Hz, 1H), 4.93(s, 2H), 4.40(q, J=7.1 Hz, 2H), 1.42(t, J=7.1 Hz, 3H)

[0969] In the same manner as in Reference example 14(c), a compound of the following Reference example 69 was obtained.

Reference Example 69

Ethyl-2-{4-(6,7-difluoroquinolin-2-ylethenyl)phenoxymethyl}-4-fluorobenzoate

[0970] Appearance; pale yellowish solid

[0971] CI-MS(m/z); 464(M++1)

[0972] 1 H-NMR(δ, DMSO-d6); 8.35-7.06(m, 13H), 5.48(s, 2H), 4.30(q, J=7.1 Hz, 2H), 1.30(t, J=7.1 Hz, 3H)

[0973] In the same manner as in Reference example 14(d), a compound of the following Reference example 70 was obtained.

Reference Example 70

2-{4-(6,7-Difluoroquinolin-2-ylethenyl)phenoxymethyl}-4-fluorobenzoic acid

[0974] Appearance; yellowish solid

[0975] CI-MS(m/z); 436(M++1)

[0976] 1 H-NMR(δ, DMSO-d6); 8.34-6.92(m, 13H), 5.52(s, 2H)

Claims

1. A tricyclic compound represented by the formula (I):

2. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a bromine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a carboxyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a propyl group, an isopropyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a 2-fluoroethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 2-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a 2-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-1-propenyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a 2-fluoroethoxy group, a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group and an isopropylsulfonyl group.

3. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a hydroxyl group, a nitro group, a cyano group, a carbamoyl group, a formyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, an ethyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxyethyl group, a 1-hydroxy-1-methylethyl group, a 1-hydroxypropyl group, a vinyl group, a 1-propenyl group, an allyl group, an ethynyl group, a 1-propynyl group, a 1-butynyl group, a methoxy group, an ethoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, an ethylthio group, a methylsulfinyl group, an ethylsulfinyl group, a methylsulfonyl group and an ethylsulfonyl group.

4. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a nitro group, a cyano group, a formyl group, a methoxycarbonyl group, a 1H-tetrazol-5-yl group, a methyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, a 1-hydroxy-1-methylethyl group, a vinyl group, an ethynyl group, a methoxy group, a difluoromethoxy group, a trifluoromethoxy group, a methylthio group, a methylsulfinyl group and a methylsulfonyl group.

5. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R1 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a cyano group, a trifluoromethyl group and an ethynyl group.

6. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R2 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, a nitro group, a cyano group, a methyl group, an ethyl group, a methoxy group and an ethoxy group.

7. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R2 of the compound represented by the formula (I) is selected from the group consisting of a hydrogen atom, a fluorine atom, a chlorine atom, methyl group and methoxy group.

8. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R2 of the compound represented by the formula (I) is a hydrogen atom.

9. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the ring shown by A of the compound represented by the formula (I) is selected from the group consisting of furan, thiophene, oxazole, thiazole, imidazole, pyrazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, benzofuran, benzothiophene, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline and quinoxaline rings.

10. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the ring shown by A of the compound represented by the formula (I) is selected from the group consisting of oxazole, thiazole, imidazole, pyrazole, thiadiazole, pyridine, pyrimidine, pyridazine, pyrazine, benzoxazole, benzothiazole, benzimidazole, quinoline, quinazoline and quinoxaline rings.

11. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the ring shown by A of the compound represented by the formula (I) is selected from the group consisting of thiazole, thiadiazole, pyridine, pyrimidine, benzoxazole, benzothiazole, quinoline and quinazoline rings.

12. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the ring shown by A of the compound represented by the formula (I) is selected from the group consisting of pyridine, benzothiazole and quinoline rings.

13. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 12, wherein said heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent selected from the group consisting of fluorine, chlorine, bromine atoms, nitro, cyano, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, methoxy, ethoxy, propoxy, isopropoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2-fluoroethoxy, methylthio, ethylthio, propylthio, isopropylthio, trimethylene and tetramethylene groups.

14. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 12, wherein said heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent selected from the group consisting of fluorine, chlorine atoms, nitro, cyano, methyl, ethyl, isopropyl, t-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylthio, ethylthio, trimethylene and tetramethylene groups.

15. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 12, wherein said heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent selected from the group consisting of fluorine, chlorine atoms, nitro, cyano, methyl, isopropyl, t-butyl, difluoromethyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, methylthio and tetramethylene groups.

16. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 9 to 12, wherein said heteroaromatic ring group or fused heteroaromatic ring group is substituted by at least one substituent selected from the group consisting of fluorine, chlorine atoms, trifluoromethyl and tetramethylene groups.

17. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein A of the compound represented by the formula (I) is selected from the group consisting of 2-oxazolyl, 2-thiazolyl, 2- or 4-imidazolyl, 3-pyrazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2- or 4-pyrimidinyl, 3-pyridazinyl, 2-pyrazinyl, 2-benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, quinolin-2-yl, quinazolin-2-yl, quinoxaline-2-yl, 4-methyl-2-thiazolyl, 4-ethyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-ethyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-diethyl-2-pyridyl, 6-trifluoromethyl-2-pyridyl, 6-methylthio-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidine-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoroquinazolin-2-yl, 7-chloro-5-fluoroquinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl and 5,6,7-trifluoroquinazolin-2-yl groups.

18. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein A of the compound represented by the formula (I) is selected from the group consisting of 2-thiazolyl, 1,3,4-thiadiazol-2-yl, 2-pyridyl, 2-pyrimidinyl, 2-benzoxazolyl, 2-benzothiazolyl, quinolin-2-yl, quinazolin-2-yl, 4-methyl-2-thiazolyl, 4-isopropyl-2-thiazolyl, 4-t-butyl-2-thiazolyl, 4-trifluoromethyl-2-thiazolyl, 5-methyl-1,3,4-thiadiazol-2-yl, 5-isopropyl-1,3,4-thiadiazol-2-yl, 5-t-butyl-1,3,4-thiadiazol-2-yl, 5-trifluoromethyl-1,3,4-thiadiazol-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6-dihydroclopenta[b]pyridin-2-yl, 5,6,7,8-tetrahydroquinolin-2-yl, 5,6-difluoro-2-pyrimidinyl, 5,6-dichloro-2-pyrimidinyl, 5,6-dimethyl-2-pyrimidinyl, 6-trifluoromethyl-2-pyrimidinyl, 5,6-dihydrocyclopenta[d]pyrimidin-2-yl, 5,6,7,8-tetrahydroquinazolin-2-yl, 6-fluoro-2-benzoxazolyl, 5-fluoro-2-benzoxazolyl, 5,6-difluoro-2-benzoxazolyl, 6-chloro-2-benzoxazolyl, 5-chloro-2-benzoxazolyl, 5,6-dichloro-2-benzoxazolyl, 5-chloro-6-fluoro-2-benzoxazolyl, 5-methyl-2-benzoxazolyl, 5-cyano-2-benzoxazolyl, 5-trifluoromethyl-2-benzoxazolyl, 5-methylthio-2-benzoxazolyl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoro-quinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyanoquinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl, 5,6,7-trifluoroquinolin-2-yl, 5-fluoroquinazolin-2-yl, 6-fluoroquinazolin-2-yl, 7-fluoroquinazolin-2-yl, 5-chloroquinazolin-2-yl, 6-chloroquinazolin-2-yl, 7-chloroquinazolin-2-yl, 7-methylquinazolin-2-yl, 7-trifluoromethylquinazolin-2-yl, 7-methoxyquinazolin-2-yl, 7-difluoromethoxyquinazolin-2-yl, 7-trifluoromethoxyquinazolin-2-yl, 5,7-difluoroquinazolin-2-yl, 6,7-difluoroquinazolin-2-yl, 5,7-dichloroquinazolin-2-yl, 6,7-dichloroquinazolin-2-yl, 5-chloro-7-fluoroquinazolin-2-yl, 6-chloro-7-fluoroquinazolin-2-yl, 7-chloro-5-fluoroquinazolin-2-yl, 7-chloro-6-fluoroquinazolin-2-yl, 7-chloro-6-cyano-quinazolin-2-yl, 7-cyano-6-fluoroquinazolin-2-yl, 6-fluoro-7-trifluoromethylquinazolin-2-yl and 5,6,7-trifluoroquinazolin-2-yl groups.

19. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein A of the compound represented by the formula (I) is selected from the group consisting of 2-pyridyl, 2-benzothiazolyl, quinolin-2-yl, 5,6-difluoro-2-pyridyl, 5,6-dichloro-2-pyridyl, 5,6-dimethyl-2-pyridyl, 5,6,7,8-tetrahydroquinolin-2-yl, 6-fluoro-2-benzothiazolyl, 5-fluoro-2-benzothiazolyl, 5,6-difluoro-2-benzothiazolyl, 6-chloro-2-benzothiazolyl, 5-chloro-2-benzothiazolyl, 5,6-dichloro-2-benzothiazolyl, 5-chloro-6-fluoro-2-benzothiazolyl, 5-methyl-2-benzothiazolyl, 5-cyano-2-benzothiazolyl, 5-trifluoromethyl-2-benzothiazolyl, 5-methylthio-2-benzothiazolyl, 5-fluoroquinolin-2-yl, 6-fluoroquinolin-2-yl, 7-fluoroquinolin-2-yl, 5-chloroquinolin-2-yl, 6-chloroquinolin-2-yl, 7-chloroquinolin-2-yl, 7-methylquinolin-2-yl, 7-trifluoromethylquinolin-2-yl, 7-methoxyquinolin-2-yl, 7-difluoromethoxyquinolin-2-yl, 7-trifluoromethoxyquinolin-2-yl, 5,7-difluoroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 5,7-dichloroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 5-chloro-7-fluoroquinolin-2-yl, 6-chloro-7-fluoroquinolin-2-yl, 7-chloro-5-fluoroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 7-chloro-6-cyano-quinolin-2-yl, 7-cyano-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl and 5,6,7-trifluoroquinolin-2-yl groups.

20. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein A of the compound represented by the formula (I) is selected from the group consisting of 7-fluoroquinolin-2-yl, 7-chloroquinolin-2-yl, 6,7-difluoroquinolin-2-yl, 6,7-dichloroquinolin-2-yl, 7-chloro-6-fluoroquinolin-2-yl, 6-fluoro-7-trifluoromethylquinolin-2-yl and 5,6,7,8-tetrahydroquinolin-2-yl groups.

21. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 20, wherein B in the formula (I) is a formula: —OCH2—, a formula: —CH2O— or a formula: —CH2CH2—.

22. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 20, wherein X in the formula (I) is a methylene group, a sulfur or oxygen atom.

23. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y in the formula (I) is a methylene, ethylene, trimethylene, tetramethylene, pentamethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-methoxyethylene, 2-methoxyethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 2,2-diethyltrimethylene, 2-methoxytrimethylene, 3-methoxytrimethylene, 2,2-dimethoxytrimethylene, 3,3-dimethoxytrimethylene, 1,2-phenylene, 1, 3-phenylene group, a group shown by a group (a) wherein o=0, p=0 and q=1, a group wherein o=0, p=1 and q=1, a group wherein o=0, p=1 and q=2, a group wherein o=1, p=0 and q=1, a group wherein o=1, p=1 and q=1 and a group wherein o=1, p=1 and q=2.

24. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y in the formula (I) is a methylene, ethylene, trimethylene, fluoromethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-fluorotrimethylene, 2-fluorotrimethylene, 3-fluorotrimethylene, 1,1-difluorotrimethylene, 2,2-difluorotrimethylene, 3,3-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene group, , in a group shown by the formula (a), a group wherein o=1, p=0 and q=1, a group wherein o=1, p=1 and q=1 and a group wherein o=1, p=1 and q=2.

25. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y in the formula (I) is a methylene, ethylene, trimethylene, difluoromethylene, 1-fluoroethylene, 2-fluoroethylene, 1,1-difluoroethylene, 2,2-difluoroethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 2,2-difluorotrimethylene, 1-methyltrimethylene, 2-methyltrimethylene, 1,1-dimethyltrimethylene, 2,2-dimethyltrimethylene, 3,3-dimethyltrimethylene, 1,2-phenylene and in a group shown by the formula (a), a group wherein o=1, p=1 and q=1.

26. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Y in the formula (I) is a methylene, ethylene, trimethylene, 1-methylethylene, 2-methylethylene, 1,1-dimethylethylene, 2,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1,2-phenylene and in a group shown by the formula (a), a group wherein o=1, p=1 and q=1.

27. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a 1H-tetrazol-5-yl, a formula: —SO3H, methanesulfonylamino, ethanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, p-fluorophenylsulfonylamino, p-chlorophenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, p-trifluoromethylphenylsulfonylamino, o-methoxyphenylsulfonylamino, p-methoxyphenylsulfonylamino, p-difluoromethoxyphenylsulfonylamino, p-trifluoromethoxyphenylsulfonylamino, p-nitrophenylsulfonylamino, p-cyanophenylsulfonylamino, methanesulfonylaminocarbonyl, ethanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, p-fluorophenylsulfonylaminocarbonyl, p-chlorophenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl, p-methylphenylsulfonylaminocarbonyl, p-trifluoromethylphenylsulfonylaminocarbonyl, o-methoxyphenylsulfonylaminocarbonyl, p-methoxyphenylsulfonylaminocarbonyl, p-difluoromethoxyphenylsulfonylaminocarbonyl, p-trifluoromethoxyphenylsulfonylaminocarbonyl, p-nitrophenylsulfonylaminocarbonyl and p-cyanophenylsulfonylaminocarbonyl groups.

28. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a 1H-tetrazol-5-yl, a formula: —SO3H, methanesulfonylamino, trifluoromethanesulfonylamino, phenylsulfonylamino, o-methylphenylsulfonylamino, p-methylphenylsulfonylamino, methanesulfonylaminocarbonyl, trifluoromethanesulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, o-methylphenylsulfonylaminocarbonyl and p-methylphenylsulfonylaminocarbonyl groups.

29. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein Z in the formula (I) is selected from the group consisting of a carboxyl, a formula: —SO3H, methanesulfonylamino, trifluoromethanesulfonylamino, methanesulfonylaminocarbonyl and trifluoromethanesulfonylaminocarbonyl groups.

30. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein m in the formula (I) is an integer of 1, 2 or 3.

31. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 and 6 to 8, wherein n in the formula (I) is an integer of 1 or 2.

32. A tricyclic compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound represented by the formula (I) is at least one selected from the group consisting of: [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]oxyacetic acid, [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thioacetic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2,2-dimethylpropionic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-ethylpropionic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-3,3-dimethylpropionic acid, {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}benzoic acid, [2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylacetamide, 3-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio-N-methanesulfonylpropionamide, 2-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}ethanesulfonic acid, 4-[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]butanoic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, {1-[[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-8-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[7-cyano-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio]propionic acid, 3-{[2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-7-trifluoromethyl-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[7-ethynyl-2-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio]propionic acid, 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, {1-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-7-fluoro-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, 3-}[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[2-[(E)-2-(7-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid, {1-[[2-[(E)-2-(7-chloro-6-fluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, {2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepine-11-yl}thioacetic acid, 3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid, {1-[[2-[(E)-2-(7-chloro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}-2-methylpropionic acid, {1-[[2-[(E)-2-(5,6,7,8-tetrahydro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thiomethyl]cyclopropyl}acetic acid, 3-{[2-[(E)-2-(6-fluoro-7-trifluoromethyl-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid, 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}propionic acid, 3-{[3-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-10,11-dihydro-5H-dibenz[a,d]cyclohepten-5-yl]thio}-2-methylpropionic acid, and 3-{[9-[(E)-2-(6,7-difluoro-2-quinolinyl)ethenyl]-6,11-dihydrodibenz[b,e]oxepin-11-yl]thio}propionic acid.